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Thesis Summary 
Chronic wounds are regarded as skin wounds that fail to heal. Their chronic nature and 
requirement for long term treatment put a large financial burden on the healthcare providers. 
Prevalence of chronic wounds increases with age and is associated with diabetes; both of 
these are on the increase in western populations. This makes chronic wound research 
essential in order to understand the basic biological causes and identify potential therapeutic 
targets. 
The aim of this thesis was to characterise the response of chronic wound fibroblasts (CWFs) 
in response to Transforming Growth Factor β-1 (TGF-β1) stimulation, the cytokine 
responsible for fibroblast to myofibroblast differentiation. This differentiation is lost in chronic 
wounds, resulting in the loss of wound closure. TGF-β1 signals through two independent yet 
collaborating pathways: the classical TGF-βR and the non-classical HA-CD44-EGFR 
pathway. I aimed to explore the possible dysfunctional signalling in these pathways that may 
contribute to the loss of myofibroblast formation in CWFs. 
HAS1 was shown to have a higher basal expression of in CWFs, with increasing expression 
in response to TGF-β1. Altered HASs expression indicated a possible defective HA-CD44-
EGFR pathway. HA pericellular coat formation, essential for normal dermal fibroblasts (NFs) 
differentiation, was lost in CWFs. This loss was found to be caused by the loss of CD44-
EGFR co-localisation in CWFs. In CWFs, the EGFR was localised in a perinuclear location 
surrounded by a lipid envelope. Lipid localisation was associated with lysosomal staining 
indicating a possible role of a defective lipid metabolism or defective intracellular protein 
degradation pathways in CWFs.  
This data suggests that the non-classical pathway is the primary pathway responsible for 
the loss of myofibroblast formation. However, there are several factors that may contribute 
to this loss. Future research is required to pin-point the key players leading to aberrant 
protein, HA and lipid localisation in CWFs. 
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CWFs Chronic Wound Fibroblast 
NFs Normal Dermal Fibroblast 
ER Endoplasmic Reticulum 
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2+
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ECL  Enhanced chemiluminescence  
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EEA1  Early endosome antigen 1  
EGF  Epidermal growth factor  
EGFR  Epidermal growth factor receptor  
EMT  Epithelial to mesenchymal transition  
ERK1/2  Extracellular signal-regulated kinase (MAPK)  
FAK  Focal adhesion kinase  
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FGF  Fibroblast growth factor  
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GAPDH  Glyceraldehyde 3-phosphate dehydrogenase  
HA  Hyaluronan 
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HRP  Horseradish peroxidase  
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ICAM-1  Intercellular adhesion molecule-1  
IFNγ  Interferon γ  
IgG  Immunoglobulin  
IL  Interleukin-1  
IL-1β  Interleukin-1β  
IL-8 Interleukin-8 
JAK  Janus kinase  
kDa  Kilodalton  
KS  Keratan sulphate  
mAb  Monoclonal antibody  
MAPK  Mitogen activated protein kinase  
MCP-1  Monocyte chemotactic protein-1  
miR  MicroRNA  
miR-16  MicroRNA-16  
miR-7  MicroRNA-7  
miR-RT  MicroRNA reverse  
MMPs  Matrix metalloproteinases  
mRNA  Messenger RNA  
MSCs  Mesenchymal stem cells 
pAb  Polyclonal antibody  
PAI-1  Plasminogen activator inhibitor-1  
PBS  Phosphate buffered saline  
PDGF  Platlet derived growth factor  
PDL  Population doubling level  
PGs  Proteoglycans  
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PKC  Protein kinase C  
RIPA  Radio-immunoprecipitation assay  
RISC  RNA-induced silencing complex  
RNA  Ribosomal nucleic acid  
RNase  Ribonuclease  
ROS  Reactive oxygen species  
rRNA  Ribosomal RNA  
RT-PCR  Reverse transcription polymerase chain 
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S.D. Standard deviation  
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siRNA  Small interfering RNA  
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STAT  Signal transducer and activator of transcription  
TF  Transcription factor  
TGF-α  Transforming growth factor-α  
TGF-β  Transforming growth factor-β  
TGF-β1  Transforming growth factor-β1  
TGF-βR  Transforming growth factor-β receptor  
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1.1 Dermal Wound Healing Overview 
Skin is an intricate structure composed of the epidermis and dermis, including subcutaneous 
fat. It also has a diverse range of functions including acting as a barrier, protecting from 
harmful UV, pathogens, water evaporation and underlying organs from the external 
environment. Wound healing is an essential highly orchestrated cascade which ensures the 
repair and regeneration of the human body. Dermal wound healing is essential to maintain 
a protective barrier of skin (Lim and Nusse, 2013). When this protective barrier is damaged 
the complex cascade of wound healing develops in four overlapping phases, which have 
distinct biological characteristics: inflammation, proliferation, contraction and remodelling. 
These phases require the interaction of multiple different local and systemic cell types and 
regulatory signalling mediators, such as cytokines and growth factors. The outcome and 
speed of wound healing is dependent on numerous factors, including: moisture, infection, 
hormones, genetics, and cytokines (Buganza Tepole and Kuhl, 2013). If factors such as 
these overcome the wound healing process, it can result in a delayed or failed wound healing 
response. 
1.1.1 Haemostasis 
The haemostasis phase of wound healing is initiated immediately following an injury to limit 
blood loss. The phase results in a clot being formed, vasoconstriction of blood vessels and 
the initial recruitment of immune cells (Buganza Tepole and Kuhl, 2013). When the 
endothelium is damaged, the Extracellular Matrix (ECM) is exposed to the blood stream. 
Plasma Von Willebrand factor (vWF) binds collagen, to which activated platelets bind, 
beginning to form a clot. As the platelets aggregate, they secrete inflammatory factors: 
Interleukin-1β (IL-1β), interleukin-6 (IL-6) and macrophage inflammatory protein-1α (MIP-
1α). The release of blood plasma proteins, such as factor X and V, and thrombin, triggers 
the cleavage of soluble fibrinogen to form insoluble fibrin, which cross-links with collagen 
and platelets to form an insoluble clot. This clot stops loss of blood, but also acts as a scaffold 
for migrating immune cells. Damaged endothelial cells also release thromboxanes causing 
blood vessels to constrict, which assist the platelets to aggregate. Arriving platelets and 
monocytes continue to secrete cytokines and growth factors including, vascular endothelial 
growth factor (VEGF), platelet derived growth factor (PDGF), Epidermal growth factor 
(EGF), transforming growth factor-β (TGF-β), interleukin (IL-1β), which stimulate 
surrounding cells to undergo proliferation and differentiation (Hoffman and Monroe, 2005).  
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1.1.2 Inflammation 
The inflammatory phase is initiated within hours of injury. Neutrophils migrate to the site with 
their numbers peaking around days 1-2, becoming the predominant wound cell. These are 
the first responders of the immune system and are responsible for killing pathogens, by the 
release of proteases and Reactive oxygen species (ROS), phagocytosis of the debris and 
release of soluble mediators that attract other immune cells. Mast cells release histamines 
and other vasoactivators, which stimulate the blood vessels at the wound site to vasodilate 
and become leaky. Leaky blood vessels allow monocytes through, which then differentiate 
into macrophages around day 2 and remain at high levels until day 5. Macrophages are also 
responsible for removing bacteria and debriding dead tissue, they also remove apoptotic 
neutrophils. Macrophages secrete cytokines and growth factors that regulate the 
proliferative phase, stimulating re-epithelialization and the creation of granulation tissue and 
ECM products (Buganza Tepole and Kuhl, 2013, Gonzalez et al., 2016).  
Inflammation is an essential phase of wound healing, but requires strict regulation to ensure 
successful wound healing. Chronic wounds are thought to be trapped within the 
inflammatory phase of wound healing, with prolonged inflammation leading to non-healing. 
The presence of pathogens can extend the inflammatory phase, with most chronic wounds 
being colonized with bacteria. Targeting the inflammatory phase is the current strategy for 
chronic wound treatments, either by the reduction of bacteria or inflammatory cells and their 
pro-inflammatory products (Han and Ceilley, 2017). 
1.1.3 Proliferation 
The proliferative phase commences approx. 2-3 days following injury, as fibroblasts, 
keratinocytes and endothelial cells are stimulated to differentiate, proliferate and migrate, 
leading to the deposition of new ECM, re-epithelialisation and neovascularisation of the 
wound. A major role of the proliferative phase is to stimulate angiogenesis, which is 
imperative to supply oxygen and nutrients for the activity of the proliferative cells. Endothelial 
cells are activated from the inflammatory phase by cytokines and growth factors, such as 
angiogenin, fibroblast growth factor (FGF) and TGF-β, which are secreted by other cells. 
The platelet-fibrin clot also releases growth factors, such as VEGF, PDGF and TGF-β, 
released from de-granulated platelets. These activated endothelial cells initiate vascular 
sprouting, where they lay down a new capillary network, chemotactically led towards the site 
of injury by the hypoxic environment. Matrix metalloproteinases (MMPs) digest the 
basement membrane and ECM, creating a pathway for infiltrating vessels. Once adequate 
tissue perfusion is reached this process reduces (Velnar et al., 2009). 
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The second major role of the proliferative phase is the formation of the granulation tissue by 
the migrating fibroblasts, which become the predominant cell type by day 7. Fibroblasts 
migrate from the surrounding unaffected tissue and from circulating precursors (fibrocytes). 
They adhere to the wound fibronectin and deposit granulation tissue, which is a temporary 
ECM consisting of collagens, glycosaminoglycans (GAGs), elastin, glycoproteins and 
proteoglycans (PGs). The main components being collagen, fibronectin and hyaluronan 
(HA). Collagen type III is the predominant collagen laid down in the granulation tissue. It 
provides tensile strength for the repairing tissue and together with fibronectin, provides a 
network for the adhesion of cells. Type III collagen is later replaced by type I collagen, as 
the granulation tissue is remodelled into mature tissue (Gonzalez et al., 2016). 
1.1.4 Contraction 
Contraction commences at approximately 7 days. It is an essential phase that reduces the 
size of the wound. Without it, the wound would remain open, while excessive contraction 
results in loss of function from scar formation and fibrosis. The cell type responsible for 
contraction is the contractile α-smooth muscle actin (αSMA)-positive myofibroblast, which 
differentiates from resident fibroblasts. Myofibroblasts are attracted toward the wound edges 
by growth factors and fibronectin, where they anchor themselves to the ECM. They attach 
to wound edges and each other via desmosomes, fibronexus, collagen, fibronectin and HA, 
to create a network of myofibroblasts at the wound edge. Once adhesions are made, the 
actin within the myofibroblasts can contract, pulling the wound edges together. The 
contraction phase ends as the granulation tissue begins to be broken down and remodelled. 
This breakdown means a decrease of HA and increase in chrondroitin sulphate GAGs are 
observed, resulting in a decrease in myofibroblast migration and proliferation, triggering the 
apoptosis of the myofibroblasts (Tracy et al., 2016).  
1.1.5 Maturation and Remodelling 
The onset of the maturation phase differs greatly from person to person. It depends on the 
type, size and condition of the wound and also the person’s age and health. The aim of the 
maturation and remodelling phase is the replacement of type III collagen by type I collagen 
with the alignment of the fibres to increase the tensile strength of the tissue to its normal 
state, whilst also removing any redundant cells via apoptosis, along with degradation of HA 
and fibronectin. This phase can last for a year or longer. This phase results in the return of 
the tensile strength of the skin, however will only ever return to approx. 80% strength of the 
original tissue (Gonzalez et al., 2016, Velnar et al., 2009). 
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The presence of granulation tissue allows for epithelial cells to migrate, allowing for re-
epithelialisation of the wound. Basal keratinocytes are the main cell type responsible for re-
epithelialisation, by migrating to the wound edges (Velnar et al., 2009). This migration is 
stimulated by nitric oxide and various growth factors, including TGF-α and hepatocyte 
growth factor (HGF) together with the lack of contact inhibition of the keratinocytes (Werner 
et al., 2007). For the migration to occur, the keratinocytes become flat and elongate to make 
motility easier. Also, they break down the desmosomes and hemidesmosomes that usually 
keep them adhered to the ECM and other cells. They then begin to form pseudopodia 
containing actin filaments that contract, causing the movement of the cells (Thomason et 
al., 2012). Keratinocytes also can debride the tissue and phagocytose bacteria in their path, 
thus removing the scab as they move (Pastar et al., 2014). The mechanism by which they 
dissolve tissue, is to secrete a plasminogen activator, activating plasminogen converting it 
to active plasmin, which along with other proteases digests the scab (Kramer et al., 1995). 
Keratinocytes can only migrate over viable tissue. Therefore, they also secrete collagenases 
and proteases to digest damaged components of the ECM. Keratinocytes continue to 
migrate until they meet, where contact inhibition stimulates them to return to their static form 
and undergo the reverse of the morphological changes they underwent at the beginning 
(Martin and Nunan, 2015).  
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Figure 1.1. Phases of Dermal Wound Healing. (a) Immediately following cutaneous injury, blood elements are released from 
the damaged endothelium. Vasoconstriction follows, in response to factors released. (b) Haemostasis then occurs with the 
coagulation cascade. Platelets aggregate within a fibrin glue.  (c) Platelets release several factors initiating the inflammatory 
phase, these factors include PDGF and TGF-β1. (d) After 48 hr macrophages are the predominant immune cell present. 
Together with other immune cells they remove debris, release growth factors and begin to reorganize the ECM. (e) The 
proliferation phase begins at 72 hr as recruited fibroblasts synthesis collagen. (f) Collagen crosslinking and reorganisation 
occurs for months during the remodelling phase. Image was taken from {Beanes, 2003 #308} 
1.2 The Fibroblast 
Wound healing is a complex process and involves a variety of cell types. The fibroblast is 
the most prevalent cell in the human dermis and is responsible for the speed and efficiency 
of wound healing, the extent of scar formation and wound contraction. The fibroblast is the 
most common cell of connective tissue; it is responsible for tissue metabolism and integrity 
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by synthesising the ECM precursors such as collagens, GAGs, elastin and glycoproteins 
and biochemical mediators such as growth factors and proteases. The fibroblast is 
responsible for the synthesis, degradation and remodelling of the ECM, all important 
processes in wound healing (Tracy et al., 2016), as the ECM determines the physical 
properties of the connective tissue. 
Fibroblasts are derived from primitive mesenchyme; thus they express the intermediate 
filament vimentin. It is possible, however, for other sources to give rise to fibroblasts, such 
as epithelial cells, which can give rise to fibroblasts via a process called epithelial-
mesenchymal transition. The fact that fibroblasts can be derived from a variety of precursors 
emphasises their crucial function in maintaining tissue homeostasis.  
Phenotypically fibroblasts are flat, elongated, having multiple processes, a nucleus having 
two or more nucleoli and a large rough endoplasmic reticulum. Fibroblast shape is regulated 
by actin in their cytoskeleton, which can assemble and disassemble into various sized actin 
filaments. Actin also plays a large role in the migration of fibroblasts. Confluent fibroblasts 
in culture align in parallel clusters, but if they are not confluent they spread out to cover as 
much area as possible. There is no single specific marker for a fibroblast, which complicates 
its identification and role in diseases. The fibroblast cell is extremely plastic. In dermal skin, 
for example, different dermal layers host different subpopulations of fibroblasts, with dermis 
depth having an effect on collagen type I and type III expression and deeper fibroblasts 
expressing reduced quantities of collagenases than those in superficial layers (Tracy et al., 
2016). Fibroblasts are also very malleable cells, with altering function in differing locations 
throughout the body. It is, therefore, essential that we characterise these cells under differing 
conditions, to understand their roles. 
Fibroblast heterogeneity produces functional sub-populations which differ in size, 
morphology, proliferation rates and collagen production. For example, there are three 
identified sub-populations within skin. Two are defined according to their location in the 
dermis - the papillary and reticular dermis - and the third is associated with hair follicles 
(Sorrell and Caplan, 2004). It has been suggested that some pathological conditions are 
caused by a sub-population of fibroblasts that out-compete the others and become the 
dominant fibroblast. An example of this is chronic wound fibroblasts compared to their 
healthy dermal population, aberrantly expressing genes that regulate the ECM, cytoskeleton 
and migration. In the study by Wall et al 2008, chronic wound fibroblasts from different 
patients demonstrated very different proliferative capacity, suggesting a heterogeneous 
wound environment of wounds with the same clinical classification.  
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1.2.1 Role of Fibroblasts in Wound Healing 
The primary role of the fibroblast in skin is to maintain tissue homeostasis. Following an 
injury, however, resident cells and infiltrating inflammatory cells release cytokines that 
activate fibroblasts. Fibroblasts migrate from the wound edge into the provisional matrix 
formed by the fibrin clot. Here, they proliferate and act to restore the ECM. Fibroblasts 
replace the fibrin matrix with granulation tissue made from new ECM components, for 
example fibronectin, HA, collagens and PGs. This granulation tissue allows the infiltration of 
new blood vessels, fibroblasts, inflammatory cells, endothelial cells and myofibroblasts. 
Granulation tissue allows for the re-epithelialization and construction of a primary dermis. 
Once the fibroblasts are situated within this new matrix they are further stimulated to 
differentiate into myofibroblasts, the primary cells involved in the deposition and remodelling 
of the new ECM. Myofibroblasts also initiate the contraction of the wound, decreasing the 
size of the wound by contracting the wound edges into closer proximity (Darby et al., 2014). 
Under normal resting conditions, fibroblasts have no actin associated cell-cell and cell-matrix 
associations and produce only ECM components required for resting turnover of the tissue. 
In this normal state, fibroblasts are under continuing resting tension which allows the 
connective tissue to maintain its shape and integrity. Following injury, however, the ECM is 
continuously being remodelled and the protective structure is lost. Mechanotransduction 
signals are passed through integrins to intracellular focal adhesion complexes and the actin 
cytoskeleton. A stress stimulus signals fibroblast proliferation, increasing their numbers and 
ECM synthesis, which increases the matrix tension and applies more force to the granulation 
tissue (Wang et al., 2001). In response to this mechanical challenge, fibroblasts activate and 
differentiate into proto-myofibroblasts which have a migratory phenotype, expressing only 
β- and γ-cytoplasmic actins (Darby et al., 2014). 
1.2.2 Myofibroblastic Differentiation 
It is possible for myofibroblasts to be formed from numerous different cell types (see Figure 
1.1), however the differentiation process follows a well-documented cascade of events. 
Tissue injury initiates this cascade, which activates fibroblasts initiating the production of 
contractile stress fibres composed of cytoplasmic actins and increase in focal adhesion 
proteins. This intermediate stable phenotype is known as the proto-myofibroblast (Santiago 
et al., 2010, Hinz et al., 2007). Expression of  α-smooth muscle actin (αSMA) in stress fibres 
is the hallmark for full differentiation into a contractile myofibroblast (Rohr, 2009).  
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Myofibroblasts are specialised cells responsible for wound closure, via exerting contractile 
forces on their microenvironment, remodelling the tissue ECM and the tissue. Aberrant 
myofibroblast activation can result in the development of pathological conditions, such as 
fibrosis, disease progression, cancer invasiveness and non-healing wounds. Myofibroblasts 
are the primary cells responsible for scar tissue formation and wound closure. But, excessive 
activation can lead to impaired organ function by excessive scarring. Examples of such 
conditions include: hypertophic scars, scleroderma and Dupuytren’s disease and heart and 
kidney fibrosis. Contrasting this failed-activation of myofibroblasts leads to non-healing 
chronic wounds, such as venous, arterial, diabetic and pressure ulcers (Darby et al., 2014).  
Morphologically characteristics of myofibroblasts include a flattened, irregular shape with 
clear cell-matrix interactions and intracellular gap junctions. Myofibroblasts have structural 
properties between those of a fibroblasts and a smooth muscle cell. They express smooth 
muscle cell associated proteins, such as desmin, calponin and smooth muscle myosin 
(Tomasek et al., 2002). The most reliable and used markers for myofibroblasts include 
increased expression of specialized ECM proteins, like the EDA splice variant of fibronectin, 
and αSMA. α-SMA positive myofibroblasts have been shown to have 2-fold stronger 
contractile activity, compared to resting fibroblasts (Hinz et al., 2001). The mechanism 
responsible for this differentiation has been shown to be TGF-β dependent. Use of a TGF-
β neutralizing monoclonal antibody has shown to decrease scarring induction in the dermis 
(Shah et al., 1994). The action of TGF-β is dependent on local presence of cellular 
fibronectin splice variant EDA. EDA-fibronectin is produced by fibroblasts in the initial stages 
of wound healing with collagen type I. It has been shown that absence of either TGF-β or 
EDA-fibronectin, allows fibroblasts to differentiate to proto-myofibroblasts only (Muro et al., 
2008). 
Myofibroblasts are responsible for the remodelling and deposition of new ECM, the 
contraction of the granulation tissue and ultimately wound closure. They are also responsible 
for the subsequent wound contracture and collagen rich scar formation. They produce 
fibronectin, and later collagen type I, III, elastin, GAGs and PGs. Myofibroblasts can also 
secrete enzymes, such as MMPs and tissue inhibitors of metalloproteinase (TIMPs) of the 
ECM, which can alter ECM composition. Myofibroblasts can also function as immune cells, 
releasing chemokines, growth factors and cytokines such as monocyte chemotactic protein-
1 (MCP-1), IL -1, -6, -8, HGF, TGF-β and EGF (Darby et al., 2014). 
Both fibroblasts and myofibroblasts contribute to wound repair. Myofibroblasts however are 
only present within the wound for a finite period whilst contraction is occurring. Myofibroblast 
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differentiation is stopped once the wound is fully contracted and re-epithelialized. Following 
this few α-SMA positive myofibroblasts are found present in the wound. It is unclear how 
myofibroblasts numbers are reduced in the wound, whether they undergo apoptosis and 
therefore are terminally differentiated, or whether they revert back to fibroblasts and 
therefore are only an alternative phenotype. The signal for this remains unclear, however, 
the reconstruction of the ECM and the subsequent reduction in mechanical stress has been 
shown to be a promoter of apoptosis and myofibroblast removal (Darby et al., 2014).    
 
Figure 1.2. Myofibroblasts can be derived from a number of different cell types including fibroblasts, smooth muscle cells 
(SMC), epithelial cells, via epithelial to mesenchymal transition (EMT), endothelial cells, via endothelial to mesenchymal 
transition (EndMT) and fibrocytes. With stimuli of mechanical tension or TGF-β1, fibroblasts differentiate into 
protomyofibroblasts, with the production of cytoplasmic actins. Furthermore, mechanical tension, TGF-β1, fibronectin EDA, 
Hyaluronan Synthase 2 (HAS2), CD44 / EGFR stimuli drives protomyofibroblasts towards terminal differentiated 
myofibroblasts, expressing α-SMA. Image was adapted from (Falke et al., 2015, van den Borne et al., 2010) 
1.3 Chronic (Non-Healing) Wounds 
Chronic wounds are clinically described as skin wounds that fail to progress through the 
healing process in a timely manner, often described as detained in the inflammatory phase 
of wound healing. These wounds may never heal and therefore place high emotional and 
physical stress on the patients. Their chronic nature and the necessary duration of treatment 
places a huge financial burden on healthcare providers; this burden is expected to increase 
with the aging population and the prevalence of this wound type (Frykberg and Banks, 2015).  
Chronic wounds can be classified into 3 subgroups, vascular ulcer (e.g. venous and arterial 
ulcers), diabetic ulcer and pressure ulcers. All three share common features, including 
prolonged inflammation, recurring bacterial infections and the imbalance of ECM 
homeostasis, leaning towards ECM degradation rather than synthesis. However, all three 
ulcer types have different underlying pathophysiology.  
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Figure 1.3. Images are representative of the 3 subgroups of non-healing chronic wounds. Venous Ulcer (A) and (B) Arterial 
ulcer, both can be described as vascular ulcers. Diabetic ulcer (C) and Pressure Ulcer (D) (Larouche et al., 2018).  
Venous ulceration is caused by sustained venous hypertension, resulting from venous 
insufficiency. 10% of the western population have vascular incompetence, with 0.2% 
developing ulceration, with 70% recurrence in those with contributing risk factors such as 
obesity or suffering deep vein thrombosis (Grey et al., 2006). Arterial ulceration is caused 
by reduced blood supply to the lower limbs, the most common cause of which being 
atherosclerosis (Grey et al., 2006). Diabetic ulcers are a complication of diabetes mellitus, 
characterised by excessive inflammatory response. These ulcers have multiple contributory 
factors to their pathology including, cutaneous microcirculation deficiencies, oxidative stress 
and altered inflammatory response, which lead to dysregulated immune response and 
decrease in ECM turnover (Garcia-Honduvilla et al., 2018). Increased fibroblast apoptosis 
has been reported in this wound type, due to glucose toxicity (Berlanga-Acosta et al., 2013). 
The primary cause of pressure ulcers has been identified as ischemia reperfusion. This 
damages endothelial cells, producing an oxidative stress and a pro-inflammatory response, 
which prevents normal wound healing (Motegi et al., 2017). All types of ulcers last on 
average 12 to 13 months and also recur in up to 60% to 70% of patients. This recurrence is 
thought to be due to the co-morbidities of the patients that lead to poor circulation, 
neuropathy and reduced mobility (Frykberg and Banks, 2015). 
The pathophysiology of all types of chronic wounds can be attributed to the failure to 
progress past the inflammatory phase of wound healing, resulting in a negative loop, caused 
by increasing levels of pro-inflammatory cytokines, proteases, reactive oxygen species 
(ROS) and senescent cells, as well as persistent infections and deficiency of stem cells that 
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are often dysfunctional (Frykberg and Banks, 2015). The constant influx and stimulation of 
immune cells result in the pro-inflammatory cascade becoming amplified and persistent. In 
acute wounds proteases such as MMPs are regulated by their inhibitors, such as tissue 
inhibitor of metalloproteinases (TIMPs). In chronic wounds proteases and MMPs levels 
exceed that of their inhibitors leading to degradation of the ECM. This proteolytic destruction 
of the ECM prevents the progression into the proliferative phase of wound healing and also 
attracts more inflammatory cells, therefore amplifying the inflammation cycle. The influx of 
inflammatory cells increases the presence of ROS in the wound environment to toxic levels. 
In acute wound healing ROS are responsible for defence against infiltrating microorganisms. 
In chronic wounds, the constant influx of inflammatory cells creates a ROS, rich hypoxic 
environment. The aberrant levels of ROS further stimulate the degradation of the ECM by 
causing DNA damage, gene dysregulation, cell death and a hostile proteolytic environment 
(Dhall et al., 2014). The db/db mouse model of type II diabetes with impaired wound healing 
has been associated with the reduction of glutathione (GSH), resulting in reduced 
glutathione peroxidase (GPx) activity and thus increase in ROS (Mudge et al., 2002). The 
use of strong anti-oxidants has been shown in animal models to reduce the ROS to normal 
levels, thus reducing the chronicity of the wound (Dhall et al., 2014).  
It has previously been shown that chronic wound cells are characterized by increased 
senescence with decreased proliferation and secretory capacities, making them 
unresponsive to wound healing signals. It has also been reported that human dermal chronic 
wound fibroblasts have early induction of senescence in a telomerase-independent manner 
(Wall et al., 2008). Together with fibroblasts, chronic wounds have been shown to include 
senescent keratinocyte, endothelial and macrophage cell populations. The early 
senescence of cells in chronic wounds has been attributed to a decreased ability to 
withstand oxidative stress produced by the ROS (Wall et al., 2008). 
Mesenchymal stem cells (MSCs) play an important role in acute wound healing. Recruited 
from the circulatory system towards the site of injury, they are responsible for the remodelling 
of the new microvasculature. In diabetic mice, stem cells have been shown to be deficient 
and defective (Cianfarani et al., 2013). Circulating and/or resident MSC’s are also prominent 
pre-cursors of the wound healing cell type, the myofibroblast, in a variety of organs following 
a response to injury (Bochaton-Piallat et al., 2016). Patients with chronic wounds, therefore, 
may require deliver of healthy donor MSC’s to overcome this deficiency. 
Fibroblasts play a key role in wound healing, being responsible for ECM regulation, such as 
fibronectin and collagen production, but also wound contraction via their differentiation into 
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contractile myofibroblasts. In chronic wounds, an increase in degradative proteases results 
in a reduction in matrix proteins, such as fibronectin (Cha et al., 2008). Phenotypic changes 
in fibroblasts are also observed, with altered morphological appearance, decreased 
proliferation and unresponsiveness to certain cytokines and growth factors, such as PDGF 
and TGF-β1 (Kim et al., 2003). TGF-β1 in acute healing is responsible for the differentiation 
of fibroblasts into myofibroblasts and thus wound contracture. Wound contraction is absent 
in chronic wounds and has been considered a major cause of non-healing. The 
unresponsiveness of the fibroblast to TGF-β1 signalling has been attributed to the toxic 
hypoxic environment of the chronic wound, which has been shown to markedly reduce α-
SMA positive myofibroblasts in in-vitro studies (Sen and Roy, 2010, Van De Water et al., 
2013). This lack of myofibroblast differentiation is an important and understudied area of 
chronic wound biology, which I will address in this thesis. 
 
Figure 1.4. Chronic wounds are non-healing wounds trapped in a self-perpetuating cycle. Three types of chronic wounds exist. 
All types begin with ulceration caused by damage and can become infected. Wound healing cascade causes the induction of 
an inflammatory response which becomes chronic. This leads to an imbalance between ECM production and degradation. 
Cells become unresponsive and the wound becomes chronic causing pain. The cycle will continue to develop the ulcer without 
any medical intervention. There are numerous host risk factors that increase the prevalence of chronic wounds. Image was 
adapted from (Martin and Nunan, 2015, Shechter and Schwartz, 2013) 
1.3.1. Bacterial colonization in Chronic Wounds 
Bacterial overload is another major risk factor that determines whether a wound is in danger 
of becoming non-healing. The wounds microenvironment makes it ideal for bacteria to thrive 
as complex communities known as biofilms. Mature biofilms can develop as early as within 
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10 hours and persist indefinitely while the wound remains open. Biofilms are identifiable in 
up to 60% of chronic wounds but only 6% of acute wounds (Omar et al., 2017).   
Biofilms are enclosed in a exopolysaccharide (EPS) and are less metabolically active than 
their free-living counter parts, making them more resistant to destruction by the hosts 
immune system and highly resistant to antimicrobial treatment (Clinton and Carter, 2015). 
Many classes of antibiotics are only effective against actively dividing cells be targeting 
peptidoglycan produced in the cell wall, protein synthesis or DNA replication (Clinton and 
Carter, 2015).  Biofilms are polymicrobial and may consist of not only bacterial cells but also 
fungi, viruses, proteins and other biogenic factors, requiring a complex multi treatment 
approach to eradicate. Staphylococcus aureus, Enterococcus faecalis, Psuedomonas 
aeruginosa, coagulase-negative staphylococci are the most common cultured species in 
chronic wounds (Gjodsbol et al., 2006). Bacterial persistence in these wounds has been 
proposed due to the extreme tolerance of the bacteria to antibiotics, allowing biofilms to 
develop and the granulation tissue environment in the wound bed, hampering the 
mechanical clearance of the invading bacteria. Bacteria such as Pseudomonas aeruginosa 
can also produce rhamnolipids that efficiently shield from the phagocytic activity of 
polymorphonuclear leukocytes (PMNs). This elimination might contribute to the high levels 
of proteases and MMP’s found in the wound, which are released from PMN by cell lysis 
(Bjarnsholt et al., 2008). It is also thought that they depend upon the hosts immune response 
for nutrients and therefore contribute to the isolation of the healing cascade in the 
inflammatory phase (Costerton et al., 1999). Bacteria express virulence factors that 
upregulate pro-inflammatory cytokines, ROS and MMP’s while down regulating TIMPs. In 
chronic wounds, biofilms have been shown to disrupt epidermal barrier function by 
compromising tight junctions resulting in leaky skin measured by water loss (Roy et al., 
2014).  
A vital step in restoring wound healing in infected chronic wounds is debridement of infected 
and necrotic tissue. EPS promotes strong attachment of the biofilm to the wound bed and 
makes full debridement difficult. Even leaving a small amount of cells remaining from the 
biofilm allows easy regeneration, leading to a high rate of recurrent infections in chronic 
wounds (Clinton and Carter, 2015). 
1.4 Extracellular Matrix (ECM) 
The ECM of skin can be divided into fibre-forming structural components, which form a rigid 
three-dimensional framework of rigid proteins, giving structural strength, and non-fibre 
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forming components, which are mostly charged molecules (PGs and GAGs) giving a 
dynamic osmotic space (Tracy et al., 2016). The most prevalent fibre-forming protein is 
collagen representing 77% of the total fibre-forming proteins. The others include fibronectin, 
vitronectin, elastin and fibrillin, which all contribute to the structure of the ECM (Frantz et al., 
2010). Other structural proteins include glycoproteins such as laminin, which contributes to 
the structure of the basement membrane and intergrins which are cell membrane receptors 
for the ECM components. Both contribute to the structure of the cell during adhesion and 
migration. The most abundant non fibre-forming molecules are HA, decorin, versican and 
dermatopontin. Their role is to fill space in the ECM; they are negatively charged and 
hydrophilic. This characteristic allows them to hydrate the tissue, act as a buffer and help 
disperse molecules throughout the ECM (Frantz et al., 2010).  
1.4.1 ECM Turnover 
Tissue homeostasis is regulated by tissue remodelling enzymes, MMPs and adamalysins 
(ADAMs), proteases responsible for the degradation and remodelling of the ECM. They also 
have a role in regulation of cell signalling pathways in normal and disease states, such as 
chronic wounds. An imbalance of their production can lead to a progressive ECM 
degradation and thus non-healing (Bonnans et al., 2014). 
MMPs are a large family of enzymes produced by both inflammatory and resident cells, that 
all have a metal zinc ion at their active site. The differences between MMPs lies in the 
diversity of the substrates they target such as collagens, gelatin and PGs. Different MMPs 
may act on different parts of the same protein (Page-McCaw et al., 2007). Together as a 
family, they all act to breakdown proteins compromising the ECM. They are, therefore, very 
important in ECM turnover during tissue homeostasis and in disease states, such as chronic 
wounds. It has been found that an increase in MMP-8 targets the breakdown of collagen 
type I in chronic wounds (Danielsen et al., 2011). Another, MMP-13, not usually expressed 
by normal dermal fibroblasts, has been found to be expressed by chronic wound fibroblasts. 
MMP-13 was found to be play a role in granulation tissue maturation, inflammation, 
angiogenesis, migration and proliferation (Toriseva et al., 2012). MMP-13 knockout mice 
also demonstrated delayed organisation of myofibroblasts, indicating its role in regulating 
myofibroblast formation (Toriseva et al., 2012). 
The ADAM family of peptidase proteins also has a key role in the degradation of ECM 
proteins; they can also process membrane anchored growth factors and cytokines in a 
process of ‘ectodomain shedding’, thereby acting as post-translational regulators of these 
signalling factors (Edwards et al., 2008). Included in these are the pro-inflammatory 
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cytokine, TNF-α and all ligands of the epidermal growth factor receptor (EGFR). The 
expression of ADAMs has been shown to have a direct role in wound healing. Both ADAM-
9 and ADAM-12 knockout mice have accelerated wound repair mediated by increased 
migration of keratinocytes. ADAM-12 expression has also been reported in chronic wounds, 
indicating its possible role in preventing wound healing (Mauch et al., 2010, Harsha et al., 
2008).  
Hyaluronidases (HYALs) are a family of 6 enzymes that degrade HA, an important 
constituent of the ECM produced by fibroblasts and myofibroblasts. The main 3 family 
members are HYAL-1, -2 and -3. Hyaluronidase act by hydrolysing the disaccharides at 
hexosaminic β (1-4) linkages. The size of the HA fragments is dependent on the HYAL (Stern 
and Jedrzejas, 2006). Additional degradation can also occur by ROS (Buhren et al., 2016). 
HA fragments have size dependent effects, with high molecular weight HA associated as an 
anti-inflammatory and low molecular weight HA being pro-inflammatory. Therefore, 
regulation of these enzymes is key to successful wound healing (Buhren et al., 2016). An 
example includes the use of bovine testis HYAL to improve wound healing, through 
increased cell numbers, resulting in increased migration and proliferation of fibroblasts and 
keratinocytes, leading to improved re-epithelialization and wound closure (Fronza et al., 
2014). 
1.4.2 Collagens 
Collagen is the most abundant protein in the human body, having the vital role of providing 
tensile strength to the ECM. There are 28 members of the collagens family, the dermis 
containing of only a few (Kadler et al., 2007). The predominant collagen in skin is type I 
collagen, followed by type III. Collagen type V is found in the basement membrane of skin, 
and we also know that collagen types IV, VII and XVII play an important role in the dermis 
(van der Rest et al., 1991).  
The first type of collagens is the fibrillary collagens consisting of types I, III and V in the 
dermis. Collagen fibrils form a scaffold which allows the adhesion, chemotaxis and migration 
of cells. The fibrils form in different orientation giving diffuse strength across the tissue. 
Collagen expression is controlled via feedback from the stress in the tissue and via 
regulation by other collagens (Gelse et al., 2003). The second type of collagens found in 
skin is the non-fibrillar collagens, including types IV, VI, VII and XIV. They function by 
creating interconnecting nets of collagen connecting cells to the basement membrane, and 
they can aid in organising the formation of the fibrillary collagens (Gelse et al., 2003). Type 
VI collagen has been shown to promote fibroblast growth and inhibit their apoptosis. It is, 
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therefore, found to be upregulated for months after a wound (Theocharidis et al., 2015). 
Type VII assists with fibroblast migration and regulates cytokine expression, with topical 
application in mice showed a decrease of fibrogenic TGF-β1 and αSMA, whilst increasing 
anti-fibrogenic TGF-β3 (Wang et al., 2013). 
1.4.3 Glycoproteins 
Glycoproteins are proteins that have an oligosaccharide chain bound, via the process of 
glycosylation. Glycoproteins are matrix adhesion molecules, which include laminin, entactin, 
thrombospondin and fibronectin. Fibronectin is a high molecular weight glycoprotein, which 
mediates a wide variety of cellular interactions, having a regulatory role in cell adhesion, 
proliferation and migration (Pankov and Yamada, 2002, Tracy et al., 2016). On the basis of 
solubility, Fibronectin found in mammalian cells, can be subdivided into two forms: the first 
is a soluble plasma form found in the blood and produced by hepatocytes in the liver. The 
second is the less-soluble ECM type, which is secreted primarily by fibroblasts (Pankov and 
Yamada, 2002). EDA-fibronectin (splice variant of fibronectin) expression has been shown 
to increase in response to TGF-β1 (Shinde et al., 2015), showing fibronectin has a role in 
myofibroblast differentiation and therefore can be used as a marker.  
1.4.4 Proteoglycans 
Proteoglycans (PG) are proteins, heavily glycosylated, via the covalent binding of 1 or more 
glycosaminoglycan (GAG) chains to the protein core. The type and function of PGs are 
characterised by their size and GAG chain. The overall function of PGs is to fill space in the 
ECM by forming large complexes with other PG or other matrix components such as the 
fibrillar collagens (Kirkpatrick and Selleck, 2007). Proteoglycans have been found to have 
effects on proliferation, cell signalling and growth factor activity (Kirkpatrick and Selleck, 
2007). PGs have a distinct spatial localisation in the skin, having essential roles on tissue’s 
development, structure and wound healing. Versican is a large PG, with widespread 
distribution throughout the skin. Versican has a predominantly structural role in the ECM, 
however is capable of influencing cellular behaviour via interactions with growth factors such 
as epidermal growth factor (EGF) (Du et al., 2010). Decorin, a collagen associated PGs and 
Biglycan, a cell associated PG, are also important in skin homeostasis and wound healing. 
These two PGs are part of the small leucine rich PGs (SLRPs), which are expressed 
predominantly in the skin compared to other tissues throughout the body (Iozzo and 
Schaefer, 2010). SLRPs are also capable of interacting with TGF-β1, controlling it’s 
bioavailability and therefore skin fibrosis (Smith and Melrose, 2015).  
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1.4.5 Glycosaminoglycans 
GAGs are long unbranched polysaccharides made up or repeating disaccharide units. The 
repeating unit (with the exception of keratin sulphate (KS)) consists of an amino sugar (N-
acetylglucosamie or N-acetylgalactosamine), along with a uronic sugar (glucuronic acid or 
iduronic acid) or galactose. These long chains make them polar molecules and so 
hydrophilic; they can therefore fill space and act as a sponge or lubricant (Afratis et al., 
2012). 
 
Figure 1.5. The representative structures of disaccharides units of GAGs are shown. Repeating disaccharide units one is an 
amino sugar (D-glucosamine or D-galactosamine) and the other is typically a uronic acid (D-glucuronic acid or iduronic acid). 
Each monosaccharide can be N- or O- sulphated (Wang et al., 2017).  
There is a high level of heterogeneity in the molecular weight of GAGs, since GAG synthesis 
is dynamically modified by enzymes. There are four groups of GAGs based on their core 
disaccharide. The first two: heparin/heparan sulphate (HSGAGs) and chrondroitin/dermatan 
sulphate (CSGAGs) GAGs, are commonly synthesised in the golgi. The third group is the 
keratans which differ since they can by modified via O-linked or N-linked glycosylation. The 
fourth group is HA, which is not synthesised in the golgi, but by integral membrane HA 
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synthases (HAS). These four groups of GAGs differ in shape, which consequently effects 
their function (Prydz, 2015). 
GAG functions differ greatly. HSGAGs have a role in organizing the ECM through binding 
other matrix molecules. CSGAGs are located in the extracellular space at the cell membrane 
and also intracellularly; they are therefore capable of regulating multiple cell processes 
including proliferation, apoptosis, migration, adhesion and invasion (Afratis et al., 2012).  KS 
GAGs have distinct roles in hydration, and are an anti-adhesive. KS hydration function is 
specifically important in tissues, such as the cornea, where altered levels of KS are found 
during macular cornea dystrophy, resulting in loss of hydration and a hazy cornea (Ho et al., 
2014).  
1.5 Hyaluronan 
HA is a high molecular weight anionic, non-sulphated GAG. It is a major component of 
synovial and soft tissues. 50% of the body’s HA is found in the skin tissue. HA content 
decreases with age, resulting in the loss of moisture and laxity of skin (Buhren et al., 2016).  
 
Figure 1.6. The molecular structure of HA, a polymer made of repeated sequences of disaccharides N-acetylglucosamine and 
D-glucuronic acid, linked together by alternating β-1,2 and β-1,3 glycosidic bonds. 
HA also has interactions with matrix and cell surface receptors. Within the matrix HA binds 
HA binding proteins (HABP) (hyaladherins) e.g. hyaluronectin glial HABP, inter-α-trypsin 
inhibitor (IαI). Cell surface receptors include CD44, which has been linked to tumour 
progression and regulation of cell interactions and RHAMM (receptor for hyaluronan-
mediated motility) (Day and Prestwich, 2002). Fibroblasts, myofibroblasts, chondrocytes, 
mesothelial and certain stem cells are known to be surrounded by a pericellular HA coat, 
which is thought to protect the cells from bacteria and matrix molecules. Stem cells for 
example are found in their niche rich in HA, which may shield the stem cells from growth 
factors and thus, differentiation (Qu et al., 2014).  
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1.5.1 Hyaluronan synthesis 
HA has distinct biological functions that are determined, in part, by molecular weight for 
successful progression through the wound healing stages (Rayahin et al., 2015, Trabucchi 
et al., 2002). HA is synthesised by three membrane bound enzymes, HAS1, HAS2 and 
HAS3, of which HAS2 and HAS3 are the primary synthases functional in the dermis. Native 
HA can have a molecular weight as large as 2 x 104 kDa, but is rapidly cleaved into fragments 
ranging from 2 to 25,000 disaccharides by several mechanisms including HYAL activity 
(Reed et al., 2013). HA produced varies by cell type and hyaluronan synthase (HAS) 
isoenzyme. It is generally thought that high molecular weight HA, approx. 1 x 103 kDa and 
above inhibits proliferation and migration, and low molecular weight HA, approx. 3-300 kDa, 
promotes proliferation, migration and is pro-inflammatory. Very low molecular weight HA has 
also been connected with a reduction in CWFs proliferation (Ferguson et al., 2011).  
HAS isoenzymes in mammals are controlled by well-conserved genes with a high degree of 
homology in their amino acid sequence. But the genes coding for them are located on 
different chromosomes in humans; HAS1 on Chr 19q13.4, HAS2 Chr 8q24.12 and HAS3 
Chr 16q22.1. All three proteins contain seven membrane spanning regions, two at the N-
terminal and five at the C-terminal and a large cytoplasmic loop containing the 
glycosyltransferase catalytic site, with polymerization of HA occurring in the inner side of the 
plasma membrane (Itano and Kimata, 2002). Each HAS protein alone is capable of HA 
synthesis. It is thought, however, that each synthase is responsible for the production of 
different molecular weight HA. Each HAS differs in its ability to synthesis matrix; for example, 
it has been well-reported that HAS1 produces a smaller pericellular coat than HAS2 and 
HAS3. This is thought to be due to their differing half-life of activity and binding affinity, with 
HAS1 having a lower binding affinity and lower half-life. HAS1, therefore has a higher 
turnover and cannot retain the growing HA chain on the surface. Interestingly, both HAS1 
and HAS3 have been associated with the production of low molecular weight HA, while 
HAS2 produced high molecular weight HA. The idea that each HAS synthase has different 
enzymatic properties has been attributed to the transcriptional and post-transcriptional 
regulation of the individual HAS genes, which varies in the context of tissue type and stage 
of development. Increased transcriptional levels have been linked to increase HA production 
stimulated by growth factors and cytokines (Itano and Kimata, 2002). This subtly indicates 
that the regulation of HA biosynthesis by mammalian HAS proteins may be multifaceted, 
involving enzymatic properties and both transcriptional and posttranscriptional regulation 
(Itano and Kimata, 2002). 
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HAS2 has been long established as the primary HAS isoform active in dermal wound 
healing. Knockout mice of HAS2 also resulted in lethality, demonstrating it is essential for 
life. Knockout HAS1 or HAS3 mice did not show any phenotypic effects in normal conditions. 
Double knockout HAS1 and HAS3, however, leads to enhanced inflammation and 
accelerated wound healing (Siiskonen et al., 2015). These isoenzymes may also form homo- 
and hetero-meric complexes with each other. It has been shown that HAS2 can form 
complexes, such as HAS2-HAS1, HAS2-HAS2 and HAS2-HAS3. Heteromeric complexes 
formed with HAS1 reduced the synthesis of HA, suggesting functional co-operation and 
regulation of the iso-enzymes (Bart et al., 2015).  
HASs are membrane proteins located the cytoplasmic side of the plasma membrane. HA 
differs from other complex disaccharides, since they are not synthesised in the endoplasmic 
reticulum and completed in the golgi, but synthesised on the membrane by HAS. It has been 
recently described that HAS2 and HAS3 travel through the ER golgi, plasma membrane and 
endocytic vesicles. HAS1 has also been shown to become co-translationally inserted into 
the ER and travel through the golgi (Rilla et al., 2005).  
It has been proposed that HASs secrete extracellular HA, via the creation of an intra-protein 
lipid-pore, through which a HA-UDP chain is translocated continuously. HAS contains 
multiple transmembrane domains and its activity is regulated by / dependent on a lipid 
environment. Cholesterol is a major component in the plasma membrane, playing a role in 
membrane fluidity and architecture. Cholesterol rich micro domains play a role in 
optimization of enzyme activity and formation of ordered platforms for assembly of cell 
signalling molecules (Simons and Ikonen, 1997). This indicates that HAS enzyme activity 
might be modulated by the same way. However, to date research has only shown that HAS 
activity can be modulated by the cholesterol environment in a post-translational manner 
(Ontong et al., 2014). Purified HASs have shown to have low activity without lipids and are 
activated ~10-fold by exogenous phospholipids. Manipulation of plasma membrane 
cholesterol content in different cell types causes a decrease in HA production. Modulation 
of cholesterol might also serve to decrease intracellular synthesis, which could be 
detrimental to many cellular pathways and functions if in excess (Weigel, 2015). Multiple 
mechanisms have been suggested as to why cholesterol might affect HAS activity. One 
suggesting that cholesterol is required for GlcNAc transferase enzymes, producing GlcNAc 
for HA synthesis, may be structurally stabilized in a cholesterol rich environment (Ontong et 
al., 2014). The second it that HAS2 activity is regulated by its dimerization and therefore 
cholesterol might affect its dimerization status. This may be made possible by cholesterol 
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regulating membrane fluidity, with a richer cholesterol environment resulting in reduced 
membrane fluidity and therefore increased HAS activity (Ontong et al., 2014).  This has 
previously been shown to have this effect on NA+ and K+-ATPase enzymes, with a reduced 
membrane fluidity leading to a reduction in their activity (Bookstein et al., 1997). HAS1 differs 
from the other two isoenzymes, since only a small pool of HAS1 protein is located on or near 
the plasma membrane and it has an intracellular localisation (Siiskonen et al., 2015). This 
suggests that cholesterol regulation of the HAS enzymes by cholesterol, may be different 
dependent on their location in the cell. 
1.6 Immune Regulation of Dermal Wound Healing 
The immune system plays a central role in orchestrating the wound healing process and 
has therefore been an attractive process to target to promote tissue regeneration. The 
immune response contributes to wound healing via multiple mechanisms. For example, 
mobilizing tissue resident progenitor cells, promoting cell differentiation, increasing ECM 
deposition, stimulating growth factor and cytokine secretion and promoting angiogenesis. 
Failure of one or many of these processes can cause wound pathologies, such as chronic 
wounds or scar formation. Chronic wounds are often described having associated 
persistent infections and microbial films, which result in a prolonged, exacerbated and 
dysregulated immune and inflammatory response. The result of this are that the wounds 
are trapped within the inflammatory phase of wound healing. Many of the mechanisms 
through which immune cells act during wound healing are still unknown. Elucidating these 
pathways may aid in the development of novel strategies to promote wound healing.  
1.6.1. The Role of the Immune System in Acute Wound Healing 
Following injury, the wound healing cascade is initiated to restore tissue homeostasis. The 
wound healing cascade is typically divided into 5 phases: haemostasis, inflammation, 
proliferation, contraction, and maturation and remodelling. All 5 phases are regulated by 
various stimuli, of which the immune system plays an integral role.  
The innate immune system is considered the first line of defence against infection, 
involved in the initiation of the inflammatory response. The rapid response of the innate 
immune system is essential to eliminate the spread of infection and restore tissue 
homeostasis. This non-specific reaction of this system relies on recognition of highly 
conserved structures of invading microorganisms, pathogen-associated molecular patterns 
(PAMPs), or damage-associated molecular patterns (DAMPs). Known PAMPs include: 
bacterial lipopolysaccharides, lipopeptides, pepdidoglycan, bacterial DNA and double 
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stranded RNA, and known DAMPs include: heat shock proteins, DNA, inflammation and 
necrotic cell death (Strbo et al., 2014). These are recognised by a class of receptors called 
pattern recognition receptors (PRRs), which are expressed on antigen-presenting cells 
and immune cells. The most well characterised PPR is the Toll-like receptors (TLRs), 
which upon activation by binding of a PAMP or DAMP, stimulate the release of cytokines, 
such as IL-1, IL-6, IL-8, IL-12 and TNF-α which promote the migration of inflammatory cells 
to the site of injury (Strbo et al., 2014). The first of these cells recruited to the site of injury 
is the neutrophil, facilitated by the expression of TLRs on their surface (Prince et al., 
2011). TLR activation on neutrophils leads to the generation of: ROS, antimicrobial 
peptides and anti-microbial proteases, cytokine and growth factor production, increased 
cell survival and phagocytosis of invading pathogens with the use of neutrophil 
extracellular traps (NETs) (Larouche et al., 2018). If this signalling becomes dysregulated 
it can lead to chronic inflammation and non-healing (Prince et al., 2011). Neutrophil 
elastase has a direct role in stimulating fibroblast proliferation and differentiation into 
contractile myofibroblasts, with neutrophil elastase knockout mice displaying reduced 
myofibroblast formation (Gregory et al., 2015). Secreted cytokines and growth factors are 
both chemotactic for inflammatory cells, and promote proliferation of fibroblasts, 
keratinocytes and endothelial cells (Larouche et al., 2018). This secretion also signals 
neutrophil-mediated monocyte recruitment, the next innate immunity cell type essential for 
acute wound healing (Larouche et al., 2018).  
Monocytes differentiate into mature macrophages, which are regarded as one of the most 
abundant inflammatory cell types during all stages of wound healing, remaining at the site 
for several weeks post injury (Willenborg and Eming, 2014). Macrophages primary role 
during wound healing is to clear cellular debris and necrotic tissue, secondly find and 
destroy invading pathogens and finally synthesise numerous growth factors which 
stimulate tissue regeneration (Willenborg and Eming, 2014). It has been reported that 
following the inflammatory phase of wound healing at the initiation of the prolifaratory 
phase, macrophages transition from a pro-inflammatory state (M1 state) into an anti-
inflammatory state (M2 state). M2 macrophages are capable of secreting anti-inflammatory 
cytokines such as TGF-β1, promoting ECM synthesis and wound contraction (Larouche et 
al., 2018). The different roles that macrophages play at different phases of wound healing 
has been shown, with depletion of early stage macrophages resulting in decreased scar 
formation, mid stage macrophages resulting in sever haemorrhage, while depletion of late 
stage macrophage did not have significantly impact the outcome (Lucas et al., 2010). Loss 
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of macrophages has also been directly linked to impaired wound contracture through the 
loss of myofibroblast formation (Goren et al., 2009).  
The adaptive immune system also plays an integral role in tissue repair and homeostasis, 
with T lymphocytes (T cells) being critical for tissue remodelling and resolution of 
inflammation. T cells are recruited to the site of injury via the secretion of IFN-γ from 
macrophages. There are multiple different types of T cells, each with differential 
mechanisms that contribute to wound healing. Native γδT cells have been shown to 
stimulate keratinocyte proliferation via the secretion of various growth factors, such as 
FGF-7 and FGF-10. γδT cells have been shown to have an attenuated response in chronic 
wound model, indicating that these cells may also contribute to non-healing in chronic 
wounds (Xu et al., 2017, Larouche et al., 2018). CD4 and CD69 positive T cells have been 
shown to contribute to the initial pro-inflammatory wound environment, with αβ T cells 
capable of regulating this response with an anti-inflammatory response (Rani and 
Schwacha, 2017). Natural killer T (NKT) cells have also been shown to contribute to early 
wound repair, with the knockout NKT mice showing significantly accelerated wound 
closure, by regulating local production of TGF-β1 and collagen deposition (Schneider et 
al., 2011). 
1.6.2. The Immune System and Chronic Wounds 
It is well established that the highly coordinated wound healing cascade is halted in the 
inflammatory phase in chronic wounds, caused by an imbalance between pro- and anti-
inflammatory signals. Excess neutrophils at the wound site can lead to an overproduction 
of ROS. ROS can directly damage the ECM and cell membranes leading to premature 
cellular senescence. ROS can also activate the proteases and inactivate protease 
inhibitors (Wlaschek and Scharffetter-Kochanek, 2005, McInnes et al., 2014), which further 
degrades the ECM and can lead to the degradation of key wound healing factors such as 
TGF-β1 (Larouche et al., 2018). The excess numbers of neutrophils at the wound site, 
found in chronic wounds is thought to be caused by the loss of neutrophil apoptosis, a 
critical event for inflammation resolution. Diabetic chronic wounds in mice have shown to 
have an increased number of apoptotic cells most being neutrophils (Khanna et al., 2010). 
Infection has also been shown to effect neutrophil apoptosis, with chronic diabetic wounds 
in mice infected with S. aureus showing reduced neutrophil apoptosis (Hanses et al., 
2011).  
Macrophages are also an immune cell type affected by the chronic wound environment. 
The inability of macrophages to changes from an M1 to an M2 phenotype results impairs 
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healing in humans and mice (Sindrilaru et al., 2011). This switch has also been linked to 
the suppression of TGF-β1 synthesis, further contributing to non-healing (Okizaki et al., 
2015). Wounds with predominant M1 pro-inflammatory macrophage phenotype presence 
also results in surplus production of proteases and pro-inflammatory cytokine production 
which further contributes to ECM degradation (Larouche et al., 2018). Similarly, to 
neutrophils above, macrophages in chronic wound also show reduced apoptosis, 
prolonging their pro-inflammatory presence in the wounds (Khanna et al., 2010).  
The role of the adaptive immune system is less well understood in the context of chronic 
non-healing wounds, and therefore may be of interest in future studies. It has been found 
that there are fewer T cells present in chronic wounds and those present have been found 
to be less responsive (Xu et al., 2017, Loots et al., 1998). The loss of these cells in chronic 
wound may unveil contributory factors and it is necessary that future work is done to 
investigate their role in full. 
1.7 Genes and Wound Healing 
The genetics of wound healing is an understudied area of research. Much is known about 
the cell and tissue behaviour that lead to repair, but what genes drive these events or in 
fact which genes are affected in chronic wounds still requires much investigation. Acute 
wound healing is indicative of initial powerful transcriptional activation of pro-inflammatory 
genes. These genes include TNF and interferon activation, macrophage markers (CD163, 
FcγRI and MHC class II α chain), as were markers of T (RAB7L1 and RAB18) and B 
(immunoglobulin heavy chain) cells. If infection is absent, inflammation subsides and 
replaced by angiogenic (MMP9 and Progranulin) and remodelling (CTGF and procollagen) 
genes (Deonarine et al., 2007, Cooper et al., 2005). These genetic markers show us what 
drives the wound healing cascade. However, it would be of interest to see if genetic risk 
genes exist that predispose people to developing chronic wounds and thus enable genetic 
screening of people at risk.  
Wound healing is a complex cascade and because of this, investigations into the genetics 
of chronic wounds have proven to be difficult due to the multifactorial genetic profile that 
contribute to wound healing in general. However, genetic variations have been identified in 
patients with chronic wounds, indicating that there may be a genetic element to this multi 
factorial disease. Gene mutations in the prothrombin and coagulation factor V genes have 
been identified in patients with venous leg ulcers (VLU), (Peus et al., 1996, Jebeleanu and 
Procopciuc, 2001). Single nucleotide polymorphisms (SNPs) in the FGF 2 receptor, which 
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encodes keratinocyte growth factor receptor have been identified in VLU patients, 
indicating a cause for reduced keratinocyte proliferation and wound healing in these 
patients (Nagy et al., 2005). SNPs in TNFα gene, encoding a pro-inflammatory cytokine, 
has also been identified in VLUs linked with the lifestyle factor of obesity (Nagy et al., 
2007). A common variant of an estrogen receptor (ESRB), has also been shown to 
increase risk of VLU development, with estrogen being a well-known accelerator of wound 
healing by dampening the inflammatory response (Ashworth et al., 2005). Further 
investigation in this field may provide targets for genetic engineering biotechnologies for 
enhance chronic wound healing (Sessions et al., 2017). 
1.8 Project Aims and Objectives 
Chronic wounds are a growing c oncern and have become a significant burden on healthcare 
providers worldwide. Predominantly age- and diabetes-associated disorders, meaning 
chronic wounds will become more prevalent, more difficult to treat and have higher 
associated medical costs. Research into care for these patients has become an industry of 
its own, with care reported to cost 2-3% of a developed countries healthcare budgets 
(Frykberg and Banks, 2015). However, long term solutions are yet to be elucidated.  
The overall aim of this thesis is to identify which TGF-β1 signalling pathway is responsible 
for the loss of myofibroblast differentiation in CWFs and identify the key players and 
mechanisms responsible for this loss. In the longer term, this may reveal potential targets 
for future therapies. 
My specific aims are to: 
1. Characterise CWFs response to TGF-β1 stimulation, identifying effects on the two 
collaborating pathways, classical and non-classical, responsible for myofibroblast 
differentiation. 
2. Determine whether HA has a role in the loss of myofibroblastic differentiation 
response in CWFs. 
3. Elucidate the differences between CWFs and NFs protein synthesis, transport and 
localisation, and whether changes to protein metabolism may contribute the loss of 
the myofibroblast phenotype in CWFs. 
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Chapter 2 
Materials and Methods 
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2.1. Materials 
All general and tissue culture reagents were purchased from Sigma-Aldrich (Poole, UK), 
Thermo-Fisher Scientific (Roskilde, Denmark), BD Biosciences (San Jose, USA), and 
GIBCO/Life Technologies (Paisley, UK) unless otherwise stated. PCR and QPCR reagents 
and primers were purchased from Invitrogen and Applied Biosystems (Life Technologies, 
Paisley, UK). TGF-β1 we purchased from R&D Systems (Abingdon, UK).  
2.2. Cell Culture 
Primary human non-healing dermal CWFs (AG19642 and AG19285) and apparently healthy 
dermal NFs (GM23962 and GM23967; NIA Ageing Cell Respiratory Coriell Institute, 
Camden, USA), were cultured in using a 50:50 ratio of Dulbecco’s Modified Eagle’s Medium 
(DMEM: 11966-025; Life Technologies) and F-12 Ham Nutrient mixture (N6658; Sigma-
Aldrich) containing 5 mM glucose. This mixture was then supplemented with 2 mM L-
glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin and 10 % foetal calf serum (FCS) 
(Biologic Industries Ltd., Cumbernauld, UK). The cells were maintained at 37°C in a 
humidified incubator in an atmosphere of 5% CO2; and fresh growth medium was added to 
the cells every 3-4 days, until confluent. At confluence, cells were sub-cultured (see below). 
Prior to experimentation, all cells were growth-arrested in serum-free medium for 48 h to 
allow cell-cycle synchronisation (arrest at G0) and remove possible effects of serum-borne 
factors, an established and published technique previously used to study myofibroblast 
formation (Midgley et al., 2013, Meran et al., 2011, Webber et al., 2009, Simpson et al., 
2009, Siani et al., 2015). All experiments were performed in serum-free medium, to avoid 
any influence of serum factors. Furthermore, all experiments were performed on 
approximately equivalent cell numbers. 
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Table 2.1.  Coriell Institute Cell Information 
Type Code Wound 
Type 
Patient 
age 
Race Infection Diabetes 
NF 1 GM23967 Apparently 
healthy 
52 Caucasian No No 
NF 2 GM23962 Apparently 
healthy 
27 African 
American 
No No 
CWF 1 AG19285 Venous 
ulcer 
51 Caucasian Pseudomonas / 
Staphylococcus 
No 
CWF 2 AG19642 Pressure 
ulcer 
35 African 
American 
Yes (unkown) No 
 
2.2.1. Sub-culturing 
At confluence, the cell populations were sub-cultured at a ratio of 1:3 and either utilised for 
experiments, cultured further, or cryopreserved, as described below. Sub-culturing a 
confluent 75cm2 culture flask (~2 million cells) (T-75; scale up or down as appropriate), was 
undertaken by treatment with 5mL 0.05% (w/v) trypsin and 0.53mM EDTA in phosphate 
buffered saline (PBS). The trypsin was evenly distributed over the base of the flask and 
incubated at 37°C for 1-5min with slight agitation, or until cells became detached. When 
examined under a light microscope, detached cells appeared rounded and floating. The 
resulting cell suspension was treated with an equal volume (5mL) of FCS supplemented 
medium to neutralise the protease activity. The total volume was then transferred to a 
centrifuge tube and the suspension centrifuged at 1500×g for 6min at room temperature. 
Supernatants were carefully aspirated and the cells re-suspended in 50mL medium 
supplemented with 10% FCS. Cells were seeded into fresh tissue culture flasks for 
continued growth, or seeded onto tissue culture plates for experimentation. Fibroblasts were 
cultured, sub-cultured and cryopreserved at various passages until senescence, at which 
point, senescent cells were no longer used and were discarded. Both normal and chronic 
wound fibroblasts were determined to retain proliferative capabilities until passage 10, 
therefore all further experiments were undertaken between passage 8 and 10, this was to 
generate sufficient cells to undertake all experiments. 
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2.2.2. Cryostorage and Revival  
At sub-culture, low passage fibroblasts were harvested for cryogenic preservation. For one 
T-75 flask of confluent cells, following trypsin treatment and neutralisation, the cells were re-
suspended in a 1.5mL solution containing 10% dimethyl sulphoxide (DMSO), 30% FCS and 
60% DMEM/F12 medium. The 1.5mL was then transferred into a cryogenic vial (Thermo-
Fisher Scientific). Vials were insulated and initially placed in a -80°C freezer for 24h and 
then subsequently transferred to liquid nitrogen (-196°C) for long-term storage. Revival of 
cryopreserved cells was undertaken by rapid thawing at 37°C, using a water bath. Upon 
complete defrosting of the cryovials contents, the cell solution from each cryogenic vial was 
transferred directly into 20ml pre-warmed 37°C medium supplemented with 10% FCS. The 
cell suspension was centrifuged at 1500×g for 6min at room temperature. Supernatant was 
carefully aspirated and the cells were then re-suspended in 10mL medium supplemented 
with 10% FCS. Cells were then seeded into a fresh tissue culture T75 flask for continued 
growth. 
2.2.3. Cell Counting and Population Doubling Level (PDL) Calculations 
To assess cell numbers, fibroblasts in culture were sub-cultured, as above, using trypsin. 
Upon cell re-suspension in 10% FCS medium and prior to cell seeding, three 20μL volumes 
of cell-suspension were taken and each added to 20mL of sterile isotonic water in Coulter 
Counter compatible sample cups. The average cell counts of three readings were taken for 
each sample using a Coulter Z2 Series Cell Counter (Beckman Coulter Inc., High Wycombe, 
UK). The formulae shown below were used to calculate the total number of cells in the re-
suspension solution: 
 
Cells/mL = (Average cell number) x 2000 
𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 = (
𝐶𝑒𝑙𝑙𝑠
𝑚𝐿
) 𝑥(𝑉𝑜𝑙𝑢𝑚𝑒 𝑟𝑒𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛) 
In order to determine the PDL at the end of each passage number, the following equations 
were used: 
𝑇𝑜𝑡𝑎𝑙 𝑠𝑒𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟[1: 3 𝑟𝑎𝑡𝑖𝑜 𝑠𝑢𝑏 − 𝑐𝑢𝑙𝑡𝑢𝑟𝑒] = 𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟/3 
𝑃𝐷𝐿 = 3.32𝑥(𝑙𝑜𝑔10(𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡) − 𝑙𝑜𝑔10(𝑇𝑜𝑡𝑎𝑙 𝑠𝑒𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟) 
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Cumulative population doubling levels were calculated by adding the derived increase to the 
previous PDL.  
2.3. Cytokine Stimulations  
Following growth arrest (48 hrs), the medium was removed and the cells washed with PBS. 
Stimulations were performed by incubation of fibroblasts with the desired stimuli (10 ng/mL 
TGF-β1, 1 µg/mL IL-1β) in serum-free medium for appropriate times before analysis. 
Majority of experiments compared cells in either serum-free medium alone or serum-free 
medium containing 10 ng/mL for 72hrs. This time and duration has been well established in 
the literature to stimulate full myofibroblast differentiation (Midgley et al., 2013, Meran et al., 
2011, Webber et al., 2009, Simpson et al., 2009). The specific details of the cell-stimulations 
performed for each experiment are covered in the subsequent results chapters. 
2.4. HA ELISA  
HA ELISA (Corgenix, Inc, Peterborough, UK) was used to quantify HA concentrations. Cells 
were grown to 90-100% confluence, growth arrested for 48h and then stimulated under 
serum-free conditions. Supernatant was collected for extracellular HA analysis. Cells were 
washed with PBS followed with treatment of 500µL trypsin/EDTA and incubated for 5min at 
room temperature, to detach pericellular HA. Supernatant was collected and heated to 90̊C 
for 5 min to deactivate trypsin. Remaining cell layer was scraped and re-suspended in 500 
µl passive lysis buffer (E194A, Promega, Southampton, UK) to quantify intracellular HA. HA 
was quantified in the separated cell layers by a commercially available enzyme-linked HA 
binding protein assay. The assay used micro-wells coated with a highly specific HA binding 
protein (HABP) from bovine cartilage, to capture HA and an enzyme-conjugated version of 
HABP to detect and measure HA in the samples. Diluted samples and HA reference 
solutions were incubated in the micro-wells allowing HA to bind to immobilized HABP.  The 
wells were then washed and HABP conjugated with HRP was added to the wells. Following 
a second wash, a chromogenic substrate (Tetramethylbenzidine (TMB)/H202) was added to 
develop a coloured reaction. Stopping solution was added to the wells and the intensity of 
colour was measured using a spectrometer at 450nm. HA concentrations were analysed by 
comparing the absorbance of the samples against a reference curve prepared from the 
blank and five reference solutions (50, 100, 200, 500 and 800 ng/mL) included in the kit. The 
assay is sensitive to 10ng/mL, with no cross-reactivity with other GAG compounds. 
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2.5. Red Blood Cell (RBC) Exclusion Assay 
RBC exclusion assay was used to confirm the presence or absence of HA pericellular coat. 
Cells were grown to 70% confluence, growth arrested for 48h and then stimulated under 
serum-free conditions for 72h. Following stimulation, medium was taken off and the cells 
were washed with PBS. Formalized horse erythrocytes were washed in PBS and centrifuged 
at 1,000xg for 6min at 4 ̊C. The pellet was re-suspended in serum-free medium at an 
approximate density of 1×108 erythrocytes/ml. 500 μl of this suspension was added to each 
35-mm dish containing sub-confluent cells and swirled gently for even distribution. The 
dishes were incubated at 37°C for 15min, to allow the erythrocytes to settle around the cells. 
Control cells were incubated with 200 μg/ml bovine testicular hyaluronidase in serum-free 
medium for 30min prior to the addition of formalized horse erythrocytes. On settling, the 
erythrocytes were excluded from zones around those cells with HA pericellular coats. This 
was viewed under the microscope as an area of erythrocyte exclusion. Zones of exclusion 
were visualized on a Zeiss Axiovert 100M Inverted Microscope (Zeiss, Cambridge, UK). 
2.6. Immunocytochemistry (ICC) 
Indirect immuno-fluorescent identification of α-SMA was used as confirmation of 
myofibroblastic differentiation. All other proteins and markers were visualised to compare 
localisation in CWFs and NFs. All immunocytochemistry was performed on cells grown on 
8-well glass chamber slides (Nunc; Thermo-Fisher Scientific). Cells were grown to 70% 
confluence, growth arrested for 48h and then stimulated under serum-free conditions. 
Following stimulation, cells were fixed in cold 4% paraformaldehyde for 15min and then 
washed thoroughly in PBS. All cells were permeabilised with 0.1% Triton X-100 for 5min and 
then washed with PBS. Non-specific binding was blocked with 1% (w/v) bovine serum 
albumin (BSA, Sigma-Aldrich) in PBS (herein referred to as BSA-PBS), for 1h at room 
temperature and on a STR6 Platform Shaker (Stuart Scientific, Stone, UK). The cells were 
washed thoroughly in 0.1% (w/v) BSA-PBS. Cells were incubated with the appropriate 
primary antibody (Table 2.1), diluted in 0.1% (w/v) BSA-PBS overnight at 4°C on a plate 
Gyro-Rocker. The cells were washed repeatedly in 0.1% (w/v) BSA-PBS, then incubated 
with the appropriate secondary antibody (Table 2.2), diluted in 0.1% (w/v) BSA-PBS for 1h 
at room temperature, on a platform shaker under darkness. The cells were washed 
extensively with 0.1% (w/v) BSA-PBS, before incubation with Hoechst nuclear stain (Sigma-
Aldrich; dilution 1:2000 in 0.1% (w/v) BSA-PBS) for 30 minutes at room temperature under 
darkness. Following further thorough washes with 0.1% (w/v) BSA-PBS, the slides were 
33 
 
mounted with FluorSave mountant (Merck Millipore) and examined under UV-light on a 
Leica Dialux 20 Fluorescent Microscope (Leica Microsystems UK Ltd, Milton Keynes, UK). 
 
Table 2.2. Primary Antibodies / Markers used for ICC 
Antibody Type Host Dilution 
Anti-α-SMA (A5228, Life 
Technologies) 
Monoclonal Mouse 1:25 
HAS1 (ab198846, Abcam) Polyclonal Rabbit 1:200 
HAS2 (sc-34068, Santa Cruz) Polyclonal Goat 1:200 
CD44 V7/8 (MA5-16964, Thermo 
Fisher) 
Monoclonal Mouse 1:200 
HYAL2 (PA5-24223, Thermo Fisher) Polyclonal Rabbit 1:200 
Tubulin (ab6160, Abcam) Monoclonal Rat 1:1000 
LAMP-1 (sc-20011, Santa Cruz) Monoclonal Mouse 1:100 
EEA-1 (610457, BD Biosciences) Monoclonal Mouse 1:500 
Endoplasmic Reticulum - Calreticuln 
(ab92516 Abcam) 
Monoclonal Rabbit 1:200 
Golgi - GM130 (ab52649, Abcam) Monoclonal Rabbit 1:150 
HAPB (Merck, 385911) - - 1:100 
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Table 2.3. Secondary Antibodies / Markers used for ICC 
Antibody Type Host Dilution 
Anti-Mouse-IgG AlexaFluor 488 
(FITC) 
(A11001) 
Polyclonal Goat 1:1,000 
Anti-Rat-IgG AlexaFluor 555 
(TRITC) 
(A21434) 
Polyclonal Goat 1:1,000 
Anti-Goat-IgG AlexaFlour 555 
(A21432) 
Polyclonal Donkey 1:1,000 
Anti-Rabbit-IgG AlexaFlour 488 
(A11034) 
Polyclonal Goat 1:1,000 
Anti-Rabbit-IgG AlexaFlour 555 
(A11037) 
Polyclonal Goat 1:1,000 
Avidin (Life Technologies, A21370) - - 1:500 
 
2.7. RNA Extraction and Reverse Transcription (RT)  
Fibroblasts were grown to confluence in 35mm dishes and washed with PBS, prior to lysis 
with 500μL TRIzol reagent (Ambion; Life Technologies). RNA was purified from the samples 
according to the manufacturer’s protocol. Briefly, 100μL of chloroform was added to the 
sample and agitated by inversion for 15sec. The sample was incubated at room temperature 
for 5 minutes and then centrifuged at 12,000×g for 15min, at 4°C. The transparent aqueous 
phase was transferred to fresh eppendorfs and mixed with 250μL of isopropanol. The 
mixture was incubated at room temperature for 10min, briefly vortexed and then centrifuged 
at 12,000×g for 10min, at 4°C. The supernatant was removed and the pellet washed with 
500μL of 75% (v/v) ethanol, briefly vortexed and then centrifuged at 7,500×g for 8min, at 
4°C. The supernatant was removed and the pellet air-dried at room temperature for 15min. 
The pellet was then dissolved in 16μL of RNase-free distilled H
2
O (MilliQ; Merck Millipore). 
The absorbance was measured at 260nm and 280nm, using a Thermo Fisher Scientific 
NanoDrop Spectrophotometer. The ratio of 260:280 gave an indication of protein 
contamination (>1.8 was considered to indicate sufficiently pure RNA for further analysis). 
The concentration of RNA was calculated from the absorbance at 260nm:  
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ABS
260 
x dilution factor (50) x RNA coefficient (40) = RNA in μg/μL 
                                                     1000 
The RT was performed using the random primer method. The RT was carried out in a final 
volume of 20μL per reaction, containing 1μg of RNA sample (in 10μL RNase-free distilled 
H
2
O), 2μL of 10x RT random primers, 2μL of 10x RT buffer, 0.8μL of 25x 100mM dNTPs 
(deoxynucleotide triphosphates; mixed nucleotides: dATP, dCTP, dGTP, and dTTP), 1μL of 
Multiscribe reverse transcriptase and 1μL of RNase inhibitor. All reagents used were 
supplied as a high-capacity cDNA reverse transcriptase kit (Applied Biosystems). The RT 
was performed using a PTC-225 Peltier Thermal Cycler (Bio-Rad Laboratories Inc., 
Hertfordshire, UK). As a negative control, an RT was performed with RNase-free distilled 
H
2
O replacing the RNA sample. The solution was incubated at 25°C for 5min, to allow the 
random hexamer primers to anneal to the RNA. The primers were then extended using the 
reverse transcriptase in the presence of the dNTPs by heating to 37°C for 2h, generating 
cDNA. The cDNA was then heated to 85°C for 5min, to separate the hybridised complexes 
consisting of the RNA template and the newly synthesised cDNA, deactivating the reverse 
transcriptase in the process. The resulting single stranded complementary DNA (cDNA) was 
stored at -20°C until further use.  
2.8. Real Time Quantitative Polymerase Chain Reaction (RT-QPCR)  
2.8.1. TaqMan Gene Expression QPCR  
Following RT, cDNA samples were made up to 80μL by the addition of 60μL of RNase-free 
distilled H
2
O (MilliQ, Merck-Millipore). QPCR was carried out in a final volume of 20μL per 
reaction, containing 4μL of cDNA, 10μL of TaqMan Fast Universal PCR Master Mix (20X) 
(Thermo Fisher), 5μL of H
2
O, and 1μL of a TaqMan gene expression assay primer and probe 
mix (Thermno Fisher) (Table 2.3). A negative control was prepared with RNase-free H
2
O 
substituted for the cDNA. QPCR was simultaneously performed for 18S ribosomal RNA 
(Thermo Fisher), as a standard reference gene.  
2.8.2. Power SYBR Green QPCR  
Following RT, cDNA samples were made up to 80μL by the addition of 60μL of RNAse-free 
distilled H
2
O (MilliQ, Merck-Millipore). QPCR was carried out in a final volume of 20μL per 
reaction, containing 4μL of cDNA, 10μL of Power SYBR Green PCRMaster Mix (Applied 
Biosystems), 4.8μL of H
2
O, 0.6μL of 10μM custom-designed forward primer and 0.6μL of 
10μM custom-designed reverse primer (Table 2.4). A negative control was prepared with 
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H
2
O substituted for the cDNA. PCR was simultaneously performed for GAPDH (Table 2.4), 
as a standard reference gene.  
2.8.3. QPCR and Relative Quantification (RQ)  
QPCR was performed using the ViiA-7 Real Time PCR System (Applied Biosystems), using 
either TaqMan Universal or Power SYBR Green PCR Master Mixes (Applied Biosystems) 
following the manufacturer’s instructions. Following completion of the QPCR run, the 
comparative CT method was used for relative quantification of gene expression. The CT 
(threshold cycle where amplification is in the linear range of the amplification curve) for the 
standard reference gene (rRNA or GAPDH) was subtracted from the target gene CT, to 
obtain the delta CT (dCT). The mean dCT for the experimental control group was then 
calculated. The expression of the target gene in experimental samples relative to the 
expression in control samples was then calculated using the formula:  
2
-( dCT(Experimental Sample) - dCT(Mean Control Group) 
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Table 2.4 Taqman Gene Expression Assays 
Target Taqman Gene Expression Assay 
18S rRNA Catalog #: 4319413E 
α-SMA (ACTA2) Hs00426835_g1 
EGFR Hs01076078_m1 
CD44 Hs01075861_m1 
HAS1 Hs00987418_m1 
HAS2 Hs00193435_m1 
HAS3 Hs00193436_m1 
TSG-6 (TNFAIP6) Hs01113602_m1 
TGF-β1 Hs00998133_m1 
TGF-βR1 Hs00610320_m1 
SMAD2 Hs00183425_m1 
SMAD3 Hs00232222_m1 
HYAL1 Hs00537920_g1 
HYAL2 Hs011117343_g1 
ICAM-1 Hs00164932_m1 
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Table 2.5 Custom Designed Primers for SYBR Green Assays 
Target Custom Primer Sequence 
GAPDH Forward: 5’-CCTCTGACTTCAACAGCGACAC-3’ 
Reverse: 5’-TGTCATACCAGGAAATGAGCTTGA-3’ 
EDA-Fibronectin (EDA-FN) Forward: 5’-GCTCAGAATCCAAGCGGAGA-3’ 
Reverse: 5’-CCAGTCCTTTAGGGCGATCA-3’ 
FAP Forward: 5’-AGAACGCCCCCAAAATCTGT-3’ 
Reverse: 5’-GGAAGCTGAAGCCAGGACAA-3’ 
HYBID (KIA1199) Forward: 5’-AACCAGCTGGACATGGATGG-3’ 
Reverse: 5’-GTGAGGTAGGAGCCAGGGTA-3’ 
CD147 Forward: 5’- CAGAGTGAAGGCTGTAAGTCG-3’ 
Reverse: 5’-TCGGAGGAACTCACGAAGAA-3’ 
HC1 Forward: 5’-TCCATGGAGAACAACGGACG-3’ 
Reverse: 5’-GGGGGTACTGCAAATCCACA-3’ 
HC2 Forward: 5’-GCCATTTCGATGGTGTTCCG-3’ 
Reverse: 5’--TTCTCTGCTGTGCTACCGTG-3’ 
HC3 Forward: 5’-CCTTTCGGCTGCTTGGGAAA-3’ 
Reverse: 5’-GACGGCTCTCATGGTGACAA-3’ 
HC4 Forward: 5’-AGTCACCAAACCCGATGACC-3’ 
Reverse: 5’-GCTCCAGCTGAGTGGACATT-3’ 
HC5 Forward: 5’-ACTGTCGCTGGAGAACTGTG-3’ 
Reverse: 5’-CGGGGTCCTGATTTCATCGT-3’ 
IL-1β Forward: 5’-TCGCCAGTGAAATGATCGCT-3’ 
Reverse: 5’-TGGAAGGAGCACTTCATCTGTT-3’ 
IFN-γ Forward:5’-ATGAAATATACAAGTTATATCTTGGCTTT-3’ 
Reverse: 5’-GATGCTCTTCGACCTCGAAACAGCAT-3’ 
CCL2 Forward: 5’-CCCAAAGAAGCTGTGATCTTCA-3’ 
Reverse: 5’-TCTGGGGAAAGCTAGGGGAA-3’ 
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CCL5 Forward: 5’-CAGTCGTCTTTGTCACCCGA-3’ 
Reverse: 5’-CGGGTGGGGTAGGATAGTGA-3’ 
IL-8 Forward: 5’-TTTGGGGTGGAAAGGTTTGG-3’ 
Reverse: 5’-TCTTGGCAGCCTTCCTGATTT-3’ 
EGFR-as Forward: 5’-TCCAGGTGAAGACGCATGAA-3’ 
Reverse: 5’-GTCTTTTGCAGGCACAGCTT-3’ 
CD44s Forward: 5’-GCTACCAGAGACCAAGAC-3’ 
Reverse: 5’-GCTCCACCTTCTTGACTCCC-‘3 
CD44v2 Forward: 5’-CCTGCTACCACTTTGATGAGC-3’ 
Reverse: 5’-GTGTCTTGGTCTCCAGCCAT-3’ 
CD44v3 Forward: 5’ -TGCTACCAGTACGTCTTCAAAT-3’ 
Reverse: 5’-GTGTCTTGGTCTCTGGTGCT-3’ 
CD44v4 Forward: 5’-CTGCTACCATTTCAACCACACC-3’ 
Reverse: 5’-TGGTCTCAGTCATCCTTGTGG -3’ 
CD44v5 Forward: 5’-CAGAATCCCTGCTACCAATGT-3’ 
Reverse: 5’-TCTTGGTCTCTTGTGCTTGTAGA-3’ 
CD44v6 Forward: 5’-TGCTACCATCCAGGCAACTC-3’ 
Reverse: 5’-GGAATGTGTCTTGGTCTCCAGC-3’ 
CD44v7 Forward: 5’-GAATCCCTGCTACCACAGCCTC-3’ 
Reverse: 5’-TCTCCCATCCTTCTTCCTGCTT-3’ 
CD44v8 Forward: 5’-ATGTGTCTTGGTCTGGCGTT-3’ 
Reverse: 5’-TCCCTGCTACCAATATGGACTC-3’ 
CD44v9 Forward: 5’-CAGAATCCCTGCTACCAAGC-3’ 
Reverse: 5’-ACTGGGGTGGAATGTGTCTT-3’ 
CD44v10 Forward: 5’-TCCCTGCTACCAATAGGAATGA-3’ 
Reverse: 5’-TAAGGAACGATTGACATTAGAGTTG-3’ 
CD44v7/8 Forward: 5′AGGAAGAAGGATGGATATGGACT-3′ 
Reverse: 5′-GTCTTGGTCTCGCGTTGTCA-3′ 
*Primer efficiency was checked by melt curve analysis, for multiple products. 
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2.9. Western Blot Analysis  
Cells were grown to confluence in 35mm dishes and were scraped and collected in ice-cold 
PBS. The samples were then centrifuged at 10,000×g for 10 minutes at 4°C and the 
supernatant discarded, the cell pellet was then re-suspended in RIPA lysis buffer, containing 
1% v/v protease cocktail inhibitor, 1% v/v phenylmethylsulfonyl fluoride and 1% v/v sodium 
orthovanadate (Santa Cruz Biotechnology Inc., Texas, USA). The samples were thoroughly 
vortexed and kept on ice for 5 minutes, before being centrifuged at 10,000×g for 10min at 
4°C. The resulting supernatant was collected and transferred to fresh Eppendorf’s. Protein 
concentrations were determined by Pierce BCA Protein Assay Kit (Thermo Fisher) and the 
samples were stored at -80°C, until further use. Equal amounts of protein were mixed with 
equal volumes of 1x reducing buffer and boiled for 5min at 99°C, before being vortexed, 
briefly centrifuged and allowed to cool on ice for 5min. The samples were then loaded 
alongside a Westernsure Pre-Stained Chemiluminescent protein ladder onto 7.5% SDS-
PAGE gels. Electrophoresis was carried out at 100V for 20min, followed by 150V for 40 
minutes; using the Mini-PROTEAN II system (Bio-Rad Laboratories). The separated 
proteins were then transferred at 100V for 1h to a nitrocellulose membrane (GE Healthcare, 
Hatfield, UK). The membrane was blocked with PBS containing 0.1% (v/v) Tween-20 
(Thermo Fisher) (herein referred to as Tween-PBS) and 1% (w/v) BSA for 1h; and incubated 
with the appropriate primary antibody (Table 2.5) diluted in Tween-PBS on a plate rocker, 
at 4°C overnight. The blots were subsequently washed with Tween-PBS, prior to incubation 
with the appropriate HRP-conjugated secondary antibody (Table 2.6), for 1h at room 
temperature on a plate shaker. Proteins were visualised using enhanced 
chemiluminescence (ECL) reagent (GE Healthcare), exposed to Li-cor C-Digit Blot Scanner 
(Li-cor Biosciences, Cambridge, UK). 
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Table 2.6 Primary Antibodies and Dilutions used in Western Blot Analysis 
Antibody MW (kDa) Type Host Dilution 
P-SMAD2 (3108, 
Cell Signalling) 
60 Monoclonal Rabbit 1:1000 
P-ERK 1/2 
(197G2, Cell 
Signalling) 
42, 44 Monoclonal Rabbit 1:1000 
CD44 (217594, 
Merck Millipore) 
~85-95 Monoclonal Rat 1:1000 
Anti-EGFR 
(GR01, Merck 
Millipore) 
~170 Monoclonal Mouse 1:200 
HAS1 
(ab198846, 
Abcam) 
~65 Polyclonal Rabbit 1:500 
GAPDH 
(sc365062, 
Santa Cruz) 
37 Monoclonal Mouse 1:2000 
 
Table 2.7 Secondary Antibodies and Dilutions used in Western Blot Analysis 
Antibody Type Host Dilution 
Anti-Rat-IgG-HRP 
(ab98391, Abcam) 
Polyclonal Goat 1:5000 
Anti-Mouse-IgG-
HRP (sc2005, 
Santa Cruz) 
Polyclonal Goat 1:5000 
Anti-Rabbit-IgG-
HRP (ab97051, 
Abcam) 
Polyclonal Goat 1:5000 
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2.10. Laser Confocal Microscopy 
Cells were grown to 70% confluence on sterilised 22mm diameter glass coverslips, in 35mm 
dishes. Cells were treated and fixed using the same protocol shown in section 2.6. Cells 
were then incubated with primary and secondary antibodies shown in Table 2.7 and 2.8. 
Analysis was performed by Zeiss LSM880 Airyscan Laser Confocal Microscopy (Zeiss).  
Table 2.8 Primary Antibodies and Markers used in confocal laser microscopy 
Antibody Type Host Dilution 
Anti-EGFR (GR01, Merck Millipore) Monoclonal Mouse 1:200 
Anti-EGFR FITC 488 
(ab11401, Abcam) 
Monoclonal Rat 1:500 
Anti-CD44 (A020, Merck Millipore) Monoclonal Rat 1:200 
CTX-B AlexaFluor 555 (C22843, Life 
Technologies) 
- - 1:1000 
 
2.11. Plasmid Generation  
2.11.1. HAS2 and HAS1 Overexpression Vector  
The pCR3.1 vector containing HAS1 or HAS2 open reading frame was amplified via 
bacterial transformation into one-shot competent Escherichia coli (New England Biolabs); 
and grown overnight on agar containing ampicillin (100 µg/mL). Single colonies were 
extracted, cloned and DNA purified, according to the Miniprep Kit protocol (Sigma-Aldrich). 
Negative RT experiments were performed alongside HAS2 and HAS1 mRNA QPCR, to 
ensure that pCR-3.1-HAS2 vectors were not conveying false-positive overexpression. All 
samples were RQ1 DNAse (Promega, Southampton, UK) treated, prior to RT to prevent 
amplification of open reading frame DNA. 
2.12. Overexpression Vector Transfection  
Overexpression vectors using the pCR3.1 plasmid were transfected with the Lipofectamine 
LTX Transfection Kit, according to the manufacturer’s protocol (Life Technologies). Briefly, 
for two 22mm cell culture dishes, 750ng plasmid DNA, 0.75μL PLUS reagent and 4μL 
Lipofectamine LTX were added to 400μL OPTIMEM transfection medium, mixed well and 
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incubated at room temperature for 40min. Following incubation, 200μL of transfection 
solution was then added to each 22mm cell culture dish containing DMEM/F-12 growth 
medium with 10% FCS. Cells were incubated for 24h, before the medium was replaced with 
serum-free growth medium for further cell experimentation or analysis. As a negative control, 
an empty pCR3.1 plasmid (containing no open reading frame sequence) was transfected 
into cells.  
2.13. Small interfering RNA (siRNA) Transfection  
Transient transfection of fibroblasts was performed with specific siRNA nucleotides (Table 
2.8). Transfection was performed in 35mm dishes using Lipofectamine 2000 transfection 
reagent (Invitrogen), in accordance with the manufacturer’s protocol. Briefly, for transfection 
of a single 35mm well: two solutions were made, the first consisted of the target siRNA (final 
transfection concentration of 30nM) in 100μL OPTIMEM transfection medium. The second 
solution consisted of 4μL Lipofectamine 2000 transfection reagent in 100μL OPTIMEM 
transfection medium. The solutions were mixed together and incubated for 40min, at room 
temperature. Following incubation, an additional 800μL of OPTIMEM was added to the 
transfection solution. The cells were washed with OPTIMEM medium and 1mL transfection 
solution was added to the cells and incubated 5-7h, after which an additional 1mL of cell 
culture medium containing 20% FCS was added to the well. Following 24h of incubation, the 
medium was removed and replaced with serum-free media, in preparation for further cell 
treatments or analysis. As a negative control, cells were transfected with negative control 
siRNA (a scrambled sequence that bore no homology to the human genome) (I.D.: AM4611, 
Thermo Fisher). 
Table 2.9 siRNA Nucleotides for siRNA Transfection 
Target siRNA Nucleotides 
HAS1 s6454 (Thermo) 
HAS2 s5458 (Thermo) 
HYAL2 s428 (Thermo) 
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2.14. MicroRNA-7 RT-PCR  
RNA was extracted and purified according to the methods described in conventional RT-
PCR (Section 2.7). The RNA sample was diluted to 10ng and RT was performed for miR-7 
assay, according to the instructions provided with TaqMan miR Gene Expression Assay Kits 
(Applied Biosystems). Briefly, a master mix containing 3μL TaqMan looped miR RT primer, 
0.15μL 100mM dNTPs, 1μL MultiScribe reverse transcriptase, 1.5μL 10x RT buffer, 0.19μL 
RNase inhibitor, 4.16μL nuclease-free H
2
O was made. Each RT-PCR reaction had a final 
volume of 15μL, consisting of 10μL Master Mix and 5μL RNA sample. The RT used the 
following parameters: 30min at 16°C to allow looped RT primer to anneal to the target miR, 
30min at 42°C to allow random dNTP and transcriptase extension of the cDNA strand; and 
5min at 85°C, to dissociate the looped RT primer from the miR/cDNA strands. The RT was 
performed on a PTC-225 Peltier Thermal Cycler (Bio-Rad Laboratories Inc.). Samples were 
cooled to 4°C and then transferred to -20°C, until further use.  
2.15. MicroRNA RT-QPCR  
MicroRNA RT-QPCR was performed, according to the TaqMan MicroRNA Gene Expression 
Assay Kit protocol (Applied Biosystems). A Master Mix solution was made consisting of 1μL 
TaqMan MicroRNA Assay (20X), 10μL TaqMan 2X Universal PCR Master Mix, and 7.67μL 
nuclease-free H
2
O. Analysis was performed in triplicate on a 96-well plate with a final 
reaction volume of 20μL, consisting of 1.33μL of cDNA and 18.67μL of master mix solution. 
The plate was briefly centrifuged and the QPCR was performed using the ViiA-7 Real Time 
PCR System (Applied Biosystems), using TaqMan 2X Universal PCR Master Mix (Applied 
Biosystems), following the manufacturer’s instructions. Following the completion of the 
QPCR run, the data was calibrated against a house-keeping miR, with no expression 
change under any experimental conditions performed (miR-16), using the comparative CT 
method, as described in Section 2.8.3.  
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Table 2.10 Taqman miR Expression Assay 
Target Taqman miR Expression Assay 
miR-16 hsa-miR-16 (UAGCAGCACGUAAAUAUUGGCG 
miR-7 hsa-miR-7-5p (UGGAAGACUAGUGAUUUUGUUGU) 
 
2.16. Statistical Analysis  
Western blot images were densitometrically analysed by Image Studio (Licor). Graphical 
data are expressed as averages ± standard deviation (s.d). To test for normal distribution, 
the Shapiro-Wilk test, followed by the Two-Way ANOVA to test for variances, followed by a 
Bonferroni post-test to identify statistical significance. Data was analysed using the software 
Prism 5 (GraphPad) and *P=<0.05, **P=<0.01 or ***P=<0.001 were considered as 
significant. 
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Chapter 3 
Characterisation of Chronic Wound 
Fibroblast response to TGF-β1 
Stimulation 
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3.1. Introduction 
3.1.1. Dermal Fibroblasts and TGF-β1 Stimulation 
Dermal fibroblasts are morphologically characterised by their elongated, flattened and 
bipolar appearance. They have a branched cytoplasm surrounding a large elliptical, 
speckled nucleus, containing two nucleoli. Fibroblasts are often described as having a well-
defined endoplasmic reticulum and in culture have a differing morphology depending on 
confluence (Wall et al., 2008). Low confluence fibroblasts in culture have a large surface 
area and often have multiple protrusions. On the other hand, highly confluent fibroblasts 
have a smaller surface area, clear bipolar structure and are arranged in parallel to one 
another (Sutherland et al., 2005). 
TGF-β1 stimulates dermal fibroblast to myofibroblast differentiation, which is an essential 
process for healthy wound healing. Myofibroblasts are characterised by their contractile 
organized bundles of αSMA positive fibres, which terminate at the fibronexus on the surface 
of the cell. Functionally, these stress fibres transmit the force to the surrounding ECM. It is 
important to note that resting fibroblasts lack this contractile, fibrous apparatus (Gabbiani, 
2003). The treatment of fibroblasts in vitro with exogenous TGF-β1, has previously been 
described to have marked upregulation of α-SMA gene and protein expression, along with 
upregulation of the fibronectin variant containing the EDA domain (FN-EDA), which has 
shown to be essential for fibre formation (Shinde et al., 2015, Evans et al., 2003, Midgley et 
al., 2013).  
Fibroblasts under stress such as aged fibroblasts or CWFs present a ‘stressed morphology’, 
displaying a larger surface area, stellate appearance and evidence of internal stress fibres 
(Wall et al., 2008, Simpson et al., 2009). The phenotypic changes observed in these cells 
are associated with distinct changes in gene and protein expression. These include changes 
in key genes associated with myofibroblast formation; aged cells have been reported to have 
a reduced α-SMA gene induction and αSMA fibre formation with TGF-β1 treatment 
(Simpson et al., 2009). Dermal fibroblasts from chronic ulcers have also been shown to be 
unresponsive to TGF-β1 treatment, through the loss of gene expression associated with 
ECM production (Hasan et al., 1997). It is therefore important to understand the mechanisms 
and pathways that regulate TGF-β1 signalling. 
3.1.2. TGF-β1 signalling via the classical TGF-βR pathway 
TGF-β1 signalling for fibroblast to myofibroblast differentiation is regulated by two 
independent but co-operating pathways, the classical TGF-βR pathway and the non-
classical HA-CD44-EGFR pathway. TGF-β1 binds a family of transmembrane receptors, 
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TGF-βRI (ALK5) and TGF-βRII. TGF-βRII binding of TGF-β1 leads to the recruitment of the 
type-I receptor, forming a heterotetrameric complex which catalyses the phosphorylation of 
the GS domain of the type I receptor. Both receptors have been shown to be essential for 
the classical TGF-βR-stimulated pathway (Webber et al., 2009, Zhu et al., 2012). Following 
activation downstream signalling occurs via SMAD2 and SMAD3 phosphorylation, which 
together bind a common mediator co-SMAD4 and migrate across the nuclear membrane to 
activate transcription factors (Gu et al., 2007). Previous research has indicated that SMAD2 
is primarily responsible for the TGF-β1 independent alteration in the fibroblast phenotype 
(Evans et al., 2003). 
Research undertaken on CWFs has uncovered defects in the classical pathway that may 
contribute to the loss of response to stimulating cytokines. This defect in the classical 
pathway has been determined to be caused by the loss of the TGF-βR2 expression (Kim et 
al., 2003, Hasan et al., 1997). This loss in receptor expression was also associated with loss 
of SMAD2 and SMAD3 phosphorylation, which was found to be associated with reduced 
proliferation in CWFs (Kim et al., 2003). 
3.1.3. Non-classical HA-CD44-EGFR pathway 
The second pathway regulating the differentiation of fibroblasts into contractile 
myofibroblasts is the non-classical HA-CD44-EGFR pathway. The HA transmembrane 
receptor, CD44 can act as a co-receptor for EGFR. Under TGF-β1 stimulation, CD44 is 
mobile in the membrane and co-localises with EGFR in lipid rafts. Disruption of cholesterol-
rich lipid rafts prevents this co-localisation and thus differentiation, showing the essential 
role of lipid raft formation. Co-localisation also required a HA rich environment for HA-CD44 
binding, this interaction is stabilised by TSG-6 and the Inter-Alpha-Inhibitor (IαI) heavy 
chains, creating a pericellular coat surrounding the cell. TSG-6 interaction with the HC5 of 
IαI, has been shown to be essential for fibroblast to myofibroblast differentiation and 
therefore responsible for stabilising the interaction between HA and CD44 (Martin et al., 
2016). The synthesis of the HA pericellular coat in fibroblasts is undertaken via HAS2, which 
is the primary HAS expressed in NFs. Loss of HAS2 in aged fibroblast has been linked to 
attenuation of myofibroblast formation, with the forced overexpression of HAS2 returning the 
myofibroblast phenotype (Simpson et al., 2010). CD44-EGFR co-localisation initiates 
downstream signalling for myofibroblast differentiation via the ERK1/2 and CAMKII 
pathways. Both ERK1/2 and CAMKII under TGF-β1, signal through a biphasic activation 
profile, with the early phase of activation being responsible for fibroblast differentiation and 
the later phase being linked to cellular proliferation (Midgley et al., 2013). 
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Aged fibroblasts, unresponsive to TGF-β1 signalling, have a compromised HA-CD44-EGFR 
pathway through the loss of EGFR expression (mRNA and protein) and a reduced motility 
of CD44 throughout the cellular membrane. This effect was caused by an increased 
expression of micro-RNA-7 (miR-7), which directly targets EGFR mRNA for breakdown, 
indirectly causing a downregulation of HAS2 expression. As a result, there is a reduction in 
HA produced and therefore decrease in HA binding to its receptor CD44. The loss of the 
HA-CD44 interaction leads to a reduction in CD44 membrane motility which leads to reduced 
CD44 and EGFR interaction (Midgley et al., 2014). The result of this loss in CD44 and EGFR 
interaction is seen downstream where a reduction of ERK1/2 signalling is observed in the 
aged fibroblasts. Similarly, this reduction in ERK1/2 phosphorylation has also been reported 
in CWFs, which has been hypothesised to be cause by the loss of the TGF-βR pathway. 
However, it could indicate dysfunction in the HA-CD44-EGFR pathway (Kim et al., 2003, 
Hasan et al., 1997). To date no one has explored the possibility of a defective non-classical 
pathway in CWFs, this will be addressed in this chapter. 
 
Figure 3.1.1. TGF-β1 stimulated and HA-mediated fibroblast to myofibroblast mechanism. Fibroblasts are stimulated by 
TGF-β1, TGF-βR is phosphorylated (P), signalling through Smad2/3 and co-Smad4. HA-mediated CD44/EGFR signalling, in 
membrane bound lipid-rafts, is through ERK1/2 / CaMKII. When both pathways signal in parallel the cell undergoes 
differentiation into a myofibroblast. Image adapted from (Simpson et al., 2010, Meran and Steadman, 2011) 
3.1.4. Genes Associated with Fibroblast Activation 
Fibroblast activation protein (FAP) is a homodimeric integral membrane gelatinase 
belonging to the serine protease family, expressed by stromal fibroblasts in the granulation 
tissue of healing wounds (Wang et al., 2014). Fibroblasts over-expressing endogenous FAP 
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have been found to promote fibroblast proliferation and invasion in cancers, and therefore 
its presence in cancer is unfavourable (Yang et al., 2013). Its activation during wound 
healing coincides with elevated α-SMA expression, and therefore identifies TGF-β1 
activated fibroblasts (Gao et al., 2009, Tillmanns et al., 2015). FAP activation is also 
associated with increased apoptosis, adhesion and migration, in the fibrotic cell LX-22 
hepatic stellate cells. FAP co-localises with collagen and fibronectin, which are essential 
proteins expressed by myofibroblasts. FAP overexpression is shown to increase expression 
of the HA receptor CD44, indicating a potential role in the non-classical pathway (Wang et 
al., 2005). Loss of FAP expression in CWFs may be a novel contribution of this protein has 
towards non-healing chronic wounds.  
Cluster of differentiation (CD)147, also known as basigin (BSG) or extracellular matrix 
metalloproteinase inducer (EMMPRIN), is another HA-CD44 associated transmembrane 
glycoprotein, with its expression associated with inflammation, cancer and tissue 
remodelling (Grass et al., 2014). CD147 is capable of stimulating HA production and co-
localises with the HA receptor, CD44, on the membrane, possibly contributing to CD44 
membrane motility (Marieb et al., 2004, Slomiany et al., 2009). CD147 also plays a role in 
intracellular trafficking of proteins from the ER to the plasma membrane (Slomiany et al., 
2009). Recently, more evidence demonstrated its involvement in fibroblast to myofibroblast 
differentiation through an induction of α-SMA in an MMP independent manner (Huet et al., 
2008b, Xu et al., 2013). Furthermore, CD147 has been shown to have a regulatory role in 
Wnt/β-catenin signalling, which controls cell migration, proliferation and the development of 
fibrosis in the lungs (Hasaneen et al., 2016). Overall, CD147 may be a major contributor to 
CWFs dysfunction.  
HYBID (KIA1199) is a novel HA binding protein, that plays a role in HA degradation 
independently of hyaluronidase, in dermal fibroblasts (Yoshida et al., 2013b, Yoshida et al., 
2013a). HYBID expression increased in disease states, with a subsequent increase in HA 
degradation (Yoshida et al., 2013a). HYBID expression is supressed by TGF-β1 signalling, 
correlating with an increase in HAS2 expression (Nagaoka et al., 2015). We know from 
previous work that HA synthesis via HAS2 is essential for fibroblast differentiation (Simpson 
et al., 2009). 
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The aims of this chapter are: 
I. Characterise the dermal fibroblasts (normal and chronic) and assess their response 
to TGF-β1 stimulation. 
II. Determine the role of the classical TGF-βR pathway, in the loss of CWFs response 
to TGF-β1. 
III. Analyse the regulation of the non-classical HA-CD44-EGFR pathway, in the loss of 
the myofibroblast phenotype in CWFs. 
IV. Compare HA metabolism in NFs and CWFs and discover whether its dysregulation 
has a role in CWFs biology. 
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3.2. Results 
3.2.1. Dermal fibroblast characterisation 
Initial characterisation of the 4 cell types purchased from Coriel biorepository was 
undertaken to establish the difference between dermal NFs and CWFs. Phase contrast light 
microscopy was used to image cells in culture, to define their phenotypic structure. The NFs 
cells had a typical resting fibroblastic phenotype. The CWFs had a very different structure 
and morphology, with an enlarged polygonal appearance and prominent stress fibres 
(Figure 3.1A). 
The proliferative lifespans were assessed in all four cell types. CWFs had a decreased 
replicative life span compared to the NFs, with CWFs reaching their limit at approx. 17 
compared to the NFs, which did not reach their limit until approx. 35 PDs. It was also clear 
that the proliferative capacity of the CWFs was reduced, compared to NFs with reduced 
population doubling levels observed in CWFs, compared to the NFs following the same 
period in culture (Figure 3.1B).  
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Figure 3.1 Characterisation of dermal fibroblasts. A. Representative phase contract micrographs of normal and chronic wound 
dermal fibroblasts in media containing 10% foetal calf serum (FCS). Original magnification 250x. Scale bar: 100µm. B. At each 
passage (Passage: Confluent T75 flask) cells were counted using a Coulter Particle Count and Size Analyser (Coulter) to 
calculate PDs. All cells except were still replicating at passage between passage 8-11 and therefore this range was used for all 
following experiments. 
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3.2.2. Characterisation of CWFs response to TGF-β1 stimulation 
Further to the phenotypic characterisation of the cells, it was important to define their 
response to the stimulatory cytokine, TGF-β1, which induces myofibroblastic differentiation. 
The two NFs cells showed clear morphological changes (larger surface area) in response 
to TGF-β1 stimulation and prominent α-SMA positive fibre formation (Figure 3.2A). TGF-β1 
treatment of the CWFs did not induce changes to the same effect. Morphologically, CWFs 
surface area increased and some α-SMA positive fibres were seen. However, the CWFs 
response to TGF-β1 was greatly attenuated, compared to that in NFs. 
To assess the cellular response to TGF-β1 at a transcriptional level, α-SMA and EDA-FN 
were measured using qRT-PCR. Both α-SMA and EDA-FN gene expression have been 
shown to increase in response to TGF-β1 stimulation and are essential for myofibroblast 
formation. A significant increase in α-SMA and EDA-FN gene expression was observed in 
the two NFs in response to TGF-β1 treatment (Figure 3.2B/C), thus demonstrating that these 
cells respond to treatment and underwent myofibroblast differentiation. On the other hand, 
the CWFs response to TGF-β1 was greatly attenuated. This demonstrates that CWFs are 
not responsive and are unable to undergo myofibroblast differentiation. 
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Figure 3.2 Characterisation of CWFs and Normal TGFβ1 induced Myofibroblast Differentiation. A. Cells were grown 
to 60% confluence and growth arrested for 48hrs. Cells were then incubated in serum-free medium alone (-TGF) or in medium 
containing 10 ng/mL TGFβ1 (+TGF) for 72hrs. The expression of α-SMA (green) was examined by immunocytochemistry, 
nuclei were visualised by Hoechst stain. Images shown are a representation of 3 independent experiments. Original 
Magnification x400. The mRNA expression of B. α-SMA C. EDA-FN was analysed using QPCR. Results are shown as the 
mean ± s.d. of 3 individual experiments. Statistical analysis was performed by a 2 way ANOVA with post Bonferroni test: **, 
p <0.01, **, p<0.001** 
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3.2.3. TGF-β1 Induction of the Classical TGF-β1 Pathway 
Initial results above have indicated that myofibroblast differentiation is lost in CWFs. 
However, it was still necessary to determine at which point in the pathways (classical or non-
classical pathways), this signalling was lost. To determine this, genes associated with the 
classical TGF-β pathway were measured by qRT-PCR in both the NFs and CWFs, with and 
without stimulation with TGF-β1. TGF-β1 and its receptor TGF-βR expression were found 
to significantly increase in response to TGF-β1 stimulation in both the NFs (Figure 3.3 A/B). 
CWFs also had a significant induction of TGF-β1 gene expression to TGF-β1 treatment. 
However, TGF-βR gene expression in the CWFs did not respond to TGF-β1 treatment. This 
may indicate a contributing factor to the loss of differentiation. In order to assess the 
downstream effects of a loss of TGF-βR induction in the CWFs, the mRNA was measured 
for the downstream signalling proteins of the TGF-βR (SMAD2 and SMAD3). Overall, no 
significant change was seen with TGF-β1 treatment in either the NFs or CWFs (Figure 3.3 
C/D). This meant that no measurable trend was observed in the NFs, to compare to the 
dysfunctions in the CWFs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Characterisation of the classical TGF-β1 pathway at mRNA level. A/B/C/D. Cells were grown to 
100% confluent monolayers and growth arrested for 48hrs. Cells were then incubated in serum-free medium alone 
(-TGF) or in medium containing 10ng/mL TGF-β1 (+TGF) for 72hrs. The expression of TGF-β1 (A), TGF-βRI (B), 
SMAD-2 (C) and SMAD-3 (D) were analysed by QPCR. Results are shown as the mean ± s.d. of 3 individual 
experiments. Statistical analysis was performed by a 2 way ANOVA with post Bonferroni test: *, p <0.01, ***, p<0.001. 
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3.2.4. Analysis of the Downstream Signalling of the Classical TGF-β1 Pathway 
To confirm the previous result, protein analysis was undertaken over a time course to 
measure SMAD2 phosphorylation and therefore, downstream signalling from the TGF-βR. 
The NFs saw the greatest increase in SMAD2 phosphorylation at 1h and 3h (Figure 3.4 
A/B). Phosphorylation remained increased from 0h up until 72h. This indicates that SMAD 
downstream signalling was responding to TGF-β1 stimulation and contributing to the 
differentiation in the NFs. However, the two CWFs had donor specific responses, with 
Chronic 2 responding more than Chronic 1 to TGF-β1 treatment. Both CWFs showed slightly 
higher basal levels of phosphorylation at 0hrs compared to NFs. However, increases in 
SMAD2 phosphorylation were induced at 1hr and 24/72hrs (Depending on donor). This 
demonstrates that, although apparently different signalling pattern to NFs, CWFs were 
responding to TGF-β1 signalling via the TGF-βR with downstream signalling via 
phosphorylation of SMAD2. 
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Figure 3.4. SMAD2 phosphorylation, showing downstream signalling of the classical TGF-β1 pathway, is not 
effected in CWFs. Cells were grown to 100% confluent monolayers and growth arrested for 48h. Cells were then 
incubated in medium containing 10ng/mL TGF-β1 (+TGF) for either 0, 1, 2, 3, 24 or 72h. Phosphorylation of SMAD2 
was analysed by Western blotting. Total GAPDH proteins were used as loading controls. B. Images shown are 
representative of 2 independent experiments. A. Densitometric analysis of p-SMAD2, normalised to total GAPDH. Graph 
shows mean with range of 2 independent experiments. 
A B 
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3.2.5. TGF-β1 Induction of the Non-Classical CD44 / EGFR Pathway 
The previous results indicate that the classical TGF-β pathway is largely intact in CWFs and 
not contributing to the loss of differentiation. The non-classical pathway is an independent 
yet essential pathway for myofibroblast differentiation. Two main contributors to this pathway 
are CD44 and EGFR. Both, proteins were measured in the NFs and CWFs, with and without 
TGF-β1 treatment at mRNA and protein levels. All cells demonstrated a decrease in EGFR 
expression with TGF-β1 treatment and only Normal 1 exhibited a non-significant decrease 
(Figure 3.5A). The protein expression followed the same trend, with a decrease in protein 
quantity measured in all stimulated cell types, compared to their unstimulated controls 
(Figure 3.5B). CD44 expression also showed a similar trend across all cell types, with 
decreased expression in response to TGF-β1 treatment (Figure 3.5C). There was no overall 
trend in CD44 protein expression observed (Figure 3.5D). The similarities between NFs and 
CWFs demonstrated that production of these proteins were unaffected in CWFs. 
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3.2.6. Analysis of the Downstream Signalling of the Non-Classical CD44 / EGFR 
Pathway 
The previous result indicated that the production of the two key regulators of the non-
classical pathway were unaffected in CWFs. It was, therefore, of interest to quantify the 
downstream signalling from the non-classical via ERK1/2 phosphorylation (Figure 3.6 A/B). 
ERK1/2 phosphorylation was quantified across a time-course using Western blotting. Donor 
specific responses were apparent in all cell types. Normal 1 showed induction at 1h and 3h, 
whereas, Normal 2 showed induction at 1h and remained at an increased level at 2h and 
3h. Chronic 1 phosphorylation followed a similar pattern to Normal 1, with induction at 1h. 
But, phosphorylation then remained increased at 2h and 3h. On the other hand, Chronic 2 
had a high basal level of phosphorylation, which increased slightly at 1h and then slowly 
decreased over 2h and 3h. Overall, all cell types showed increased ERK1/2 phosphorylation 
at 1h, demonstrating that the cells were responding to TGF-β1.  
Figure 3.5. Characterisation of CD44 and EGFR expression. Cells were grown to 100% confluent monolayers and growth 
arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10ng/ml TGF-β1 for 
72h (+TGF). The expression of (A) EGFR and (C) CD44 were analysed by QPCR. Results are shown as the mean ± s.d. of 
3 individual experiments. Statistical analysis was performed by a 2-way ANOVA with post Bonferroni test: *, p <0.05, ***, 
p<0.001. Western blot analysis of total (B) EGFR and (D) CD44 protein in TGF-β1 treated (+TGF) and control (-TGF) 
fibroblasts. GAPDH was used as a loading control. Representative blot is shown. Densitometry graph shows mean with range 
of 2 independent experiments. 
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Figure 3.6. ERK phosphorylation showing downstream signalling of the non-classical pathway, is not effected 
in CWFs. Cells were grown to 100% confluent monolayers and growth arrested for 48h. Cells were then incubated in 
medium containing 10ng/mL TGF-β1 (+TGF) for either 0, 1, 2, 3, 24 or 72h. Phosphorylation of ERK 1/2 was analysed 
by Western blotting. Total GAPDH proteins were used as loading controls. B. Images shown are representative of 2 
independent experiments. A. Densitometric analysis of p-ERK 1/2, normalised to total GAPDH. Graph shows mean with 
range of 2 independent experiments. 
A B 
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3.2.7. HA Associated Gene Response to TGF-β1 
HA is another key player in the non-classical pathway responsible for fibroblast 
differentiation. Four HA associated genes were therefore measured in the two cell types in 
response to TGF-β1 stimulation. Firstly, there was a significant increase in FAP mRNA 
expression in the two NFs in response to TGF-β1 treatment, whereas its expression did not 
change in the CWFs (Figure 3.7A). The loss of this response may contribute to the loss of 
differentiation in CWFs. Secondly, the overall trend observed in HYBID expression was a 
significant decrease in its expression with TGF-β1 in all cell types. Since no obvious trend 
in response was observed between the NFs and CWFs, HYBID can be discounted as having 
an effect in CWFs (Figure 3.7B). 
CD147 and miR-7 expression were more difficult to analyse since, as seen previously, donor 
specific responses were apparent. Only Normal 2 showed a significant response with 
treatment, where all other cells had a non-significant response to TGF-β1. Similarly, all cell 
types showed a non-significant response in miR-7 expression with treatment. The overall 
trend from these two indicated that they had no role in the loss of CWFs differentiation 
(Figure 3.7C/D).  
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Figure 3.7 Characterisation of HA associated genes in response to TGFβ1 treatment. A/B/C/D. Cells were 
grown to 100% confluent monolayers and growth arrested for 48hrs. Cells were then incubated in serum-free medium 
alone (-TGF) or in medium containing 10ng/mL TGF-β1 (+TGF) for 72hrs. The expression of (A) FAP, (B) HYBID, 
(C) CD147 and (D) miR-7 were analysed by QPCR. Results are shown as the mean ± s.d. of 3 individual 
experiments. Statistical analysis was performed by a 2 way ANOVA with post Bonferroni test: *, p <0.05, **, p<0.01 
***, p<0.001. Data unavailable for Chronic 2 in A and B, experiments considered pilot experiments.  
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3.2.8. Hyaluronidase Isoform Expression in CWFs 
HA metabolism has been shown to be an essential determinant of fibroblast differentiation. 
HA breakdown is undertaken via two enzymes, HYAL1 and HYAL2. Aberrant expression of 
these in CWFs could contribute to dysregulation of the non-classical pathway. mRNA 
expression of the hyaluronidases was measured using qRT-PCR. No significant difference 
in expression was found between control and TGF-β1 treated cells in any of the cell types. 
This indicates that the production of these enzymes was unaffected in CWFs and therefore 
they did not contribute to CWFs dysfunction (Figure 3.8).  
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Figure 3.8. Regulation of HA metabolism via Hyaluronidase. Cells were grown to 100% confluent monolayers and growth 
arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10ng/mL TGF-β1 
(+TGF) for 72hrs. The expression of HYAL-1 and HYAL-2 were analysed by QPCR. Results are shown as the mean ± s.d. 
of 3 individual experiments. Statistical analysis was performed by a 2 way ANOVA with post Bonferroni test: All non-
significant (N/S). 
63 
 
3.2.9. HAS Isoform Expression in CWFs 
HA is synthesised in mammals via a family of three HAS isoenzymes. The expression of 
these were measured to obtain any differences between NFs and CWFs. HAS2 has been 
previously described as the primary HAS isoenzyme involved in the production of the HA 
coat responsible for myofibroblast formation. Overall, all cell types showed no significant 
change in HAS2 expression with TGF-β1 treatment (Figure 3.9B). However, a clear trend 
was seen where HAS2 increased in NFs and decreased in CWFs with TGF-β1 stimulation. 
This trend maybe contributing to a dysfunctional HA metabolism in CWFs. There was no 
significant change in HAS3 expression with TGF-β1 in either cell types. The difference with 
HAS3 compared to HAS2 was that a similar trend was observed in both cell types, with a 
slight increase in HAS3 expression with TGF-β1 (Figure 3.9C). The most significant finding 
was from HAS1 expression, where only the CWFs showed a significant increase in 
expression with TGF-β1 (Figure 3.9A). This was also matched by a higher basal expression 
observed in the CWFs compared to the NFs. Generally, these results indicate a significant 
shift in the HAS enzymes, contributing to HA metabolism dysfunction. 
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Figure 3.9. HAS isoform expression in normal and chronic fibroblasts. Cells were grown to 100% confluent monolayers 
and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10ng/Ml 
TGF-β1 (+TGF) for 72h. The expression of HAS1 (A), HAS2 (B), HAS3 (C) were analysed by QPCR. Results are shown as 
the mean ± s.d. of 3 individual experiments. Statistical analysis was performed by a 2 way ANOVA with post Bonferroni test: 
**, p <0.01, ***, p<0.001. 
A 
B 
C 
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3.2.10. TSG-6 and Heavy Chains 
HA binding to its receptor, CD44, is stabilised via TSG-6 and IαI heavy chain interactions. 
Their expression was therefore measured to understand if they could enlighten further 
contributions to the dysfunction HA metabolism and non-classical pathway. The overall trend 
observed with TSG-6 expression was an increase in expression with TGF-β1 treatment, in 
all cell types. However, it was only a significant increase in Chronic 1 (Figure 3.10A). 
The heavy chain expression uncovered some differences between the two cell types. HC1 
expression significantly increased with TGF-β1 treatment in the NFs, whereas no changes 
were observed in the CWFs. The same result was also seen with HC4 and HC5. The 
opposite result was observed in HC3, with a significant increase in its expression only seen 
the CWFs. HC2 and HC6 showed no significant change with treatment in either of the cell 
types (Figure 3.10B. These results might have uncovered further mechanisms that 
contribute to CWFs dysfunction). 
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Figure 3.10 Tumour-necrosis-factor-stimulated-gene-6 (TSG-6) and inter-α-inhibitor (IαI) heavy chains expression in 
NFs and CWFs. Cells were grown to 100% confluent monolayers and growth arrested for 48hrs. Cells were then incubated 
in serum-free medium alone (-TGF) or in medium containing 10ng/Ml TGF-β1 (+TGF) for 72hrs. The expression of TSG-6 
and heavy chain (HC) 1-6 were analysed by QPCR. Results are shown as the mean ± s.d. of 3 individual experiments. 
Statistical analysis was performed by a 2 way ANOVA with post Bonferroni test: *, p>0.05, **, p <0.01, ***, p<0.001. 
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3.3. Discussion 
This initial chapter characterises CWFs and their responses to TGF-β1 treatment, in the 
context of the two contributing pathways that signal myofibroblast differentiation. Insights 
are provided about possible allied genes to the two pathways and the roles they may play 
in the loss of CWFs myofibroblast formation. The data reported here build on previous 
findings on TGF-β1-induced differentiation in NFs, uncovering possible genes that 
contribute to the loss of the myofibroblast response in CWFs. 
CWFs have been previously characterised to have a reduce proliferative lifespan, early 
onset of senescence with an altered response to TGF-β1 signalling, resulting in the loss of 
their differentiation capabilities (Kim et al., 2003, Wall et al., 2008). Since the cells used in 
this thesis had not yet been characterised, specifically in the context of their TGF-β1 
response, initial findings from this chapter characterised these cells at a proliferative and 
differentiation level. The two CWFs showed early onset of senescence and reduced 
proliferative lifespans, with similar morphologies seen in previous publications such as Wall 
et al., 2008, confirming their chronic wound phenotype. Further characterisation was 
undertaken to measure their response to TGF-β1 stimulation and resulting differentiation 
capacity, as measured via the up-regulation of genes associated with myofibroblasts and 
the formation α-SMA fibres. Previous studies have shown CWFs to be unresponsive to the 
stimulatory cytokine TGF-β1 (Hasan et al., 1997, Wu et al., 1999), with other studies 
demonstrating that the myofibroblast phenotype is absent from the chronic wound 
environment (Olerud et al., 1995), caused by hypoxia and the loss of granulation tissue from 
the myofibroblast niche (Alizadeh et al., 2007, Modarressi et al., 2010, Sen and Roy, 2010). 
To date however, no studies have investigated CWFs α-SMA response in vitro and 
compared to NFs under identical conditions. These results confirmed that CWFs have 
defective response to TGF-β1 stimulation in the context of differentiation, showing that 
myofibroblast differentiation is lost in CWFs. This was confirmed with the loss of α-SMA and 
FN-EDA gene expression, and α-SMA fibre formation in response to TGF-β1 stimulation. 
Both these genes are known to be essential for the formation of the contractile α-SMA fibres 
in myofibroblasts (Shinde et al., 2015, Bochaton-Piallat et al., 2016). 
The differentiation of fibroblasts to myofibroblasts is regulated by two independent but co-
operating pathways, the classical TGF-βR and the non-classical HA-CD44-EGFR pathway. 
Since differentiation capacity is lost in the CWFs, it was important to establish whether 
dysregulated signalling in one or both pathways was responsible for this loss. CWFs still 
significantly responded to TGF-β1 treatment with the upregulation of the TGF-β1 gene. 
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However, this upregulation was not matched by the upregulation of the receptor TGF-βRI 
(ALK-5), lost in the CWFs. Previous studies have also shown that TGF-β1 expression does 
not change between normal and ulcer tissue, but receptor expression is lost in CWFs (Jude 
et al., 2002, Kim et al., 2003). Since, the loss of receptor expression is apparent in CWFs it 
was important to measure the downstream signalling from these receptors and therefore 
gene expression of SMAD2 and SMAD 3 was measured. However, did not show any 
differences in expression between NFs and CWFs. SMAD2 phosphorylation was 
subsequently measured over a time-course to compare to previous publications that have 
indicated that loss of the TGF-β receptor results in the loss of SMAD phosphorylation (Kim 
et al., 2003). It is apparent from these results that SMAD2 phosphorylation is different 
compared to NFs, but since the cells used here are not patient matched, they are not directly 
comparable. Both CWFs show induction of SMAD2 phosphorylation with TGF-β1 at 1h, 
which is comparable to the 30min induction seen in Kim et al., (2003). These results 
confirmed previous findings, that SMAD2 phosphorylation is affected in CWFs, but these 
results also show that SMAD phosphorylation is evident but attenuated, indicating that the 
TGF-β1 signalling pathway is intact in the CWFs. Aberrant SMAD signalling has also been 
attributed to a range of other cellular processes, including proliferation, which we know is 
affected in CWFs (Ten Dijke et al., 2002, Wall et al., 2008). These results clearly indicate 
that the classical TGF-β1 pathway is affected but intact in CWFs and does not seem to 
implicate this pathway in the loss of differentiation in CWFs. 
The second pathway regulating fibroblast to myofibroblast differentiation is the non-classical 
pathway, HA-CD44-EGFR. In aged fibroblasts, resistant to myofibroblast differentiation, this 
pathway has been shown to be impaired, with downregulation of EGFR mRNA and protein 
expression and reduced CD44 membrane motility (Midgley et al., 2014). Comparatively, the 
results from this chapter show that neither EGFR or CD44 are affected in CWFs. Combined 
with the result from Figure 3.7D, showing no difference in miR-7 expression between the 
CWFs and NFs, confirms that EGFR expression is not affected like the in vitro aged 
fibroblasts shown by Midgley et al, (2014). It has previously been shown that ERK1/2 
phosphorylation is lost in the presence of an inhibitor of the EGFR (Midgley et al., 2014). 
Since EGFR expression is unaffected in the CWFs, it was thought that the downstream 
signalling via the ERK1/2 pathway would also be unaffected. The results from this chapter, 
similarly to the SMAD2 phosphorylation results above, show donor specific signalling 
responses. Overall, ERK1/2 phosphorylation does respond to TGF-β1 treatment in all cell 
types, with a clear induction seen after 1h. This similarity to the SMAD2 result, conflicts 
previous evidence that states that ERK1/2 phosphorylation is lost in CWFs (Kim et al., 2003). 
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This research, however, only examined activation at 30mins, other studies have indicated 
that TGF-β1 is capable of direct activation of ERK1/2 (Lee et al., 2007). Activation of this 
pathway may also regulate other cell systems such as proliferation during this time-course 
(Zhang and Liu, 2002). Simpson et al., (2010) clearly demonstrated that ERK1/2 
phosphorylation caused by EGFR signalling was at 10min post TGF-β1 stimulation, which 
were not assessed. Although these results show discrepancies between ERK1/2 signalling 
in CWFs and NFs (Kim et al., 2003), they do not conclusively show that the non-classical 
pathway is inhibited in CWFs and therefore, further associated genes with this pathway were 
investigated.  
FAP is an inflammation and CD44 associated molecule, which has been connected with 
increased cellular proliferation, adhesion, migration and apoptosis, via TGF-β1 stimulation 
(Chen et al., 2009, Wang et al., 2005, Bauer et al., 2006). It was therefore interesting to see 
that FAP induction is lost in CWFs treated with TGF-β1. No current literature directly links 
FAP activation to myofibroblast formation. However, this loss and the documented co-
localisation of FAP and variants of CD44, might indicate its contribution to dysfunction in 
CWFs (Wang et al., 2005). Another HA-CD44 associated proteins, is the transmembrane 
glycoprotein, CD147, which is associated with inflammatory diseases, cancer and most 
importantly tissue remodelling (Grass et al., 2014). Overexpression of CD147 in corneal 
fibroblasts upregulates αSMA expression and the subsequent contractile potential of these 
fibroblasts (Huet et al., 2008a). Overall, the results did not indicate any differential 
expression between NFs and CWFs in response to TGF-β1, thus indicating the lack of a 
role of CD147 in CWFs biology. The final HA associated gene investigated was HYBID 
(KIA1199) which has been associated with regulating HA metabolism and synthesis 
(Nagaoka et al., 2015). In this paper they showed that TGF-β1 stimulation in NFs, decreased 
HYBID expression which correlated with an increase in HAS2 expression. In Figure 3.7B, 
NFs also showed a decrease in expression with TGF-β1 treatment. This result is shared 
with the CWFs, therefore discounting any direct effects HYBID may be having on the loss 
of the myofibroblast phenotype in CWFs. 
CD44 is the receptor for HA, the binding of the two forms a pericellular HA coat that has 
been shown to be essential for myofibroblast formation. Loss of this coat leads to a non-
healing phenotype, such as that shown by in vitro aged fibroblasts (Simpson et al., 2009). 
HA metabolism is therefore a major contributing factor to the successful pro-fibrotic 
signalling in fibroblasts. HA metabolism is regulated by the enzymes responsible for HA 
synthesis, HAS1, 2 and 3 and the enzymes responsible for its degradation, the HYALs. 
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HYALs via their action on HA are modulators of the inflammatory response and are thus 
generally induced in inflammatory diseases such as chronic ulcers (Fronza et al., 2014, 
Dechert et al., 2006). HYAL2 has also been specifically linked to TGF-β1 localisation, 
indicating an interaction (Hsu et al., 2009). The results in Figure 3.8 demonstrated that there 
were no significant difference in HYAL1 or HYAL2 expressions with TGF-β1 treatment in 
either NFs or CWFs, indicating it does not have a direct role in the loss of CWFs 
differentiation. Although, HA degradation does not seem to be affected in CWFs, synthesis 
of HA was greatly altered. Figure 3.9 demonstrates that HAS1 becomes the predominant 
HAS isoenzyme expressed in the CWFs compared to HAS2 in NFs. This is evident by a 
higher resting basal level of HAS1 in CWFs, which has been documented before (Wall et 
al., 2008), which is also further induced by TGF-β1 stimulation. Corresponding with this was 
a slight decrease in HAS2 expression in CWFs with TGF-β1, in contrast to the increase seen 
in the NFs. It has been well documented that HAS2 is the predominant HAS isoenzyme 
responsible for HA pericellular coat formation in NFs (Simpson et al., 2009). The 
replacement of this HAS might be significantly detrimental to HA coat formation and thus 
ability of the CWFs to produce a myofibroblast phenotype.  
Changes in HA metabolism are apparent in CWFs but, it is yet to be elucidated whether the 
HA pericellular coat is lost in this cell type, causing the loss of differentiation. For successful 
HA coat formation, the interaction between HA and its cell surface receptor, CD44, needs 
to be stabilised. HA coat stabilisation is undertaken via interaction of TGS-6 and IαI HC5; as 
knockdown of either inhibits myofibroblast formation (Martin et al., 2016). TSG-6 and HC5 
have been shown to respond to TGF-β1 signalling and promote a fibrotic phenotype in 
fibroblasts (Martin et al., 2016). Although TSG-6 response in CWFs remains similar to that 
observed in NFs, HC5 response is lost in the CWFs, indicating that the HA coat is lost in 
these cells. Interestingly, HC1 and HC4 responses are also lost in the CWFs, with HC1 
being associated with leukocyte binding to an inflammatory HA matrix (Petrey and de la 
Motte, 2016) and HC4 being associated with fibrosis in the liver of patients with chronic 
hepatitis C (Sira et al., 2014). The loss of the response in these two heavy chains may again 
elucidate contributions to the loss of the pro-fibrotic phenotype in CWFs. HC3 was the only 
HC that responded to TGF-β1 in CWFs without showing a response in NFs, this may indicate 
its role in stabilizing the HAS1 produced HA matrix in CWFs. 
At this point we cannot exclude that more than one abnormality, possibly several 
independent ones, exist in CWFs, including aberrant TGF-βR expression and the 
phosphorylation of key signalling proteins of the SMAD and ERK family. This chapter has 
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characterised the NFs and CWFs, confirming their chronic wound phenotype and 
determined that their ability to differentiate into contractile α-SMA positive myofibroblast is 
lost. This loss however, is not due to the classical TGF-βR pathway that remains intact, 
responding to TGF-β1 stimulation. Analysis of key regulators of HA metabolism and 
stabilisation indicate dysregulation of the non-classical HA-CD44-EGFR pathway. The loss 
of HAS2 congruent with the overexpression of HAS1 indicates a different HA matrix is being 
synthesised by CWFs, together with the loss of HC5, further adds to the hypothesis that the 
HA pericellular coat maybe lost in the CWFs, leading to the loss of myofibroblast 
differentiation signalling.  
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Chapter 4 
The Role of Hyaluronan in The 
Loss of the Myofibroblast 
Response in Chronic Wound 
Fibroblasts 
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4.1. Introduction 
In the previous chapter, it was found that the loss of myofibroblast differentiation in CWFs 
was not due to defective TGF-β1/TGF-βR pathway or its downstream signalling via SMAD 
phosphorylation. However, the independent non-classical pathway described previously 
(Midgley et al., 2013), might be affected in CWFs, as a result of the differential aberrant HAS 
isoform expression observed in the CWFs treated with TGF-β1. HAS1 had a higher basal 
expression in the CWFs and its expression was further induced with TGF-β1 treatment, 
whereas NFs had a very low expression. Previous studies have shown that HA plays a large 
role in the differentiation mechanism of fibroblasts. HA binds its cell surface receptor, CD44, 
which causes the formation of a HA pericellular coat surrounding the differentiated 
myofibroblasts. The loss of this coat prevents differentiation, HA metabolism is therefore 
essential for differentiation to occur (Meran et al., 2007). HA is synthesised by HAS 
enzymes, HAS2 has been found to be the primary HAS isoform responsible for producing 
HA for the formation of the pericellular coat during differentiation in NFs. HAS2 expression 
is vital for differentiation, with silencing HAS2 resulting in the loss of the myofibroblast 
phenotype (Simpson et al., 2009).  
4.1.1. Hyaluronan’s role in wound healing 
HA is a ubiquitous GAG component of the ECM, found in almost all connective tissues. 50% 
of the body’s HA is found in the skin, which indicates HA’s vital role in wound healing (Buhren 
et al., 2016). Due to its unique physical qualities, HA creates an excellent wound healing 
environment. HA synthesis is induced following injury to the skin and has been found to have 
vital roles in scarless foetal wound healing (Zgheib et al., 2014). In addition, its exogenous 
application has been found to enhance wound healing in animal models. HA via its receptors 
can modulate cell inflammation, migration, adhesion, proliferation, differentiation and 
angiogenesis (Su et al., 2014). 
The action of HA is dependent on its molecular weight size. High molecular weight HA has 
an anti-inflammatory, anti-angiogenic and immunosuppressive function by modulating the 
immune response. High molecular weight HA also supports cell integrity and is highly 
expressed in normal tissues. High molecular weight HA can cause cell-cycle arrest, and also 
protect against apoptosis mediated by nuclear factor kappa-B (NFs-κB) (Wolf et al., 2001). 
On the other hand, low molecular weight HA is a potent pro-inflammatory, angiogenic and 
immune stimulatory molecule. The presence of small HA fragments is associated with 
tissues under stressed conditions. Very small fragments, such as the tertrasaccharides, 
however, have been found to regulate the intensity of effects caused by the intermediate 
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low molecular weight HA, by identifying tissue injury through toll-like receptors (Litwiniuk et 
al., 2016, Aya and Stern, 2014). The increased catabolism of high molecular weight into low 
molecular weight fragments by the actions of the hyaluronidases, has been linked to 
inflammatory conditions (Harada and Takahashi, 2007). 
HA can exist in a number of forms. HA can be membrane bound to HA-binding proteins 
known as hyaladherins, such as CD44, or soluble in the ECM or cytoplasm. HA can also be 
synthesised intracellularly under stressed conditions. The exact role of intracellular HA is 
still uncertain. Intracellular HA has been linked to: mitosis (by providing a more favourable 
milieu for nuclear division), endoplasmic reticulum stress and the formation of HA cables 
(which facilitate monocyte binding and inflammation). The accumulation of perinuclear HA 
is observed in rat kidney diabetic models, which again was linked to an influx of monocytes 
and macrophages. Chronic inflammation is proposed to be caused by the lack of breakdown 
of this uniquely pro-inflammatory HA matrix (Hascall et al., 2004). Multiple cell types have 
been shown to breakdown and endocytose HA, such as macrophages and keratinocytes, 
mediated by the cell surface receptor CD44 (Harada and Takahashi, 2007).  
4.1.2. Hyaluronan’s role in myofibroblast differentiation 
HA has functions throughout the wound healing cascade, influencing cellular adhesion, 
proliferation, migration and a central role in orchestrating myofibroblastic differentiation, via 
the non-classical HA-CD44/EGFR pathway. This pathway is an independent but 
collaborating pathway to the classical TGF-β1/TGF-βR pathway, the loss of either pathway 
results in loss of differentiation. In the non-classical pathway HA binds its cell surface 
receptor, CD44, creating a HA-rich pericellular coat. CD44 also co-localises with EGFR 
within lipid rafts on the membrane surface. This co-localisation leads to downstream 
signalling via the ERK1/2 and CAMKII pathway which signals for differentiation (Midgley et 
al., 2013). Loss of this HA coat leads to failed differentiation. HA regulates fibroblasts 
response to TGF-β1 by altering the levels of HA produced, via HAS2 expression (Midgley 
et al., 2013). 
4.1.3. HAS2 regulation and synthesis of HA pericellular coat 
HA is synthesised via three identified mammalian HA synthase isoenzymes, of which HAS2 
shows the greatest expression in NFs. Each synthase has been shown to produce different 
quantities and sizes of HA, with HAS2 producing large amounts of high molecular weight 
HA (Ferguson et al., 2011). Endogenous treatment of TGF-β1 in fibroblasts has shown to 
induce HAS2 mRNA expression. Loss of HAS2 expression in aged fibroblasts results in the 
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loss of the cells ability to produce a pericellular coat. Overexpression of HAS2 expression in 
aged fibroblasts, restored their ability to produce a pericellular coat and thus, differentiation 
(Simpson et al., 2009). HAS2 ability to create a pericellular coat is due to its membrane 
association, however this has also been detectable in an ER-golgi area (Bart et al., 2015). 
4.1.4. HAS1 expression in CWFs 
HAS1 expression during embryogenesis is more limited than HAS2 and HAS3, with 
knockout HAS1 animals having no apparent phenotype, compared to knockout HAS2 which 
is lethal during early embryogenesis. Because of its low expression in normal tissue, 
research into its function has remained elusive. The expression of HAS1 and its splice 
variants is found to increase under disease states (Siiskonen et al., 2014). It has previously 
been shown that CWFs have a higher basal expression of HAS1 compared to normal dermal 
fibroblasts (Wall et al., 2008). HAS1 expression is very low in NFs, however induction has 
been observed following TGF-β1 and IL-1β stimulation (Siiskonen et al., 2014). The location 
of HAS1 has been well reported as an intracellular isoenzyme, being present diffusely 
throughout the cytoplasm, or in patches, with possible co-localisation with the golgi 
apparatus (Ghosh et al., 2009). This may indicate that HAS1 is responsible for intracellular 
HA synthesis. 
4.1.5. HAS1 synthesised HA and inflammation 
HA is generally accepted as a regulator of inflammation, with low molecular weight HA 
fragments found to be pro-inflammatory (Termeer et al., 2002). HAS1 has been associated 
with the production of low molecular weight HA (Itano and Kimata, 2002). The previous 
chapter demonstrated that HAS1 expression can be regulated via the presence of cytokines, 
such as TGF-β1, with HAS1 expression generally being associated with pro-inflammatory 
cytokines. IL-1β is a pro inflammatory cytokine implicated in pain, inflammation and 
autoimmune conditions (Ren and Torres, 2009). HAS1 expression has been shown to be 
induced by the action of IL-1β, which indicates its role in the inflammatory response 
(Yamada et al., 2004, Kao, 2006). Numerous other pro-inflammatory cytokines have also 
been shown to regulate HAS1 expression including, interferon gamma (IFN-γ), tumour 
necrosis factor alpha (TNF-α) (Campo et al., 2006). Not only does HAS1 respond to 
cytokines, HA produced by HAS1 may contribute to the regulation of cytokines. These 
include the pro-inflammatory cytokines, monocyte chemoattractant protein 1 (MCP-1 also 
known as CCL2), intercellular adhesion molecule 1 (ICAM1) and interleukin 8 (IL-8) that are 
induced in the presence of low molecular weight HA, that may be produced by HAS1 (Beck-
Schimmer et al., 1998, McKee et al., 1996, Oertli et al., 1998). Other pro-inflammatory 
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mediators such as regulation on activation, normal T-cell expressed and secreted (RANTES 
also known as CCL5) may contribute to the expression of CD44 molecules expressed on T-
cells, allowing them to bind HA present at wound sites (Oertli et al., 1998). Clearly, there is 
an association of HAS1 derived HA and pro-inflammatory cytokines which may indicate a 
potential reason for the higher expression of HAS1 in CWFs, observed in the previous 
chapter. This association between HAS1 and inflammation will be investigated further in this 
chapter. 
4.1.6. The aims of this chapter are: 
I. Determine the role of HA in the dysregulation of myofibroblastic differentiation in 
CWFs. 
II. Analyse the location of HAS isoenzymes in relation to endogenously synthesised 
HA. 
III. Attempt to recover the myofibroblast phenotype in CWFs by manipulation of the HA 
metabolism. 
IV. Explore the role of HAS1 expression in CWFs. 
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4.2. Results 
 Localisation of Total HA does not change with TGF-β1 Treatment 
Total HA (intracellular and pericellular) distribution was analysed using HABP and 
fluorescence microscopy. Both CWFs and NFs were grown to 60-70% confluence, growth 
arrested and then either incubated in serum free media or media stimulated with TGF-β1 
(10 ng/mL) for 72h. Stimulation of the NFs with TGF-β1 resulted in HA being organised into 
clear parallel lines (Figure 4.1). Distribution of HA in the CWFs seemed less organised, with 
possible areas of HA clustering. Overall, the intensity of HA staining between the control 
and the TGF-β1 stimulated cells did not change in either cell type, which demonstrated only 
a change in HA distribution in CWFs. 
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Figure 4.1 Localisation of total Hyaluronan does not change with TGF-β1 treatment. A. Cells were grown to 60-70% 
confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium 
containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression of total HA GAG was examined by immunocytochemistry; nuclei 
were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original Magnification 
x400. Scale bar 100µm. 
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 Visualisation of HA Pericellular Coat Using Red Blood Cell (RBC) Exclusion 
Assay 
It has previously been described that fibroblasts under the stimulation of TGF-β1 produce a 
HA pericellular coat. To determine if HA coat formation was lost in CWFs a RBC exclusion 
assay was used to visualise the pericellular HA coats of both NFs and CWFs, in the absence 
and presence of exogenous TGF-β1. In the absence of TGF-β1 stimulation both NFs and 
CWFs showed no HA coat present (Figure 4.2). The NFs responded to TGF-β1 treatment, 
with the induction of a clearly defined HA pericellular coat surrounding the cells. CWFs 
showed some RBC exclusion, although to a lesser extent than seen in the NF’s. The coat 
was confirmed to be formed by HA by using a hyaluronidase treated negative control. This 
eradicated the HA coat and RBC distribution in the TGF-β1 stimulated NFs.  
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Figure 4.2. Visualisation of HA pericellular coat using Red Blood Cell (RBC) exclusion assay. A. Cells were grown to 
60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium 
containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression visualisation of HA was examined by RBC exclusion assay. 
Yellow arrows show HA coat presence. Images shown are a representation of 2 independent experiments. Original 
Magnification x200. Hyaluronidase treated cells were used as a control, removing pericellular HA. Scale bar: 100µm. 
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 Distribution of HA by ELISA 
Given the importance of HA in myofibroblastic differentiation, endogenous HA was 
quantified using a HA ELISA. HA was quantified from three separate areas: extracellular, 
pericellular and intracellular. Trypsin was used to isolate pericellular HA, following this 
treatment the remaining cells were lysed releasing intracellular / cytoplasmic HA. Media was 
collected prior to the trypsin digestion, which allowed extracellular HA to be quantified. Cells 
were growth arrested and then incubated for 72hrs in either serum-free conditions or media 
stimulated with TGF-β1. 
Extracellular HA was quantified from the media collected following the 72h incubation. Only 
Normal 1 and Chronic 2 showed a significant induction of HA with TGF-β1 stimulation 
(Figure 4.3A). Normal 2 and Chronic 1 were not significant, however these did show a trend 
of HA induction with TGF-β1 stimulation. No overall difference was observed between the 
NFs and CWFs, since all cells responded to TGF-β1 treatment with the induction of 
extracellular HA. 
Cytoplasmic HA was quantified by the lysis of cells following trypsin treatment to remove 
surface HA. Only Normal 1 showed a significant induction of intracellular HA with TGF-β1 
treatment (Figure 4.3B). Normal 2 was not significant, but did show an increase of 
intracellular HA production with TGF-β1. Both the CWFs showed no significant difference in 
intracellular HA between control and stimulated cells. Overall intracellular HA only increased 
with TGF-β1 in NFs. 
Pericellular HA was isolated using a trypsin digestion, removing surface bound HA. Both 
NFs’s (Normal 1 and 2) demonstrated a significant induction of pericellular HA with the 
addition of exogenous TGF-β1 to the medium, demonstrating the formation of a pericellular 
coat (Figure 4.3C). However, the CWFs did respond to TGF-β1 stimulation with an increase 
of pericellular HA seen. However, this increase was not significant in Chronic 1, and overall 
was considerably lower induction that that observed in the NFs. Thus, the formation of a HA 
pericellular coat was attenuated in CWFs. 
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Figure 4.3. Quantification of HA by ELISA. Cells were grown to 90-100% confluence and growth arrested for 48h. Cells 
were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. Media 
was collected before cell lysis to quantify extracellular HA (A). Trypsin was used to isolate the pericellular (C) and cytoplasmic 
(B) HA. Results are shown as the mean ± s.d. of 3 individual experiments. Statistical analysis was performed by a 2 way 
ANOVA with post Bonferroni test: **, p <0.05, **, p<0.01, ***, p<0.001**. 
A 
B 
C 
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 HAS2 Localisation 
Given the loss of HAS2 mRNA induction with TGF-β1 treatment in CWFs shown in the 
previous chapter, the location of HAS2 was examined, comparing its location in resting and 
TGF-β1 stimulated cells. In both NFs HAS2 localisation did not change between resting and 
stimulated cells. HAS2 had a diffuse staining pattern and was shown to be present within 
nucleoli (Normal 1, +TGFβ1). HAS2 location in CWFs was similar to that seen in the NFs, 
however Chronic 1 showed strong staining of HAS2 within the nucleoli and Chronic 2 
showed very strong staining in a perinuclear location. This perhaps reveals HAS2 becoming 
predominantly intracellular in CWFs (Figure 4.4).  
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Figure 4.4. HAS2 Localisation. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells were then 
incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression of 
HAS2 (green) was examined by immunocytochemistry, nuclei were visualised by Hoechst stain. Images shown are a 
representation of 2 independent experiments. Original Magnification x400. Scale bar: 100µm. 
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 HAS1 clusters in a perinuclear location in TGF-β1 Treated CWFs 
The previous chapter demonstrated that CWFs had increased basal expression of HAS1, 
with HAS1 also responding to TGF-β1 signalling in CWFs alone. It was therefore interesting 
for me to examine the location of HAS1. In treated CWFs HAS1 showed to cluster into 
multiple individual bunches, in a perinuclear location. HAS1 therefore not only responds to 
TGF-β1 at an mRNA level but also at a protein level in CWFs. HAS1 staining in the NFs also 
showed a predominantly intracellular staining pattern, but, with no significant differences 
seen between resting and stimulated cells (Figure 4.5). Differences seen are thought to be 
due to the change in cellular morphology, increasing surface area and thus, the HAS1 stain 
spreads with it, giving a different staining pattern.  
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Figure 4.5 HAS1 clusters in a perinuclear location in TGF-β1 Treated CWFs. Cells were grown to 60-70% confluence 
and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 
ng/mL TGFβ1 (+TGF) for 72h. The expression of HAS1 (red) was examined by immunocytochemistry, nuclei were visualised 
by Hoechst stain. Images shown are a representation of 3 independent experiments. Original Magnification x400. Scale bar: 
100µm. 
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 Intracellular HA clusters in a perinuclear location in CWFs 
The results from both Figure 4.3, showed that intracellular HA quantification does not 
change in CWFs with TGF-β1 treatment. However, Figure 4.1 already demonstrated that 
differences can be seen in HA localisation without changes in the quantity of HA. This 
evidence combined with the intracellular location of HAS1, prompted an investigation into 
the intracellular location of HA in CWFs. Intracellular HA was imaged using HABP and 
fluorescence microscopy on cells pre-treated with hyaluronidase 30min prior to fixation, to 
remove surface HA. Intracellular HA in NFs did not differ between resting and TGF-β1 
treated cells (Figure 4.6). However, intracellular HA distribution in CWFs was concentrated 
in a perinuclear location. Some cells (Chronic 1) showed a ring like staining pattern 
surrounding the nucleus of cells, which could be acting as a barrier. This pericellular location 
of HA was not observed in any NFs, making this a key finding in CWFs cell biology. 
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Figure 4.6. Intracellular HA clusters in a perinuclear location in CWFs. Cells were grown to 60-70% confluence and 
growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL 
TGFβ1 (+TGF) for 72h. The expression of intracellular HA was examined by immunocytochemistry; nuclei were visualised 
by Hoechst stain. Cells were pre-treated with Streptomyces Hyaluronidase (H1136, Sigma-Aldrich) 30min prior to fixation, to 
remove pericellular HA. Images shown are a representation of 2 independent experiments. Original magnification x400. 
Scale bar: 100µm. 
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 Silencing HAS1 does not recover a myofibroblast phenotype in CWFs 
The evidence collated throughout this and the previous chapter shows that HA metabolism 
is altered in CWFs. HAS1 has been implicated to be a key player in the altered and 
dysregulated HA production in CWFs during attempted TGF-β1 induced myofibroblast 
differentiation, I therefore sought to silence the expression of HAS1 in CWFs, to a similar 
level of expression observed in NFs, in order to elucidate whether this would recover a 
myofibroblast phenotype in CWFs. Initially the optimum concentration of siHAS1 to use was 
calculated (Figure 4.7B), with 100nmol of siHAS1 showing the greatest decrease in HAS1 
expression compared to scramble negative control. Cells were visually checked for viability 
before lysis. No difference was observed in α-SMA induction at an mRNA level in the cells 
transfected with siHAS1 compared to scramble control, elucidating that silencing HAS1 did 
not induce α-SMA mRNA expression and thus a myofibroblast phenotype (Figure 4.7C). To 
confirm this cells were transfected with 100nmol of siHAS1 and α-SMA was visualised using 
immunocytochemistry. Although, possible αSMA fibres were visualised in CWFs, induction 
observed in siHAS1-transfected CWFs was not as great as previously seen in treated NF 
(figure 3.2), confirming that silencing HAS1 could not recover a myofibroblast phenotype to 
a comparable level as that observed in the NFs (Figure 4.7A).  
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Figure 4.7. Silencing HAS1 does not recover a myofibroblast phenotype in CWFs. A. Cells were grown to 60-70% confluence 
and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 
(+TGF) for 72h. The localisation of α-SMA was examined by immunocytochemistry; nuclei were visualised by Hoechst stain. Images 
shown are a representation of 2 independent experiments. Original Magnification x400. Scale bar: 100µm. B/C. CWFs 1 and 2 were 
grown to 90-100% confluent monolayers and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) 
or in medium containing 10ng/mL TGF-β1 (+TGF) for 72h. The expression of αSMA and HAS mRNA was analysed by QPCR. Results 
are shown as the mean with range of 2 individual experiments. 
B C 
91 
 
 Overexpression of HAS1 does not induce a CWFs phenotype in NFs 
To confirm the results obtained in Figure 4.7, HAS1 was overexpressed in NFs to determine 
whether this would induce a chronic wound phenotype, resistant to TGF-β1 stimulated 
differentiation. Transfection of the overexpression vector was confirmed by the 
measurement of HAS1 at mRNA and protein levels. Both showed an increase of HAS1 
following transfection of the HAS1 vector (Figure 4.8 B and C). To assess the affect, the 
overexpression vector had on the myofibroblast phenotype, cells were treated with TGF-β1 
(10 ng/mL) and stained using α-SMA antibody. Following transfection and stimulation, no 
loss of α-SMA fibre formation was observed in either NFs (Figure 4.8A), demonstrating again 
that HAS1 does not have a direct role in the myofibroblast differentiation machinery. 
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Figure 4.8. Overexpression of HAS1 does not induce a CWFs phenotype in NFs. A. Cells were grown to 60-70% confluence and growth 
arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. 
The localisation of αSMA protein was examined by immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a 
representation of 2 independent experiments. Original Magnification x400. Scale bar: 100µm. B. Cells were grown to 90-100% confluent 
monolayers and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10ng/mL 
TGF-β1 (+TGF) for 72h. The expression of HAS1 mRNA was analysed by QPCR. Results are shown as the mean ± s.d. of 3 individual 
experiments. **, p<0.01, ***, p<0.001. B. Western blot densitometry of HAS1 normalised to GAPDH. Results are one individual experiment. 
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 Overexpression of HAS2 does not recover a myofibroblast phenotype in 
CWFs 
Since it was apparent that HAS1 was not the primary HAS isoform responsible for the loss 
of myofibroblast differentiation in CWFs, attention turned to HAS2. HAS2 has been 
previously described as the primary HAS enzyme responsible for HA production during 
differentiation. The previous chapter also unveiled that CWFs have a decreased response 
of HAS2 mRNA expression with TGF-β1 treatment. I therefore wished to clarify whether the 
loss of HAS2 response to stimulation in CWFs, was to blame for the loss of differentiation in 
CWFs by overexpressing HAS2 in the CWFs. Successful transfection of the overexpression 
HAS2 vector was confirmed, with an increase in HAS2 mRNA expression in transfected 
cells, compared to cells transfected with an empty vector control (Figure 4.9A). α-SMA 
mRNA was measured in the transfected cells, to determine whether HAS2 overexpression 
induced α-SMA expression and thus differentiated into myofibroblasts. No significant 
induction of α-SMA was observed between cell transfected with HAS2 and those transfected 
with an empty vector. Therefore, over expressing HAS2 in CWFs did not return a 
myofibroblast phenotype.    
 
 
 
 
 
94 
 
C
hr
on
ic
 1
 (E
m
pt
y)
C
hr
on
ic
 1
 O
E
H
2
C
hr
on
ic
 2
 (E
m
pt
y)
C
hr
on
ic
 2
 O
E
H
2
0
1
2
3
4
50
100
150
200
250
-TGF
+TGF
N/S
N/S
N/S
N/S
R
e
la
ti
v
e
 H
A
S
2
 m
R
N
A
e
x
p
re
s
s
io
n
 (
R
Q
)
 
C
hr
on
ic
 1
 (E
m
pt
y)
C
hr
on
ic
 1
 O
E
H
2
C
hr
on
ic
 2
 (E
m
pt
y)
C
hr
ni
c 
2 
O
E
H
2
0
5
10
15
-TGF
+TGF*
*
R
e
la
ti
v
e
 A
lp
h
a
 s
m
o
o
th
m
u
s
c
le
 a
c
ti
n
 (
a
S
M
A
)
m
R
N
A
 e
x
p
re
s
s
io
n
 (
R
Q
)
N/S
N/S
 
 
 
 
Figure 4.9. Overexpression of HAS2 does not recover a myofibroblast phenotype in CWFs. Cells were grown 
to 90-100% confluent monolayers and growth arrested for 48h. Cells were then incubated in serum-free medium 
alone (-TGF) or in medium containing 10ng/Ml TGF-β1 (+TGF) for 72h. Fibroblasts were transfected with an 
overexpression HAS2 vector or empty vector for 24h, prior to TGF-β1 treatment for 72h. The expression of HAS2 
and αSMA mRNA were analysed by QPCR. Results are shown as the mean ± s.d. of 3 individual experiments. 
Statistical analysis was performed by a 2 way ANOVA with post Bonferroni test: *, p <0.05. 
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 HAS1 has No Association with Pro-Inflammatory Cytokines 
Previous literature has linked HAS1 expression in cells with activating a pro-inflammatory 
phenotype, inducing the expression of various pro-inflammatory mediators. To confirm this, 
the expression of an array of pro-inflammatory gene markers, investigating whether gene 
expression of these were induced in CWFs compared to NFs and whether they were further 
induced by TGF-β1 stimulation. mRNA levels were measured for IL-1β, IFN-γ, CCL2, IL-8, 
CCL5 and ICAM1. Overall, there was no obvious trend to show that HAS1 expression in 
CWFs induced pro-inflammatory mediator gene expression. IFN-γ showed induction in 
CWFs with stimulation, while it was not in NFs. CCL5 showed a differing response in CWFs 
and NFs, in response to stimulation, although this was not significant (Figure 4.10A).   
To confirm this, I also treated cells with IL-1β to measure whether HAS1 or HAS2 were 
induced in CWFs. Interestingly HAS1 was significantly increased in treated CWFs. Although 
not significant, HAS2 also seemed to increase with treatment in CWFs. In both NFs there 
was no significant change, however a trend showed a decrease in HAS1 and HAS2 with IL-
1β treatment (Figure 4.10B). This did indicate that CWFs were more responsive to pro-
inflammatory cytokines, which alter HA metabolism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
 
 
N
or
m
al
 1
C
hr
on
ic
 1
0.0
0.5
1.0
1.5
2.0
2.5
-IL-1
+IL-1
NS
NS
R
e
la
ti
v
e
 H
A
S
2
 m
R
N
A
e
x
p
re
s
s
io
n
 (
R
Q
)
N
or
m
al
 1
C
hr
on
ic
 1
0
2
4
6
8
-IL-1
+IL-1
***
R
e
la
ti
v
e
 H
A
S
1
 m
R
N
A
e
x
p
re
s
s
io
n
 (
R
Q
)
N/S
 
 
 
Figure 4.10. HAS1 has No Association with Pro-Inflammatory Cytokines. A. Cells were grown to 90-100% 
confluent monolayers and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) 
or in medium containing 10ng/ml TGF-β1 (+TGF) for 72h. B. Cells were then incubated in serum-free medium alone 
(IL-1β) or in medium containing 10 ng/mL IL-1β (+IL-1β) for 72h The expression of IL-1β, IFN-γ, CCL2, IL-8, CCL5, 
ICAM, HAS1 and HAS2 mRNA were analysed by QPCR. Results are shown as the mean ± s.d. of 3 individual 
experiments. Statistical analysis was performed by a 2-way ANOVA with post Bonferroni test: *, p <0.05, ***, 
p<0.001. 
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4.3. Discussion 
The results from this chapter demonstrate for the first time the synthesis and location of HA 
in response to TGF-β1 stimulation in CWFs, together with investigating HAS1’s role in the 
loss of myofibroblast response in CWFs. findings have novel relevance to the impaired 
wound healing associated with chronic wounds. Chapter 3 confirmed other studies (Simpson 
et al., 2009) showing that the primary HAS isoenzyme expressed by NFs is HAS2, and that 
HAS1 was predominant in CWFs (Wall et al., 2008). It was therefore of interest to investigate 
the location of these HASs and their production of HA.  
Initial findings of this chapter characterised the distribution of HA in CWFs under the 
influence of TGF-β1. CWFs’s showed that total HA staining patterns where that didn’t 
change with TGF-β1 treatment. NFs’s showed highly organised HA in clear parallel lines, 
which indicate association with the NFs cytoskeleton. This supports previous studies 
showing that HA associates via the ECM protein fibronectin, while its splice variant EDA-
fibronectin is essential for myofibroblast differentiation and associated with the myofibroblast 
marker protein α-SMA in vitro (Evanko et al., 2015, Shinde et al., 2015). CWFs did show 
slightly less organisation of cytoskeletal HA which could be attributed to the loss of 
fibronectin-EDA expression shown in chapter 3 (Figure 3.2). The remaining organisation 
observed in the CWFs could be due to focal adhesions and other cytoskeletal proteins, 
which are not lost in the CWFs (Evanko et al., 2015). 
Previous studies have shown the importance of the formation of a HA pericellular coat, 
formed by the binding of HA to its cell surface receptor CD44, for successful myofibroblast 
formation (Midgley et al., 2013, Simpson et al., 2009). It was therefore of particular 
importance to investigate whether the loss of a pericellular coat could be responsible for the 
loss of differentiation in CWFs. Using the RBC exclusion assay, I found that, in-line with 
previous findings, NFs responded to TGF-β1 stimulation by forming a clearly defined HA 
pericellular coat. This result was further supported by the HA ELISA data on the pericellular 
fraction of the cells, which again showed a significant increase in HA with TGF-β1 
stimulation, confirming the presence of the HA pericellular coat. On the other hand, CWFs 
did not show the formation of a HA coat by RBC exclusion. The HA ELISA did show that 
CWFs’s did respond to TGF-β1 treatment with an attempt of HA pericellular coat formation. 
This induction was not significant, and only an attenuated smaller HA coat could therefore 
be formed. It has been established that HA coat loss causes dysfunctional differentiation in 
fibroblasts, and therefore illuminated a novel finding in the explanation of the CWFs non-
healing phenotype. Previous studies have also reported small HA coat formation and 
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attributed this to differential HAS enzyme expression. HAS1 has been shown to only 
produce attenuated small HA coats surrounding cells, since HAS1 requires a higher 
concentration of cellular uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) than 
HAS2 and HAS3 (Rilla et al., 2013). Increasing the concentration of glucose in the media of 
cells, increases the cell surface HA in breast cancer MCF-7 cells. This could explain the 
smaller coat produced in these CWFs, since all cells were grown in low glucose (5mM) 
medium (Siiskonen et al., 2014). This study also highlighted that HAS1 coat formation is 
dependent on CD44 localisation on the membrane, and also ER-golgi-plasma membrane 
traffic. Previous work has shown that ER stress is a major contributor to diseases linked to 
inflammation, such as chronic wounds (Chaudhari et al., 2014).  
The attenuation of HAS1 enzymatic activity due to low glucose availability in the media could 
also help explain the localisation of other fractions of HA shown by the HA ELISA, in the 
extracellular and intracellular fractions. Firstly, both NFs and CWFs demonstrated that HA 
synthesis was induced with TGF-β1 treatment, since both cell types demonstrated an 
increase of HA found in the extracellular space quantified from the collected media. This 
result was interesting since it is thought that extracellular HA deposition increases after injury 
and during disease states, such as those found in chronic wounds. Extracellular HA is 
responsible for immune cell recruitment to the site of injury (Litwiniuk et al., 2016, Petrey 
and de la Motte, 2014). This result may indicate that the endogenous fibroblasts present in 
chronic wounds are not the key players in producing pro-inflammatory extracellular HA for 
the recruitment of immune cells and it is in fact other factors that contribute to the persistent 
inflammation in chronic wounds. Secondly, intracellular / cytoplasmic HA concentrations in 
NFs increased with TGF-β1 treatment. CWFs, on the other hand, did not show this response 
of increased intracellular HA. This was a surprising finding since a number of studies have 
identified intracellular HA as a marker of inflammation and chronic wounds are well 
documented to be an inflammatory disease (Hascall et al., 2004). This reduction of HA 
synthesis could again be due to the physiological levels of glucose in the media and thus 
HAS1 attenuated enzymatic activity observed. To confirm this result HABP staining following 
hyaluronidase treatment was used to visualise intracellular HA. The results from this show 
a different picture, since it may not be quantity of HA synthesised that changes in CWFs, 
but the intracellular location of HA. HA localisation in the NFs did not change with TGF-β1 
and showed diffuse staining throughout the cytoplasm. Contrasting this, intracellular HA in 
the CWFs was found in a perinuclear location in both unstimulated and stimulated cells. The 
accumulation of HA, visually resembled an intracellular barrier, which could be contributing 
to the loss of differentiation in these cells. It was found in a similar location to HAS1 
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expression in CWFs. HAS1 expression was shown to respond to TGF-β1 stimulation in the 
previous chapter. Here, we see that it also responds at a protein level, with cytoplasmic 
clusters forming in response to the treatment. This was not seen in the NFs. Previous studies 
have shown that HAS1 is found in an intracellular / perinuclear location in cells (Siiskonen 
et al., 2015). However, the current novel finding shows that HAS1 localisation is changed 
under cytokine treatment. This change in HAS1 location with the abnormal expression of 
intracellular HA in the CWFs may be contributing to the loss of an organised pericellular 
coat, with HA being trapped in a perinuclear location unable to reach the membrane. The 
loss of the coat is shown to be contributing to the loss of differentiation of these cells. 
Therefore, modifying the expression of HAS1 was hypothesised to reverse the dysfunction 
HAS expression and thus, HA distribution.  
HAS1 was targeted for silencing, since its actions were thought to be causing the 
disorganised accumulation of HA and loss of the pericellular coat, contributing to the loss of 
the myofibroblast phenotype. Figure 4.7B demonstrates that transfecting CWFs proved to 
be difficult, with only very high concentrations resulting in sufficient knockdown of HAS1 
expression. It was thought the difficulty in transfection was due to the decreased proliferation 
of the CWFs. However, other studies have demonstrated that HA can act as a barrier 
preventing gene transfer. The intracellular HA found in a barrier formation surrounding the 
nucleus in CWFs, may explain the poor transfection efficiency of these cells (Ruponen et 
al., 2003). 
To elucidate HAS1 actions on effecting the differentiation of fibroblasts both silencing HAS1 
in CWFs, to recover a myofibroblast phenotype and overexpression of HAS1 in NFs, to 
induce a CWFs phenotype, was attempted. Both silencing HAS1 or overexpressing HAS1 
had no effect on the phenotype of the fibroblasts, using α-SMA as a marker of differentiation. 
These results demonstrated that HAS1’s role was not integral to the loss of myofibroblast 
differentiation in CWFs, since it did not affect α-SMA mRNA expression or protein fibre 
formation. Previous studies have demonstrated that neither over-expression or down-
regulation of HAS1 in NFs, has an effect on their differentiation (Meran et al., 2007). These 
cells, however, do not have a high basal expression of HAS1, leaving the question what role 
does HAS1 have in CWFs? 
HAS1 has been well-reported to be up-regulated in inflammatory disease states (Siiskonen, 
et al., 2015). To test this the cells were treated with pro-inflammatory cytokine IL-1β to 
assess its effect on HAS expression. HAS1 showed a significant increase in expression in 
responce to IL-1β treatment in the CWFs alone. This may indicate that these cells are more 
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sensitive to expressing the pro-inflammatory HAS1 isoenzyme. To test whether HAS1 
induction in the CWFs correlated with an increase in an increase of pro-inflammatory 
mediators, IL-1β, IFN-γ, CCL2, IL-8, CCL5, and ICAM-1 were measured. There was no 
significant induction of the pro-inflammatory cytokines, with only a non-significant trend 
being observed where IFN-γ being induced with TGF-β1 in the CWFs, and not in the NFs. 
This result suggests that although an increase in HAS1 is observed in these cells, the HA 
formed may not be acting endogenously and in fact only affecting surrounding cells.  
The question regarding the cause for the loss of pericellular coat and differential intracellular 
HA localisation in CWFs still remains following investigation into HAS1 as the primary cause. 
HAS1 has not been attributed as the primary HAS isoenzyme expressed in normal 
myofibroblasts, since it is HAS2 which is responsible for normal HA pericellular coat 
formation. HAS2 location was investigated again finding differences between the NFs and 
CWFs. HAS2 in the NFs showed a diffuse staining pattern found throughout the cell 
cytoplasm, membrane and nucleus. On the other hand, in the CWFs, HAS2 was found with 
distinct staining patterns in a perinuclear location and within the nucleoli of the cells. Chapter 
1 of this thesis showed that HAS2 expression was not induced with TGF-β1 in the CWFs 
but was in the NFs, even though this finding was not significant, together with the evidence 
of aberrant protein localisation strengthened HAS2 as the cause of the loss of the pericellular 
coat in the CWFs. HAS2 was targeted for overexpression in CWFs in the attempt to recover 
the myofibroblast phenotype. Although using α-SMA as the marker for differentiation, the 
over expression of HAS2 did not induce α-SMA expression and thus induce differentiation. 
Previous studies overexpressing HAS2 in senescent fibroblasts, also resistant to 
differentiation, only resulted in partial restoration of the myofibroblast phenotype. This was 
linked to other dysfunctional proteins within the non-classical pathway that contributed to the 
loss of differentiation. This may also be true of CWFs, with other dysfunctional proteins being 
the primary cause for the loss of differentiation (Midgley et al., 2014). 
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Chapter 5 
Trafficking and Localisation of 
Proteins in Chronic Wound 
Fibroblasts 
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5.1. Introduction 
5.1.1. The HA Receptor CD44 
CD44 is a transmembrane glycoprotein that interacts with HA, regulating cell adhesion, 
migration, proliferation, differentiation and signalling (Prochazka et al., 2014, Midgley et al., 
2013, Meran et al., 2011). A combination of alternative splicing and posttranscriptional 
modification leads to multifunctional isoforms, known as CD44 variants, of the protein, which 
have different tissue specific effects. The protein has one variable region. Theoretically 
alternative splicing can produce over 103 different isoforms of the variable region of the 
receptor. Standard CD44 (CD44s) is expressed when all variable exons (V2-v10 and exon 
18 in humans) are spliced out, this is the most abundant variant expressed. Molecular weight 
of the CD44 variants range from 85-250 kDa (Fox et al., 1994, Prochazka et al., 2014, 
Screaton et al., 1992).  
All CD44 variant proteins express three domains; an extracellular, a transmembrane and a 
cytoplasmic tail domain. The size of the protein is varied because of an insertion of a stem 
region between the extracellular and transmembrane domain. This, therefore, results in the 
translation of the exons within the variable region of the gene. The extracellular domain is 
the HA binding domain, and regulates the receptor interaction with the ECM. The amino 
domain is also capable of binding ECM proteins such as collagen, laminin and fibronectin 
(Faassen et al., 1992, Jalkanen and Jalkanen, 1992). A stem region links the amino domain 
to the transmembrane domain, it is in this that variably spliced exons are incorporated. 
Modifications in the amino terminal and stem region control the interactions of the receptor 
with the ECM, which are isoform specific. Posttranslational modifications include N- and O-
linked glycosylation, phosphorylation and GAGs attachment, with CD44s being N-
glycosylated while variants are mostly O-glycosylated (Hanley et al., 2005). The interaction 
of the receptors with the ECM, determine their function. This is also true of the cytoplasmic 
domain, which is capable of binding HA causing differential clustering of the receptor on the 
surface. This indicates that the receptor can be regulated from outside or inside the cell 
(Perschl et al., 1995).  
The transmembrane domain is composed of 23 hydrophobic amino acids and a single 
cysteine residue. It’s function is not entirely understood, however it is known to play a role 
in modulation of CD44-HA associations (Liu and Sy, 1997). The transmembrane region has 
also been associated with lipid raft interaction, indicating CD44 membrane motility and ability 
to act as a co-receptor with other transmembrane receptors, such as EGFR (Neame et al., 
1995, Midgley et al., 2013).  
103 
 
TGF-β1 can affect the expression of CD44 and its variant isoforms, with CD44s expression 
being essential for HA pericellular coat formation and the regulation of TGF-β1 driven 
fibroblast to myofibroblast differentiation (Midgley et al., 2013). CD44v6 has been shown to 
be highly expressed in fibrogenic lung fibroblasts treated with TGF-β1 (Ghatak et al., 2017). 
The presence of V3 during obstructive nephropathy, increased proliferation in tubular 
epithelial cells and prevented renal fibrosis development, compared to CD44s which had the 
opposite effect and increased fibrosis (Rampanelli et al., 2014). CD44 can also interact with 
downstream signalling molecules of the TGF-βR pathway, with CD44 binding SMAD3, 
inhibiting recruitment of splicing machinery, thereby promoting expression of CD44s, a 
tumour promoting factor (Tripathi et al., 2016). CD44v7/8 has been identified as an anti-
fibrotic variant, with its expression becoming upregulated following BMP-7 treatment, 
leading to antagonism of the myofibroblast phenotype. This mechanism involves the 
translocation of HYAL2 to the nucleus, displacing components of CD44 splicing machinery 
causing the loss of CD44s and the accumulation of the anti-fibrotic CD44v7/8 at the cell 
surface (Midgley et al., 2017). 
Figure 5.1 Human CD44 structure and alternative splicing. A. Intron-exon structure of CD44 pre-mRNA. The 5′ and 3′ 
common regions are present in all CD44 splice variants. Exon 18 is removed before translation, and exons 6 to 14 are 
differentially expressed in different CD44 variant isoforms. B. CD44s mRNA contains only 5’ and 3’ common regions. C. The 
CD44v7/8 mRNA contains the same common region exons as CD44s plus the addition of the variably expressed exons 11 
and 12. D. CD44 protein structure. The globular N-terminal region contains 3 disulphide bonds and 2 HA binding motifs. The 
cytoplasmic tail contains intracellular signalling motifs and medicates cytoskeletal interaction. The blue variable region is 
missing from CD44s. Adapted from (Midgley et al., 2017, Prochazka et al., 2014). 
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5.1.2. EGFR Signalling 
EGFR is a cell surface transmembrane receptor activated by the binding of its ligands; EGF, 
TGF-α and Heparin binding (HB)-EGF (Leahy, 2004). Upon ligand biding, EGFR undergoes 
a transition from an inactive monomeric form to an active homodimer (Yu et al., 2002). There 
is evidence of the existence of inactive dimers, whose activity is regulated by other proteins, 
receptors or lipids. EGFR co-localisation with CD44 has been previously described to be 
essential for myofibroblast formation, with this co-localisation occurring within membrane 
bound lipid rafts (Meran et al., 2011, Midgley et al., 2013). The loss of EGFR expression in 
cell types resistant to TGF-β1 treatment such as in vitro aged fibroblasts, demonstrates its 
importance as a pro-fibrotic receptor (Midgley et al., 2014). EGFR expression can also be 
modulated by its anti-sense strand, with over-expression of EGFR anti-sense, reducing the 
expression of EGFR (Brader et al., 1998).  EGFR dimerization stimulates auto 
phosphorylation of several tyrosine residues in the C-terminal domain of EGFR. This 
phosphorylation activates downstream signalling cascades through MAPK/ERK, protein 
kinase B (Akt), c-Jun N-terminal kinases (JNK) and Janus kinase (JAK) pathways. These 
signals contribute to cellular proliferation, migration, adhesion and differentiation (Andl et al., 
2004, Meran et al., 2011, Cordero et al., 2012, Hashimoto et al., 1999).  
5.1.3. Intracellular Molecular Synthesis and Modification 
The site of protein and lipid synthesis is the ER, which is made up of the nuclear envelope 
and interconnected flattened membrane sacs called cisternae. There are two compartments 
called the rough and smooth ER. The Rough ER contains ribosomes, which are the sites of 
protein synthesis. The smooth ER lacks ribosomes and therefore is responsible for lipid 
synthesis and acts as the site of vesicle binding and fusion. The rough ER is very prominent 
in fibroblasts, cells that produce large amounts of the ECM proteins, and the smooth ER is 
especially abundant in adrenal cells that secrete large amounts of steroids (Shibata et al., 
2006, Li and Wang, 2011). 
Rough ER manufactures transport vesicles such as lysosomes and is responsible for initial 
protein N-linked glycosylation. There is no continuous membrane between the ER and golgi, 
therefore membrane-bound transport vesicles shuttle proteins and lipids between these two 
organelles (Watson and Stephens, 2005). Only correctly folded proteins are transported 
from the rough ER to the golgi; unfolded proteins cause a stress response in the ER, leading 
to accumulation of unfolded proteins and potentially cause damage in hypoxia, insulin 
resistance and other disorders (Ozcan et al., 2004). 
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The Golgi is composed of several flattened stacks of membranes devoid of ribosomes. 
Individual stacks have unique functions, and are thus classically labelled, cis, median, trans, 
and trans-Golgi network according to their function. The Golgi constantly receives material 
from the ER, which it must sort and package to their desired destination, such as the, 
endosomal and lysosomal compartments, the plasma membrane or extracellular space. The 
Golgi is the main contributor of post-translational modification of lipids and proteins and 
defective post-translational modification has been associated with multiple different 
diseases (Potelle et al., 2015). Correct Golgi functioning is essential for stability, activity, 
trafficking and sub-cellular localization of many proteins. 
The previous chapter demonstrated that CWFs had specific intracellular localisation of HA 
coinciding with the loss of pericellular coat, indicating that dysfunctional transport of key 
regulators of the differentiation pathway may be effected in CWFs. The previous chapter 
also reported intracellular accumulation of HAS1 and HAS2 in the CWFs. Previous work has 
demonstrated that HAS1 accumulates in the Golgi whilst HAS2 accumulates in the ER, 
indicating that they have a reserve pool of isoenzymes to recruit for rapid HA synthesis 
(Torronen et al., 2014, Rilla et al., 2005). The dysfunctional synthesis or transport of these 
proteins may divulge a dysfunction in the loss of CWFs differentiation.  
5.1.4. Intracellular Transport 
Intracellular transport is the movement of vesicles and substances within the cell along 
microtubules and actin filaments within the cytoskeleton. Transport vesicles are small 
structures that have the capacity to hold cargo and transport to specific cellular 
compartments. To ensure they reach the desired destination, special motor proteins attach 
to the vesicles and carry them along the cytoskeleton. Failure in this system results in the 
accumulation or inaccurate transport of molecules leading to disease (Ando et al., 2015). 
Endocytosis is the process where material is taken into the cell via inward budding of the 
plasma membrane into early endosomes. The cargo is then sorted to specific destinations, 
which include being recycled back into the plasma membrane, the ER, intraluminal vesicles 
for sorting, lysosomes or to the biosynthetic pathway. These early endosomes, slowly 
mature into late endosomes which eventually fuse with lysosomes, and the cargo is then 
degraded by lysosomal hydrolases (Raiborg et al., 2015). A key function of endocytosis is 
the regulation of cell surface receptor expression at the plasma membrane (Maxfield, 2014). 
Endosomes are responsible for transporting many key regulators of myofibroblasts 
formation. These include TGF-βR, whose internalisation regulates TGF-β1 signalling (He et 
al., 2015, Chen, 2009), HAS transport from the ER / Golgi to the plasma membrane (Deen 
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et al., 2014) and CD44 transport to the membrane (Maldonado-Baez et al., 2013). The loss 
of receptor presentation at the surface could cause serious complications in disease states 
such as chronic wounds. 
Lysosomes develop from late endosomes, they are membrane enclosed organelles that 
contain an array of enzymes capable of breaking down all types of biological polymers-
proteins, nucleic acids, carbohydrates and lipids. It therefore, serves to degrade materials 
taken up externally from the cell and digest obsolete components as an auto-phagosome. 
Its correct function is essential for intracellular homeostasis (Sridhar et al., 2013, Mauvezin 
et al., 2015). It has an intracellular pH of approximately 5, which all lysosomal enzymes are 
active. These enzymes are essential for regulation of molecules associated with 
myofibroblast formation. Lysosomes have an important role in cholesterol homeostasis, 
which may indicate its role in lipid raft formation and transport (Lange et al., 2012). An 
enzymatically active form of HYAL1 has been identified in lysosomes confirming other 
studies suggesting it contributes to the breakdown of HA (Boonen et al., 2014). Lysosomes 
have also been shown to contribute to TGF-βR and CD44 degradation, suggesting that 
lysosomal function is essential for the pro-fibrotic signalling pathways to function and this 
may be lost in CWFs (Bai et al., 2014, Haakenson et al., 2015).  
 
Figure 5.2. Membrane Transport into and out of the Cell. Endocytosis occurs when the membrane engulfs particles 
outside the cell and forms an endosome. Its contents are digested as it merges with vesicles containing enzymes from 
the Golgi, transforming the endosome into a lysosome. Cholesterol, produced by hydrolysis of cholesterol esters by 
lysosomal acid lipase. Exocytosis is the process of membrane transport that releases contents outside the cell. Here, 
transport vesicles from the Golgi or elsewhere merges with the membrane and releases its contents. Membrane transport 
also occur between the endoplasmic reticulum and the Golgi. Adapted from: (Maxfield, 2014) 
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Microtubules are filaments of the cytoskeleton, with fundamental roles in cell division 
and intracellular transport, acting as rails to facilitate transport. Microtubules form 
through the polymerisation of αβ-tubulin heterodimers, powered by the hydrolysis of 
guanosine triphosphate (GTP) bound to β-tubulin. Microtubules have both a plus-end 
and minus-end of assembly. This enables microtubules to switch between catastrophes, 
where disassembly via depolymerisation occurs and rescues, where assembly is re-
initiated (Akhmanova and Steinmetz, 2015). Motor proteins use the microtubules as 
tracks to transport; proteins, lipids and other cellular materials. Kinesins and Dyneins are 
the two types of motor proteins, which move to the plus-end or minus-end respectively 
(Franker and Hoogenraad, 2013). Microtubule formation has been found to have a role 
in ER to Golgi transport (Fokin et al., 2014), essential for intracellular trafficking. As part 
of the cytoskeleton they are also essential for myofibroblast formation, having cross-talk 
with the actin cytoskeleton (Sandbo et al., 2016, Po'uha et al., 2013). Destabilisation of 
the microtubule network would affect both intracellular trafficking and the modification of 
the cytoskeleton to allow myofibroblast formation (Mian et al., 2012). 
The aims of this chapter are: 
1. Analyse the co-localisation of CD44 and EGFR in membrane bound lipid rafts, to 
determine whether this mechanism is affected in CWFs differentiation. 
2. Understand the role of CD44 variants and EGFR antisense in the context of 
CWFs differentiation capacity. 
3. Examine intracellular protein synthesis and transport system in NFs and CWFs, 
identifying any discrepancies that may cause CWFs to lose their differentiation 
ability. 
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5.2. Results 
5.2.1. Intracellular localisation of EGFR in CWFs and Reduced Co-localisation with 
CD44 on the Membrane Compared to NFs 
Previous papers have reported the importance of the TGFβ1 stimulated co-localisation 
of the HA receptor CD44 with EGFR on the membrane, for myofibroblast differentiation 
to occur (Midgley et al., 2013). To determine whether the loss of co-localisation of these 
proteins might be contributing to the loss of differentiation, fluorescence co-staining 
(CD44 and EGFR) with confocal microscopy was undertaken. Cells were grown to 60-
70% confluence and then incubated with either TGF-β1 in serum free media, or media 
alone. Both NFs showed staining of CD44 and EGFR on the membrane of the TGF-β1 
stimulated cells. Merging these images confirmed that the two proteins were co-localised 
within the membrane of the treated cells, and therefore capable of differentiating (Figure 
5.1). However, the two CWFs showed very strong staining of EGFR intracellularly, with 
reduced staining on the membrane. The CD44 staining in CWFs still remained on the 
membrane and merging the staining showed attenuation of the co-localisation of CD44 
and EGFR on the membrane. The EGFR was not in a specific perinuclear location, 
however a ring like pattern surrounding the nucleus could be seen. This specific 
intracellular staining was not observed in any of the NFs, making this a novel finding in 
CWFs cell biology  
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 Figure 5.1. Intracellular localisation of EGFR in CWFs and reduced co-localisation with CD44 on the membrane, 
compared to NFs. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-
free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of EGFR (green) and 
CD44 proteins (Red) were examined by immunocytochemistry and confocal microscopy; nuclei were visualised by Hoechst 
stain. Images shown are a representation of 3 independent experiments. Original magnification x620. Scale bar: 50µm. 
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5.2.2. EGFR and Lipid Intracellular Localisation in CWFs with Reduced Co-
localisation on the Membrane Compared to NFs 
CD44 and EGFR (FITC-EGFR-ab11401) co-localisation has been shown to occur within 
lipid rafts on the membrane of fibroblasts (Midgley et al., 2013). Since the staining 
pattern of EGFR was different in CWFs, compared to that observed in NFs, EGFR and 
lipid localisation was imaged to assess whether the loss of lipid rafts was causing the 
decrease in CD44-EGFR co-localisation. NFs treated with TGF-β1 showed co-
localisation of EGFR and lipids on the membrane with diffuse staining throughout the 
cell (Figure 5.2). EGFR was imaged intracellularly with a diffuse staining pattern in 
CWFs. The CTX stain was also observed intracellularly in both the treated and non-
treated CWFs. Once the images were merged CWFs showed some co-localisation of 
intracellular EGFR and lipids. This is an interesting finding, since CD44 was previously 
thought to be mobile in lipid rafts and EGFR static. 
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Figure 5.2. EGFR and lipid intracellular localisation in CWFs with reduced co-localisation on the membrane, compared 
to NFs. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium 
alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of EGFR protein (green) and lipids (Red) 
were examined by immunocytochemistry and confocal microscopy; nuclei were visualised by Hoechst stain. Images shown are a 
representation of 3 independent experiments. Original magnification x620. Scale bar: 50µm. 
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5.2.3. Comparison of EGFR Antisense expression at mRNA level 
A number of studies have demonstrated that antisense therapy is a growing field for 
diseases, since antisense transcription can act independently to sense transcription to 
modulate chromatin and therefore, possibly be a method for cellular control (Murray and 
Mellor, 2016, Alper et al., 2000). Both NFs and CWFs showed a significant decrease in 
EGFR antisense expression following TGF-β1 treatment (Figure 5.3 A). Comparing this 
to standard EGFR expression (Figure 5.3 B), this too decreased in both cell types with 
TGF-β1 treatment, indicating EGFR antisense does not have a direct role in aberrant 
EGFR protein localisation in CWFs. 
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Figure 5.3 No change in EGFR anti-sense expression between CWFs and NFs. Cells were grown to 100% 
confluent monolayers and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) 
or in medium containing 10ng/mL TGF-β1 (+TGF) for 72h. The mRNA expression of (A) EGFR anti-sense and (B) 
EGFR standard was analysed by QPCR. Results are shown as the mean ± s.d. of 3 individual experiments. Statistical 
analysis was performed by a 2-way ANOVA with post Bonferroni test: **, p <0.01. 
A 
B 
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5.2.4. Comparison of CD44 variant expression at mRNA level 
Alternative splicing produces distinct isoforms of the protein CD44, which have shown 
to have significant effects on disease progression, such as cancer and also have 
differential expression throughout the skin (Prochazka et al., 2014, Hale et al., 1995). It 
was therefore of interest to investigate the expression of the 10 variant exons of CD44 
in CWFs and compare this to their relative expression in NFs, in response to TGF-β1 
treatment. CD44s (standard) expression showed significant decreased expression in 
response to TGF-β1 stimulation in both NFs and CWFs, as shown in chapter 3 (Figure 
5.4). Variant 2 and 3 also showed a similar pattern, with decreased expression in both 
cell types. 
Variant 5 was not expressed in either NFs or CWFs. Variant 4, 7, 8, 9 and 10 showed 
no significant difference between control and TGF-β1 stimulated cells. However, variant 
10 showed a trend where its expression increased with treatment in the CWFs, but 
decreased in NFs. Variant 6 showed the greatest difference, with a significant decrease 
in response to TGF-β1 only seen in the NFs. Variant 6 did decrease in the CWFs 
following TGF-β1, but this was not significant. The overall trend therefore showed no 
significant difference in CD44 variant expression, contributing towards non-healing in 
CWFs.   
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Figure 5.4. Comparison of CD44 variant expression at mRNA level. Cells were grown to 90-100% confluent 
monolayers and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium 
containing 10ng/mL TGF-β1 (+TGF) for 72h. The CD44 variants mRNA expression were analysed by QPCR. Results 
are shown as the mean ± s.d. of 3 individual experiments. Statistical analysis was performed by a 2 way ANOVA 
with post Bonferroni test: *, p <0.05, **, p<0.01, ***, p<0.001. 
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5.2.5. CD44 variant 7/8 localisation and expression 
Previous studies have confirmed that CD44v7/8 is associated with prevention and 
reversal of the myofibroblast phenotype and thus is anti-fibrotic (Midgley et al., 2017, 
Midgley et al., 2015). Since CWFs do not differentiate and propagate fibrosis, it was 
hypothesised that the anti-fibrotic variant, CD44v7/8, might be upregulated in CWFs, 
contributing to the loss of differentiation. Analysing the variant expression in response to 
TGF-β1 stimulation (Figure 5.5B) showed that neither the NFs or CWFs had a significant 
response, although the CWFs showed a trend where the variant expression decreased 
with treatment, while in the NFs it increased. Comparing the basal expression with the 
CT values, clearly showed a higher overall expression of the anti-fibrotic variant within 
the CWFs compared to the NFs (Figure 5.5C). Hence it could be contributing to the non-
healing nature of the CWFs.  
To assess whether the localisation of the variant protein changed in the CWFs, ICC and 
fluorescence microscopy were performed (Figure 5.5A). There was diffuse staining 
throughout the NFs cells, including membrane-bound staining, with no change between 
the control and TGF-β1 stimulated cells. There was a similar observation in the CWFs, 
with no change in localisation following treatment, and a diffuse staining pattern 
throughout the cells. 
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Figure 5.5. CD44 variant 7/8 localisation and expression. A. Cells were grown to 60-70% confluence and growth arrested 
for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 
72h. The localisation of CD44 v7/8 protein was examined by immunocytochemistry; nuclei were visualised by Hoechst stain. 
Images shown are a representation of 2 independent experiments. Original magnification x400. Scale bar: 100µm. B/C. Cells 
were grown to 90-100% confluent monolayers and growth arrested for 48h. Cells were then incubated in serum-free medium 
alone (-TGF) or in medium containing 10ng/mL TGF-β1 (+TGF) for 72h. The expression of CD44 v7/8 mRNA was analysed 
by QPCR. Results are shown as the mean ± s.d. of 3 individual experiments. B. Shows relative expression C. Shows 40-CT 
values 
B C 
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5.2.6. HYAL2 perinuclear localisation in CWFs. Silencing HYAL2 doesn’t recover a 
myofibroblast phenotype 
The previous research undertaken on CD44v7/8 has shown its actions are facilitated by 
the translocation of HYAL2 to the nucleus of the cells, it was therefore of interest to 
visualise the location of HYAL2 in CWFs, confirming the variant was acting through the 
same mechanism (Midgley et al., 2017). Using fluorescence microscopy, the localisation 
was imaged in both control and stimulated, NFs and CWFs. Under stimulation, HYAL2 
in the NFs became highly organised, aligning with the cytoskeleton (Figure 5.6A). 
However, CWFs showed internalisation of HYAL2 with TGF-β1 treatment, although 
some organisation and membrane staining was still present.  
To determine a potential role for HYAL2 in the loss of CWFs differentiation, HYAL2 
expression was successfully silenced in both NFs and CWFs (Figure 5.6B). α-SMA 
expression was then quantified in cells with knockdown HYAL2 expression, and 
compared to scramble controls. Silencing HYAL2 in the NFs did induce a greater 
response to TGF-β1 stimulation (Figure 5.6C). However, silencing HYAL2 in the CWFs 
did not recover the α-SMA response. 
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Figure 5.6. HYAL2 perinuclear localisation in CWFs. Silencing HYAL2 doesn’t recover a myofibroblast phenotype. A. Cells 
were grown to 60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in 
medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of HYAL2 protein was examined by immunocytochemistry; 
nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original magnification 
x400. Scale bar: 100µm B/C. Fibroblasts were transfected with a scrambled siRNA sequence or siRNA targeting HYAL2 for 24h, 
prior to TGF-β1 treatment for 72h. The expression of (B) HYAL2 and (C) αSMA mRNA was analysed by QPCR. Results are shown 
as the mean ± s.d. of 3 individual experiments. ** P=<0.01, *** P=<0.001 
B C 
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5.2.7. No difference in lysosome localisation was observed between CWFs and NFs 
From the findings throughout this and the previous chapter, it is clear that protein, lipid, 
and GAG localisation is affected in CWFs. Because of this it was thought that the 
dysregulation of their localisation was due to dysfunctional transport and therefore 
important to image key intracellular transport vesicles and their response to TGF-β1 
stimulation. Using fluorescence microscopy, the localisation of lysosomes was imaged 
in both control and stimulated, NFs and CWFs. The localisation of lysosomes in the 
NFs’s did not appear to change following TGF-β1 stimulation. The staining pattern 
remained in an intracellular location with accumulation towards the surface of the cells 
and reduced staining surrounding the nucleus (Figure 5.7). This was more clearly seen 
in the treated cells, since these were larger. There was no change in lysosome number 
under either of the two serum conditions. Lysosomes in CWFs showed a similar staining 
pattern as observed in NFs. Furthermore, no significant change in lysosomal 
concentration is seen between control and stimulated cells. Lysosomal localisation and 
quantification does not seem to be affected by TGF-β1 treatment, nor abnormally 
expressed in CWFs compared to NFs. 
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Figure 5.7. No difference in lysosome localisation was observed between CWFs and NFs. A. Cells were grown to 
60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in 
medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of LAMP-1 protein was examined by 
immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent 
experiments. Original magnification x400. Scale bar: 100µm 
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5.2.8. No difference in endosome localisation was observed between CWFs and NFs. 
To confirm that intracellular vesicular trafficking was acting normally in CWFs, as 
described in the previous lysosomal result, endosomal localisation was imaged in the 
two cell types, with and without TGF-β1 treatment. Endosomal localisation was very 
different to that of lysosomes (Figure 5.8). Endosomal staining was specifically localised 
in a more perinuclear location with reduced staining further from the nucleus. No 
significant change in localisation or intensity was observed between the unstimulated 
and stimulated NFs, demonstrating that TGF-β1 does not change localisation of action 
or quantity of endosomes. The CWFs showed a similar staining pattern, with endosomes 
again being localised in a perinuclear location. There was no change in fluorescence 
intensity and thus endosome quantities were similar between NFs and CWFs. Overall 
intracellular transport did not seem to be responsible for the abnormal staining patterns 
observed in this and previous chapters regarding protein, HA and lipid localisation. 
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Figure 5.8. No difference in endosome localisation was observed between CWFs and NFs. A. Cells were grown to 
60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in 
medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of EEA-1 protein was examined by 
immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent 
experiments. Original magnification x400. Scale bar: 100µm. 
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5.2.9. No difference was seen between ER staining between CWFs and NFs 
Since it was apparent that intracellular transport was not responsible for the aberrant 
staining patterns of key molecules involved in the differentiation mechanism, it was 
hypothesised that dysfunctional organelles responsible for protein synthesis may be 
causing accumulation of incorrectly synthesised molecules. It has previously been 
shown that ER stress can contribute to loss of cellular function, with impeded ability to 
fold or post-translationally modify secretory and transmembrane proteins (Oakes and 
Papa, 2015). The endoplasmic reticulum was therefore imaged in the two cell types. 
Staining in both NFs and CWFs showed clear staining in the nucleus, excluding the 
nucleolus, and diffuse staining throughout the cytoplasm (Figure 5.9). Since, no 
difference was seen between the NFs and CWFs, the ER was believed to be functioning 
normally and therefore not responsible for the abnormal staining patterns previously 
described. 
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Figure 5.9. No difference was seen between E.R. staining of CWFs and NFs.  A. Cells were grown to 60-70% 
confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium 
containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression of E.R. protein, calreticulin was examined by 
immunocytochemistry. No nuclei stain was used to show localisation within the nucleus. Images shown are a 
representation of 2 independent experiments. Original magnification x400. Scale bar: 100µm. 
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5.2.10. No differences in Golgi staining was observed between CWFs and NFs 
The secondary organelle that may be responsible for trafficking and folding of protein 
aggregates and thus the abnormal staining patterns observed previously may be due to 
Golgi abnormalities. It has previously been shown that the Golgi in pathological 
conditions may cause the loss of cell surface determinants (Morre, 1991). This may be 
the case, which is in-line with the previous finding of intracellular EGFR in CWFs 
compared to their membrane location in NFs. The Golgi was therefore imaged using 
ICC. No change was seen with TGF-β1 treatment in either cell type. Comparing the NFs 
to the CWFs, also did not uncover any significant differences in the size, structure, or 
staining intensity of the Golgi, with clear Golgi networks visible in both cells types, 
indicating that the Golgi was not under stress in the CWFs.  
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Figure 5.10. No differences in Golgi staining was observed between CWFs and NFs. A. Cells were grown to 60-
70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in 
medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The Golgi protein, GM-130 was examined by 
immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent 
experiments. Original magnification x400. Scale bar: 100µm. 
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5.2.11. No difference in microtubule formation between CWFs and NFs 
Microtubules are essential to cellular microstructure and serve as intracellular transport 
tracks. Microtubules have been shown to undergo ‘catastrophe’ events, where growth 
ceases and breakdown increases, these events have been associated with age and 
pathology (Akhmanova and Steinmetz, 2015). It was therefore important to image the 
microtubule network in CWFs, to observe whether the network was affected by TGF-β1 
stimulation and thus explain the aggregation of intracellular molecules in CWFs.  
The NFs demonstrated a clearly defined, dense microtubule network in both the 
unstimulated and stimulated cells. The CWFs’ microtubule network was also clearly 
defined in both the unstimulated and stimulated cells.  
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Figure 5.11. No difference in tubulin positive microtubule formation between CWFs and NFs. Cells were grown 
to 60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or 
in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. Tubulin was examined by immunocytochemistry; nuclei were 
visualised by Hoechst stain. Original magnification x400. Images shown are a representation of 2 independent 
experiments. Scale bar: 100µm. 
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5.3. Discussion 
The previous chapter highlighted the loss of the HA pericellular coat in CWFs together with 
an intracellular accumulation of HA. The loss of the coat was not due to aberrant HAS1 
isoform expression. Therefore, the aim of this chapter was to investigate other possible 
causes for the loss of the HA coat. Although both CD44 and EGFR expression remained at 
comparatively normal levels in the CWFs (Figure 3.5), it has not yet been elucidated where 
these receptors are located in CWFs and whether they co-localise within lipid rafts on the 
membrane, a process shown to be essential for normal differentiation (Midgley et al., 2013). 
The initial aim of this chapter was to investigate the role of CD44 and EGFR in the loss of 
the HA pericellular coat. The results indicated intracellular localisation of both EGFR and 
lipids, indicating the discovery of a novel dysfunctional mechanism for the loss of 
myofibroblast signalling in chronic wounds, leading to their non-healing phenotype. From 
this result I investigated the role of intracellular trafficking and molecular synthesis, to find 
the cause of dysfunctional transport of the EGFR to the plasma membrane.  
Previous studies have demonstrated that EGFR expression is essential for differentiation to 
occur (Meran et al., 2011). EGFR co-localises with the HA receptor within lipid rafts on the 
surface, enabling HA pericellular coat formation and downstream signalling of fibrosis 
(Midgley et al., 2013). Here, CWFs are shown to lose the expression of EGFR on the surface 
of CWFs, coinciding with the intracellular accumulation of lipids. The loss of EGFR location 
on the membrane is caused by a post-translational modification, since both mRNA and 
protein expression are not effected in the CWFs (Figure 3.5) and any other significant effect 
of post-transcriptional regulation by EGFR anti-sense was also not discovered (Alper et al., 
2000).  
As described in chapter 3, we cannot exclude that more than one abnormality, possibly 
several independent ones, exist in CWFs. The results from this chapter also highlight the 
increase in expression of the known anti-fibrotic phenotype CD44v7/8 in CWFs. Previously 
this variant has been shown to complete its action via the translocation of HYAL2 to the 
nucleus and displacing the spliceosome. This prevented splicing to create the fibrotic CD44s 
and subsequent accumulation of the anti-fibrotic CD44v7/8 at the cell surface (Midgley et 
al., 2017). This mechanism was not apparent in the CWFs, with variant 7/8, having diffuse 
staining through the cytoplasm in the CWFs and not being membrane specific. However, 
HYAL2, although not translocated to the nucleus as expected if the mechanism described 
by Midgley et al (2017) was functioning, was located intracellularly in a perinuclear location, 
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similar to the location imaged for EGFR. However, modification of HYAL2 expression with 
siHYAL2 did not recover the myofibroblast phenotype, confirming the internalisation of 
HYAL2 was not contributing to the loss of differentiation in the CWFs. The CD44v7/8 
mechanism may be contributing to the loss of differentiation, but the two overlapping results 
of perinuclear located EGFR and HYAL2 may indicate a greater upstream cause of the loss 
of the correct localisation of key regulating molecules. The cause may be through the 
dysregulation of synthesis or trafficking of these proteins. 
Intracellular budding occurs at both the ER and Golgi of vesicles responsible for intracellular 
trafficking. The two primary vesicles responsible for intracellular trafficking are endosomes 
and lysosomes, which are directed via the microtubule network. These results don’t show 
any significant differences in the presence or locations of endosomes, lysosomes or 
microtubules in CWFs or NFs. This suggests that their transporting functionality is normal. 
Although the microtubule network does not seem affected, there are other actin based 
transport systems located in cells, that may be affected in CWFs (Khaitlina, 2014). One 
substantial finding is the coincident staining seen in the lysosomal location and lipids. It is 
well documented that lysosomes have a high lipid density and have a bidirectional 
relationship with lipids, where they regulate lipid metabolism, and in turn lipids regulate their 
function (Jaishy and Abel, 2016). The novel documentation of the accumulation of lipids 
surrounding the nucleus seen in CWFs, indicated that lipid metabolism and transport were 
dysregulated in this cells type. Lipid-derived signalling, is not well understood in the context 
of wound healing. However, some have indicated that lipid metabolism does have role in 
platelet aggregation and inflammation (Dhall et al., 2015). Lipid storage in fact has a link to 
myofibroblast formation in developing mice (McGowan and McCoy, 2014). Prostaglandin E2 
a ubiquitous bioactive lipid mediator has also been shown to be anti-fibrotic and even 
capable of reversing the myofibroblast phenotype (Garrison et al., 2013). The dysregulated 
lipid metabolism in CWFs may have a substantial role in the loss of myofibroblast 
differentiation. 
The ER and Golgi are the two organelles responsible for: proteins and lipids synthesis, post-
translational modification and packaging for transport to the appropriate location. 
Dysfunctional synthesis or packaging at these sites can cause dysfunctional transport. The 
location of the accumulated EGFR, HYAL2 and lipids in this chapter and HAS2, HAS1 and 
HA in previous chapters, are concurrent with reported location of the ER and Golgi, meaning 
that these molecules may be accumulating within these organelles. The staining for the 
Golgi, looked comparable between the two cell types showing that the Golgi was not affected 
132 
 
in CWFs. The location of the Golgi also confirmed that it had no role in the accumulation of 
the molecules listed above, since it had a very specific structure and location, compared to 
the diffuse perinuclear staining observed for the accumulating molecules. 
ER stress is defined as the accumulation of unfolded, or mis-folded proteins in the lumen or 
the ER. ER stress has been associated with glucose or nutrient deprivation, viral infections, 
lipids, increased synthesis of secretory proteins and expression of mutant or misfolded 
proteins (Kaufman et al., 2002, Ozcan et al., 2004). We know that such conditions exist in 
chronic wound biology, and indicate that ER stress maybe contributing to the intracellular 
accumulation. ICC images of the ER associated protein, Calreticulin, did not show any 
differences between the ER in CWFs and NFs, suggesting that the ER of CWFs was not 
stressed. Although Calreticulin is a resident protein of the ER (Chiang et al., 2013), the 
staining pattern observed in the CWFs is not where the ER was expected as seen in other 
cells (Sanchez-Alvarez et al., 2014, Jiang et al., 2014). Calreticulin plays two major 
functions: chaperoning and regulation Ca2+ homeostasis (Michalak et al., 1999). It has also 
been found to have functions elsewhere throughout the cell, with its location in the nucleus 
associated with regulating steroid-inducible gene expression and the cytosol, where it is 
involved in the control of cell adhesion by interacting with integrins (Roderick et al., 1997). 
More staining was observed in the nucleus, associated with glucocorticoid activity, which is 
known to have a role in wound healing (Grose et al., 2002). Furthermore, calcium 
homeostasis and signalling has been linked to EGFR signalling, thus dysregulation of the 
ER may contribute to the loss of EGFR localisation (Leiper et al., 2006). The role of ER in 
CWFs dysfunction is yet to be elucidated. However, further experiments have the potential 
to uncover a link for protein localisation and accumulation. 
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Chapter 6 
General Discussion 
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This thesis characterises the response of CWFs to TGF-β1 stimulation identifying key 
contributory factors in the two TGF-β1 signalling pathways, classical and non-classical, to 
the loss of myofibroblast differentiation. At an mRNA level both CWFs and NFs were not 
found to respond significantly differently to TGF-β1 stimulation, with the exception of TGF-
βR and HAS1 expression in the CWFs. Downstream signalling of the TGF-βR pathway was 
found to respond to TGF-β1 treatment with the phosphorylation of SMAD2. In the non-
classical pathway significantly higher basal expression of HAS1 and its significantly 
increased expression in response to TGF-β1 indicated a potential difference in the non-
classical HA-CD44-EGFR pathway. Although manipulating HAS1 expression in both NFs 
and CWFs did not alter their TGF-β1 induced αSMA response, other results remained to 
indicate alterations in HA metabolism in the CWFs. This evidence included the loss of the 
HA pericellular coat, combined with aberrant HA and protein localisation of HAS1, HAS2 
and HYAL2 intracellularly in the CWFs. Further investigation unveiled the loss of CD44-
EGFR co-localisation in membrane bound lipid rafts on the surface of the CWFs, highlighting 
a possible cause for the loss of the HA pericellular coat. Under further examination, the 
accumulation of EGFR and lipids in a perinuclear location, suggesting that the lipids maybe 
creating a type of barrier surrounding the location of EGFR, preventing EGFR translocating 
to the membrane of CWFs. This result combined with other visualised aberrant intracellular 
protein locations in CWFs, prompted the hypothesis that protein synthesis and / or transport 
could be the cause. Initial investigations did not reveal any significant differences between 
protein synthesis or transport of the CWFs. Possible causes of the loss of CWFs 
differentiation will be discussed in this chapter. 
The data reported in this thesis build on previous findings on TGFβ1 induced differentiation 
in dermal fibroblasts and uncover possible affected mechanisms, that contribute to the loss 
of the myofibroblast response in CWFs. The loss of the CWFs differentiation capacity has 
long been related to the chronic wound environment, such as increased hypoxia and 
inflammatory signalling molecules (Alizadeh et al., 2007, Modarressi et al., 2010, Sen and 
Roy, 2010). This thesis characterises and compares CWFs to NFs, in vitro in identical 
conditions, nullifying in vivo wound factors. Characterisation of these cells at an mRNA and 
protein level confirmed their CWFs phenotype with loss of αSMA expression. Normal 
fibroblast to myofibroblast differentiation is regulated by two independent but collaborating 
pathways, the classical TGF-βR and the non-classical HA-CD44-EGFR pathway. Exploring 
key transcriptional differences in these two pathways, between CWFs and NFs highlighted 
two abnormal expressional differences; TGF-βRI and HAS1. These two differences 
indicated potential loss of signalling in both pathways in CWFs. 
135 
 
TGF-βR expression response to TGF-β1 was lost in the CWFs, supporting other studies 
undertaken on CWFs (Jude et al., 2002, Kim et al., 2003). However, investigation of 
downstream phosphorylation signalling in the SMAD proteins, indicated no significant loss 
in signalling downstream from the TGF-β receptor. Although differences were observed 
between NFs and CWFs, these differences were expected since cells were not patient 
matched. Aberrant SMAD signalling has also been attributed to other cellular processes, 
such as proliferation which we know from the growth curve data, was reduced in these 
senescent-like CWFs populations (Ten Dijke et al., 2002). Defective proliferation also 
contributes to non-healing in chronic wounds, and is an important area of research (Wall, et 
al., 2008). A possible future direction may be to investigate the link between the decrease 
in proliferation in CWFs and alterations in key signalling pathways, assessing these 
pathways in parallel to viability assays. Since, phosphorylation of SMAD2 and 3 occurred in 
both CWFs, signalling was taking place and thus the classical TGF-βR pathway was 
concluded to be intact and not the major player in the loss of CWFs differentiation. The 
research focus changed to investigate the non-classical pathway as the major contributor to 
the loss of differentiation. 
Previous research has identified the non-classical pathway to be the primary pathway 
responsible for the loss of differentiation in aged senescent fibroblasts. The loss of 
differentiation was associated with the aberrant expression of CD44, EGFR and HAS2 which 
resulted in the loss of their co-localisation on the surface, partially caused by higher 
expression of miR-7 (Midgley et al., 2014). It was hypothesised that this would be true for 
senescent CWFs. This thesis shows that this mechanism is not responsible for the loss of 
differentiation in CWFs, since no significant changes were seen in CD44, EGFR, HAS2 or 
miR-7 expression between CWFs and NFs responses to TGF-β1. However, evidence of 
alterations in HA metabolism in CWFs and NFs indicated that the non-classical pathway 
was still affected. HAS1 was shown to be the primary HAS in CWFs, with a large induction 
in response to TGF-β1. This was linked to attenuation of HA pericellular coat formation and 
alteration of intracellular locations of HA in the CWFs. However, transcriptional manipulation 
of HAS1 did not show direct changes to differentiation capacity in the CWFs or NFs. 
Previous research has shown that internalisation of HA is linked to the over-expression of a 
CD44 variant, V7/8, which internalises HA through the action of HYAL2 (Midgley et al., 
2017). Examination of V7/8 expression did show it to be elevated with HYAL2 protein 
internalisation observed in the CWFs. Silencing the expression of HYAL2 in the CWFs did 
not return the myofibroblast phenotype, and CD44 v7/8 localisation was not membrane 
specific as described by Midgley et al. (2017). This discovery highlights a possible 
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contributing factor to the loss of myofibroblast formation in CWFs. However, other 
mechanisms may also be defective. The attenuation of the HA pericellular coat in CWFs, is 
an important finding since previous research has indicated that this is a primary cause of the 
loss of differentiation in aged senescent fibroblast populations (Simpson et al., 2009). This 
previous research has pinpointed the loss of CD44-EGFR co-localisation in lipid rafts on the 
membrane of fibroblasts, as the cause for pericellular coat loss. This project has found that 
EGFR-CD44 co-localisation is also lost in CWFs, however the mechanism for this loss is 
unique for CWFs. Investigation of CD44 and EGFR localisation in CWFs, showed a distinct 
aggregation in an intracellular, perinuclear location. This location was further surrounded by 
lipid staining, possibly implying that lipid aggregation creates a barrier preventing EGFR 
reaching the surface of cells. This intracellular location was confirmed with the use of two 
antibodies, one targeting the extracellular domain (Merck, GR01) and one targeting an 
intracellular epitope (Abcam, ab11401). The loss of EGFR location on the membrane is 
caused by post-translational modification, since neither mRNA or protein are affected in 
CWFs and any other post-transcriptional regulation by EGFR anti-sense was not 
discovered. Future work may elucidate this post-translational modification. 
Previous studies have discussed the possibility of dysfunctional ER-golgi-plasma membrane 
trafficking also being essential for HA coat formation and the transfer of molecules to the 
membrane (Siiskonen et al., 2014). To investigate this staining was performed to assess the 
location and condition of key organelles. No significant changes were observable in ER, 
Golgi, microtubule, or endosomal staining. However, ER stress has been previously 
associated with causing protein mis-folding and hence could explain the aberrant protein 
localisation in CWFs (Kaufman et al., 2002). Although no changes in ER localisation were 
found between CWFs and NFs. A possible future direction would be to further investigate 
staining the ER with other antibodies such as GRP94 to verify the ER location and condition 
of the ER in CWFs. Protein mis-folding, caused by ER stress, maybe a contributing factor 
to the accumulation of intracellular proteins. However, it has been well documented that ER 
stress is a pro-fibrotic response and is capable of driving fibroblast differentiation without a 
TGF-β1 stimulus (Matsuzaki et al., 2015, Baek et al., 2012). This mechanism is based on 
the activation of the unfolded protein response (UPR) of the cell. The UPR reduces stress 
by activating three adaptive pathways: the transcriptional induction of ER chaperone 
proteins to help protein folding, the translational attenuation of protein synthesis and the 
promotion of the degradation of misfolded or unfolded proteins. Without successful 
activation of the UPR, cells eventually enter apoptosis (Baek et al., 2012). It could be said 
that activation of the UPR in CWFs is unsuccessful leading to the build-up of intracellular 
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proteins. Assessing the three pathways responsible for UPR activation, we can say that, no 
evidence of inhibition of protein synthesis was found in the CWFs. Western blots of CD44 
and EGFR in CWFs showed comparable quantities to those in NFs, therefore showing that 
overall protein synthesis was not effected in CWFs. However, a future direction would be to 
assess pathways involved in the degradation of proteins in CWFs, since aberrant 
degradative pathways may also contribute to protein build-up within the cells. 
The proteasome is a complex protease complex that carries out selective hydrolysis of 
intracellular proteins. Polymerization of ubiquitin, serves as a degradation signal for 
numerous target proteins broken down by the proteasome (Tanaka, 2009). The proteasome 
has been found to be important during wound healing. Inhibitors of the 20S proteasome, 
responsible for intracellular protein degradation, have been shown to have anti-fibrotic 
effects. Inhibiting proteasome 20S can downregulate the inflammatory response, block TGF-
β1 fibrotic effects and alter MMP and TIMP expressions (Walker et al., 2013). Furthermore, 
ER stress has been found to compromise the proteasome system, therefore natural 
inhibition of the proteasome can result from ER stress (Menendez-Benito et al., 2005). 
Proteasome dysfunction maybe a contributing factor to the loss of intracellular protein 
clearance in the CWFs. It has been reported that upon proteasome failure, aggregates are 
transported via microtubule transport to the centrosome, forming an organelle known as an 
aggresome. A distinct finding by Zaarur (2014) was that upon proteasome failure, lysosomes 
clustered around the aggresome in a perinuclear location (Zaarur et al., 2014). One 
coinciding finding of this thesis was the localisation of CWFs lysosomes in a perinuclear 
location surrounding aggregating proteins. The area of the lysosomes was associated with 
an area or high lipid density, often associated with lysosomal activity (Hamer et al., 2012). 
This may be additional evidence showing that in CWFs, the proteasome is dysfunctional 
leading to the build-up of intracellular proteins. Zaarur (2014) continues to explain an 
entrapment zone of protein aggregation, surrounding the nucleus, much like that seen in the 
CWFs. However, the mechanism behind the formation of the entrapment zone, described 
by Zaarur (2014), is via loss of the microtubule network, which was found to be intact in this 
area of the CWFs. It would be of interest to measure the activity of the proteasome in CWFs, 
to assess its functionality. Future research is needed to fully attribute proteasome 
dysfunction in the CWFs pathobiology. 
The localisation of lysosomes in the CWFs, was found to be in the area of high lipid density. 
Lysosomes have been shown to have a bifunctional relationship with lipids, they are capable 
of lipid degradation but lipids can also regulate lipid function, which has also been shown to 
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have a role in regulation myofibroblast formation (Jaishy and Abel, 2016, McGowan and 
McCoy, 2014). Impaired lipid homeostasis has been associated with senescent 
characteristics in cells, such as, slow cell proliferation, as seen in CWFs (Tsukamoto et al., 
2002). Alteration in the actin cytoskeleton of cells has been found to be a key player in the 
loss of intracellular lipid transport. Alteration of the cytoskeleton is associated with CWFs, 
and may indicate a potential mechanism behind the accumulation of intracellular lipids 
(Raffetto et al., 2001, Tsukamoto et al., 2002). The novel finding of lysosomal and lipid 
intracellular accumulation in CWFs, may provide unique future directions for this project, in 
investigating the role of lipid metabolism, an area of research not yet explored in the context 
of the HA-CD44-EGFR pathway. 
The wound environment is a key player on the outcome of wound healing (Raffetto et al., 
2001). Pro-inflammatory cytokines, immune cell recruitment, infection, and oxidative stress 
all contribute to the non-healing outcome of chronic wounds, and can contribute specifically 
to the loss of fibroblast to myofibroblast differentiation. In this study, CWFs were compared 
to NFs in vitro eliminating the anti-fibrotic effects of the wound-microenvironment. Still, the 
CWFs fail to differentiate away from external wound stimuli. The question therefore remains 
what causes CWFs to lose their differentiation abilities. It has been well established that a 
hallmark of chronic wounds is the immobilisation of wound healing in the inflammatory phase 
(Zhao et al., 2016). Within this phase extensive damage occurs to the cells via the action of 
pro-inflammatory cytokines, reactive oxygen species and proteases, which is often 
exacerbated in chronic wounds by bacterial colonisation (Modarressi et al., 2010, Harsha et 
al., 2008). It has been reported that chronic inflammation can potentially alter long term gene 
expression of cells (Chen et al., 2008, Vigl et al., 2011). The up-regulation of HAS1, a pro-
inflammatory HAS, in the CWFs suggests that this mechanism may be occurring in CWFs 
(Siiskonen et al., 2015). The changes to gene expression are thought to be caused by 
epigenetic modifications in response to environmental influences. These epigenetic 
modifications can include DNA methylation, methylation and acetylation of Histones and 
activation of non-coding RNAs, which all have downstream effects on gene expression 
(Bayarsaihan, 2011). Diabetic chronic wounds have been attributed to epigenetic changes, 
caused by diabetes, leading to the recruitment of dominant pro-inflammatory M1 
macrophages (Sidaway, 2015). Epigenetic DNA methylation has also been attributed in 
directly affecting genes controlling fibroblast differentiation in idiopathic pulmonary fibrosis 
(Sanders et al., 2012). Hypoxia, an environmental factor, has been shown to cause 
epigenetic changes by DNA methylation of Thy-1, a gene associated with the activation of 
TGF-β1 (Robinson et al., 2012). ROS activity has also been associated with damage to the 
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proteasome, potentially contributing to the accumulation of intracellular proteins in the CWFs 
(Aiken et al., 2011). Epigenetic changes can occur as a result of environmental stimuli. 
Although changes in the primary genes involved in the two TGF-β1 pathways have been 
analysed in this thesis and found to be at comparable expression levels, there is much need 
of further investigation to investigate whether epigenetic changes from the chronic wound 
environment, may be causing intracellular protein aggregation, changes in HA metabolism 
and ultimately the loss of the myofibroblasts phenotype in CWFs. Future, investigations 
highlighting these epigenetic changes may allow gene therapy treatments to be developed 
to modify gene expressions of the fibroblasts back towards a healing phenotype. 
6.1 Limitations  
This study has identified multiple mechanisms that are defective in CWFs, associated with 
the loss of myofibroblast differentiation. However, there are several limitations to this study 
that will need to be addressed in future work to confirm the conclusions. Although the 
study confirms the variable nature of CWF responses due to the chronic wound 
environment, this led to the generation of donor specific responses in the results.  
Therefore, as all experiments were undertaken using 4 unique individual cell lines, this 
made drawing conclusions difficult from the evidence. Although, this research sets the 
foundations, it would be beneficial to repeat the experiments increasing the patient 
population to make the results more statistically significant (e.g. as performed by Wall et 
al., 2008). There were also limitations evident in the control cells as NFs were not patient 
matched to CWFs. This made interpretation of data difficult, since responses between 
cells could not be compared and only differences in response to TGF-β1 stimulation could 
be analysed. In the future more conclusions could be drawn from this study if patient-
matched cells were used.  
The majority of findings from this study indicate that it was not gene expression or protein 
levels that were affected in CWFs, but protein localisation. As this evidence was primarily 
based on qualitative images, attempts were made to confirm significant findings with 
repeat experiments, such as the intracellular localisation of EGFR which was confirmed 
with two separate antibodies, binding an intracellular and extracellular motif. However, this 
study would benefit from quantitative experiments such as cell fractionation followed by 
ELISA on separate cellular fractions to simultaneously identify protein location and 
quantity. 
The wound milieu is a complex environment to study in vitro and therefore this study 
looked narrowly at the effect of TGF-β1 signalling and loss of fibroblast differentiation on 
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wound healing. Understanding these mechanisms is key to identifying the cause of clinical 
chronic wounds, however it is a contributing mechanisms and we know that other defective 
mechanisms may also contribute to the loss of healing. To increase our understanding 
further cell types from other different types of chronic wounds could be investigated, such 
as diabetic CWFs or CWFs from infected and non-infected chronic wounds. Experiments 
could also be designed to see the interaction of other cell types on CWFs such as 
macrophages which we know contribute to TGF-β1 signalling. Another method of 
investigating these complex interacting mechanisms and ensuring matched samples at 
high quantities, would be to study in vivo, using animal models. Appropriate diabetic 
wounding mouse models exist, such as the diabetic (db/db) mouse where chronic wounds 
can be modelled by inducing high oxidative stress following wounding. This can be 
accomplished using treatment of anti-oxidants immediately post wounding (Kim and 
Martins-Green, 2016). Pigs can be used for modelling infected and non-infected chronic 
wounds. Chronic wounds can be induced by surgically cutting blood flow to the site of 
injury, creating a hypoxic zone. This wound can then have bacteria added, to study the 
effects of various bacterial strains (Nunan et al., 2014). 
The work outlined in this thesis identifies several novel aberrant mechanisms that contribute 
to the loss of the myofibroblastic response in CWFs. At this point we cannot exclude more 
than one abnormality, possibly several independent ones, exist in CWFs, causing the loss 
of myofibroblast formation. However, this thesis has laid the foundations for future research 
to understand the cause of dysfunctional protein, lipid and HA localisation in CWFs. 
Identifying these causes may highlight possible therapeutic targets for chronic wounds in 
the future. 
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Supplementary Figure 1. αSMA Repeat 1 and 2. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone 
(-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of αSMA protein was examined by immunocytochemistry; nuclei were visualised by Hoechst 
stain. Images shown are a representation of 2 independent experiments. Original magnification x400. Scale bar: 100µm. 
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Supplementary Figure 2. Localisation of total Hyaluronan does not change with TGF-β1 treatment. Cells were grown to 60-70% confluence and growth arrested for 48h. 
Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression of total HA GAG was examined by 
immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original Magnification x400. Scale bar 
100µm. 
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Supplementary Figure 3. Visualisation of HA pericellular coat using Red Blood Cell (RBC) exclusion assay. Cells were grown to 60-70% confluence and growth arrested 
for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression visualisation of HA was examined 
by RBC exclusion assay. Yellow arrows show HA coat presence. Images shown are a representation of 2 independent experiments. Original Magnification x200. Hyaluronidase 
treated cells were used as a control, removing pericellular HA. Scale bar: 100µm. 
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Supplementary Figure 4. HAS2 Localisation. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-
TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression of HAS2 (green) was examined by immunocytochemistry, nuclei were visualised by Hoechst 
stain. Images shown are a representation of 2 independent experiments. Original Magnification x400. Scale bar: 100µm. 
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Supplementary Figure 5. HAS1 clusters in a perinuclear location in TGF-β1 Treated CWFs. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells were 
then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression of HAS1 (red) was examined by 
immunocytochemistry, nuclei were visualised by Hoechst stain. Images shown are a representation of 3 independent experiments. Original Magnification x400. Scale bar: 100µm. 
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Supplementary Figure 6. Intracellular HA clusters in a perinuclear location in CWFs. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells were then 
incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression of intracellular HA was examined by 
immunocytochemistry; nuclei were visualised by Hoechst stain. Cells were pre-treated with Streptomyces Hyaluronidase (H1136, Sigma-Aldrich) 30min prior to fixation, to remove 
pericellular HA. Images shown are a representation of 2 independent experiments. Original magnification x400. Scale bar: 100µm. 
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Supplementary Figure 7. Silencing HAS1 does not recover a myofibroblast phenotype in CWFs. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells 
were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of α-SMA was examined by 
immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original Magnification x200 (if available) or 
x400. Scale bar: 100µm. 
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Supplementary Figure 8. Overexpression of HAS1 does not induce a CWFs phenotype in NFs. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells 
were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of αSMA protein was examined by 
immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original Magnification x400. Scale bar: 100µm.  
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Supplementary Figure 9. Intracellular localisation of EGFR in CWFs and reduced co-localisation with CD44 on the membrane, compared to NFs. Cells were grown to 
60-70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) for 72h. The localisation of EGFR (green) and CD44 proteins 
(Red) were examined by immunocytochemistry and confocal microscopy; nuclei were visualised by Hoechst stain. Images shown are a representation of 3 independent 
experiments. Original magnification x620. Scale bar: 50µm. 
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Supplementary Figure 10. Intracellular localisation of EGFR in CWFs and reduced co-localisation with CD44 on the membrane, compared to NFs. Cells were grown to 
60-70% confluence and growth arrested for 48h. Cells were then incubated in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of EGFR (green) and CD44 
proteins (Red) were examined by immunocytochemistry and confocal microscopy; nuclei were visualised by Hoechst stain. Images shown are a representation of 3 independent 
experiments. Original magnification x620. Scale bar: 50µm. 
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Supplementary Figure 11. EGFR and lipid intracellular localisation in CWFs with reduced co-localisation on the membrane, compared to NFs. Cells were grown to 60-
70% confluence and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) for 72h. The localisation of EGFR protein (green) and lipids (Red) 
were examined by immunocytochemistry and confocal microscopy; nuclei were visualised by Hoechst stain. Images shown are a representation of 3 independent experiments. 
Original magnification x620. Scale bar: 50µm. 
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Supplementary Figure 12. EGFR and lipid intracellular localisation in CWFs with reduced co-localisation on the membrane, compared to NFs. Cells were grown to 60-
70% confluence and growth arrested for 48h. Cells were then incubated in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of EGFR protein (green) and 
lipids (Red) were examined by immunocytochemistry and confocal microscopy; nuclei were visualised by Hoechst stain. Images shown are a representation of 3 independent 
experiments. Original magnification x620. Scale bar: 50µm. 
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Supplementary Figure 13. CD44 variant 7/8 localisation and expression. Cells were grown to 60-70% confluence and growth arrested for 48h. Cells were then incubated in 
serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of CD44 v7/8 protein was examined by immunocytochemistry; nuclei 
were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original magnification x400. Scale bar: 100µm. 
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Supplementary Figure 14. HYAL2 perinuclear localisation in CWFs. Silencing HYAL2 doesn’t recover a myofibroblast phenotype. Cells were grown to 60-70% confluence 
and growth arrested for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of CD44 
v7/8 protein was examined by immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original 
magnification x400. Scale bar: 100µm  
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Supplementary Figure 15. No difference in lysosome localisation was observed between CWFs and NFs. Cells were grown to 60-70% confluence and growth arrested for 
48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of LAMP-1 protein was examined 
by immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original magnification x400. Scale bar: 
100µm 
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Supplementary Figure 16. No difference in endosome localisation was observed between CWFs and NFs. Cells were grown to 60-70% confluence and growth arrested 
for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The localisation of EEA-1 protein was examined 
by immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original magnification x400. Scale bar: 
100µm. 
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Supplementary Figure 17. No difference was seen between E.R. staining of CWFs and NFs.  Cells were grown to 60-70% confluence and growth arrested for 48h. Cells 
were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The expression of E.R. protein, calreticulin was examined by 
immunocytochemistry. No nuclei stain was used to show localisation within the nucleus. Images shown are a representation of 2 independent experiments. Original magnification 
x400. Scale bar: 100µm. 
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Supplementary Figure 18. No differences in Golgi staining was observed between CWFs and NFs. Cells were grown to 60-70% confluence and growth arrested for 48h. 
Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. The Golgi protein, GM-130 was examined by 
immunocytochemistry; nuclei were visualised by Hoechst stain. Images shown are a representation of 2 independent experiments. Original magnification x400. Scale bar: 100µm. 
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Supplementary Figure 19. No difference in tubulin positive microtubule formation between CWFs and NFs. Cells were grown to 60-70% confluence and growth arrested 
for 48h. Cells were then incubated in serum-free medium alone (-TGF) or in medium containing 10 ng/mL TGFβ1 (+TGF) for 72h. Tubulin was examined by immunocytochemistry; 
nuclei were visualised by Hoechst stain. Original magnification x400. Images shown are a representation of 2 independent experiments. Scale bar: 100µm. 
